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ABSTRACT 
 
The tumour suppressor PTEN is frequently lost in advanced prostate cancer leading to 
over-activation of the PI3K/AKT/mTOR pathway. Therefore targeting of the PI3K 
signalling with pathway-specific inhibitors has been proposed as a therapeutic 
strategy.  
Inhibition of AKT and mTOR kinases in prostate cancer cell lines showed a decrease in 
cell viability and reduction in phospho-biomarkers expression. Although apoptosis was 
not induced, a decrease in cell migration and G1 cell growth arrest were observed in 
LNCaP cells. 
However, in primary prostate cultures activation of the Ras/MEK/ERK compensatory 
pathway was observed following treatment with AKTi. Moreover, cell viability was less 
affected than in cell lines and autophagy was induced following treatment with AKTi. 
Surprisingly, treatment with a combination of AKTi and MEK1/2 inhibitors (MEK1/2i 
and RO-512) did not reduce phosphorylation of ERK1/2 in primary prostate cultures, 
but irreversible growth arrest-senescence, was evident. Additionally, ex vivo treatment 
of a ‘near-patient’ prostate xenograft with a combination of AKTi and mTORi 
significantly reduced tumour frequency.     
These results demonstrate that targeting the PI3K/AKT/mTOR pathway triggers 
activation of the Ras/MEK/ERK compensatory pathway and therefore blockade of one 
pathway is not sufficient to treat prostate cancer. This study also highlights the 
importance of using patient-derived tumour cells in preclinical assessment of new 
drugs rather than relying solely on cancer cell lines. 
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1. INTRODUCTION 
1.1. Human prostate gland anatomy 
The prostate is a walnut-sized major secretory gland of the male reproductive system. 
It is located in front of the rectum and just below the bladder, where it wraps around 
the upper part of the urethra (Figure 1.1 A). The human prostate is a heterogeneous 
organ, which can be divided into four zones: peripheral zone (70% of prostate 
glandular tissue), central zone (25%), transition zone (5%) and anterior zone, which is 
composed of muscular and fibrous tissue, but lacks any glandular structures (Figure 1.1 
B) (McNeal, 1981). The peripheral zone is the most common area in which prostate 
cancer arises. It accounts for up to 70% of all prostate cancers, compared to 20% 
arising in the transition zone and 10% in the central zone (McNeal, 1988).  
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Figure 1.1. Schematic illustration of location and organisation of the human prostate gland. 
The human prostate is located at the base of the bladder, where it surrounds the urethra (A). It 
consists of peripheral zone – 1, central – 2 and transition zone – 3 (B). Image adapted from 
(Harvard Prostate Knowledge).    
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1.1.1. Cellular organisation of the prostate epithelium 
The prostate epithelium consists of basal, secretory luminal and rare neuroendocrine 
cells. The luminal cells represent the major cell type in the prostate, they are 
terminally differentiated and secrete prostate-specific antigen (PSA) and prostatic acid 
phosphatase (PAP) into the glandular lumen (Figure 1.2 A). Luminal cells, unlike the 
basal cells, express high levels of androgen receptor (AR) and are dependent on 
androgens for their survival, whereas the basal cells are located at the basement 
membrane, express low levels of AR and do not have any secretory activity (Sar et al., 
1990, Kyprianou and Isaacs, 1988, Lilja and Abrahamsson, 1988, Bonkhoff and 
Remberger, 1993). Basal cells can be further subdivided into distinct subpopulations:  
stem cells, transit-amplifying and committed basal cells on the basis of expression of 
cell surface markers, including α2β1 integrins, CD44 and CD133 (Figure 1.2 B).  
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Figure 1.2. Anatomy and organisation of the human prostate gland.  
Cross-section of the prostatic duct showing organisation of the epithelial cells (A) and 
schematic organisation of the prostate epithelium (B). Adapted from (Collins and Maitland, 
2006).  
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Basal and luminal cells can be discriminated on the basis of their localisation, 
morphology and expression of specific cytokeratins (CK), such as cytokeratin 5 and 14 
(expressed by basal cells) and cytokeratin 8 and 18 (expressed predominantly by 
luminal cells) (Sherwood et al., 1991).  
Neuroendocrine cells are principally located within the basal compartment, they are 
terminally differentiated and androgen-independent (Bonkhoff et al., 1995). They are 
responsible for the production and secretion of neuroendocrine peptides, such as 
calcitonin, chromogranin and serotonin and therefore essential for homeostatic 
regulation of the secretory processes in the prostate gland (Abrahamsson, 1999).  
The basal layer of cells strongly adheres to the basement membrane, which forms a 
structural barrier between the epithelial compartment and the stroma (Figure 1.3). 
The prostatic stromal cells secrete growth factors, including epidermal growth factor 
(EGF) and fibroblast growth factor (FGF), which are essential for epithelial cell 
maintenance and differentiation (Hall et al., 2002, Berry et al., 2008).   
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Figure 1.3. Schematic representation of the architecture of the human prostate epithelium. 
 Stem cells and neuroendocrine cells are located in the basal compartment of the prostate and 
together with luminal layer form the prostate epithelium. Stromal cells, including 
myofibroblasts, fibroblasts and smooth muscle cells, are separated from the epithelium by the 
basement membrane. Adapted from (Oldridge et al., 2012).    
 
  
 
24 
 
1.1.1.1. Prostate epithelial stem cells  
Multipotent adult stem cells are an essential component of tissue homeostasis and 
their main functions include tissue regeneration following injury or replacement of 
terminally differentiated cells. Adult stem cells have limited differentiation potential 
depending on the specific lineages of the tissue in which they reside. However, these 
cells are able to self-renew and differentiate throughout the lifespan of an adult 
because of their unlimited growth and asymmetrical division capacity (Morrison and 
Kimble, 2006). The progeny of adult stem cells named transit amplifying (TA) cells, 
have limited proliferative capacity before they terminally differentiate (Figure 1.4) (Hall 
and Watt, 1989).  
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Figure 1.4. Hierarchical organisation of the human prostate epithelium. 
Quiescent stem cells produce rapidly proliferating transit amplifying progeny, which then 
produce cells committed to differentiation. Committed basal cells differentiate further to 
secretory luminal cells, which are mainly senescent. Adapted from (Oldridge et al., 2012). 
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1.2. Diseases of the prostate 
1.2.1. Prostatitis 
Prostatitis is an inflammatory disorder of the prostate whose main symptom is 
difficulty or pain in passing urine. It is the most common disease of the prostate in men 
age 36 to 65 with an incidence rate of 2-10% (Krieger, 2004). There are many potential 
causes of the disease, such as acute and chronic bacterial infections, stress, physical 
injury or autoimmune reaction. Prostatitis can be successfully treated with antibiotics 
or anti-inflammatory drugs (Stevermer and Easley, 2000). Research evidence suggests 
that inflammation of the prostate is a significant factor for benign prostatic hyperplasia 
(BPH) initiation in older men (Kramer and Marberger, 2006, Kramer et al., 2007).  
 
1.2.2. Benign prostatic hyperplasia (BPH) 
BPH is a non-malignant, age-related disease, which originates in the transition zone of 
the prostate gland. Clinical symptoms are associated with an enlarged prostate and 
they include decrease in force and calibre of urinary stream and the sensation of 
incomplete bladder emptying (Figure 1.5) (Oesterling, 1991). Transurethral resection 
of the prostate (TURP) is often performed in order to alleviate symptoms (Schroder 
and Blom, 1989). Other treatment options for BPH include: 
- Alpha blockers, for example tamsulosin and alfuzosin which relax the smooth 
muscle of the prostate and bladder improving urine flow (Urology Care 
Foundation, 2013, National Health Service UK, 2013); 
 
- 5-alpha-reductase inhibitors such as finasteride and dutasteride which block 
the effects of hormone dihydrotestosterone (DHT) and reduce the enlarged 
prostate (Urology Care Foundation, 2013, National Health Service UK, 2013); 
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Figure 1.5. Schematic representation of the normal prostate and BPH.  
The illustration shows a normal prostate and undisturbed flow of urine through the urethra (A) 
and an enlarged prostate, due to BPH, pressing on the bladder and urethra blocking the flow of 
urine (B). Adapted from (National Cancer Institute).  
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1.2.3. Prostatic intraepithelial neoplasia (PIN) 
Prostatic intraepithelial neoplasia (PIN) represents a precancerous stage of the 
prostate. Two grades of PIN are recognized: low and high grade. In low grade PIN, the 
cells within ducts and acini are irregularly spaced, their nuclei are elongated and 
nucleoli are small, whereas in high grade PIN, the cells are crowded, their nuclei are 
enlarged and often multiple nucleoli are present (Bostwick et al., 2004). PIN is 
characterised by abnormal cellular proliferation which disturbs the bilayer of the 
prostatic epithelium, but the basement membrane remains intact. The most common 
location for PIN is the peripheral zone of the prostate, the area in which the majority 
(70%) of prostatic carcinomas occur. The frequency and severity of PIN in prostates 
with cancer is significantly increased when compared with prostates without cancer. 
High grade PIN is considered the ultimate pre-invasive stage of invasive carcinoma 
(Bostwick et al., 2004).   
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1.2.4. Prostate cancer 
Prostate cancer is a slow-growing, heterogeneous disease; with the majority (>70%) of 
tumours originating in the peripheral zone, 15-20% in the central zone and the 
remaining 10-15% in the transitional zone. Prostate cancer progression has been 
shown to correlate with loss of tumour suppressor genes, such as phosphatase and 
tensin homolog deleted on chromosome ten (PTEN), Retinoblastoma (Rb) and p53 
(Figure 1.6) (Shen and Abate-Shen, 2010, Abate-Shen and Shen, 2000). 
 
 
Figure 1.6. Human prostate cancer progression. 
A schematic illustration of the stages of progression from normal prostate epithelium, through 
to prostatic intraepithelial neoplasia (PIN), invasive carcinoma and ultimately to metastatic 
prostate cancer. Stages of progression correlate with loss of specific chromosome regions and 
tumour suppressor genes. Adapted from (Shen and Abate-Shen, 2010). 
 
1.2.4.1. Prostate cancer incidence and mortality 
Prostate cancer is the most common cancer in men in the UK (Cancer Research UK, 
2011). There are over 40,000 new cases of prostate cancer diagnosed every year, 
which accounts for 25% of all new cases of cancers in males. The incidence of prostate 
cancer is strongly related to age, and its highest rate of 800 per 100,000 men is in the 
75-79 age group (Figure 1.7).  
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Figure 1.7. Incidence of prostate cancer.  
The average number of new cases per year and age-specific incidence rates of prostate cancer 
in the UK between 2009 and 2011. Taken from (Cancer Research UK). 
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Prostate cancer is the second most common cause of cancer death in men in the UK 
(Cancer Research UK, 2011). The mortality rate of prostate cancer is strongly related to 
age; it rises sharply from age 50 and its highest rates are observed in the 85+ age 
group (Figure 1.8).  
 
Figure 1.8. Mortality of prostate cancer. 
Average number of deaths per year and age-specific mortality rates of prostate cancer in the 
UK between 2010 and 2012. Taken from (Cancer Research UK). 
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1.2.4.2. Diagnosis of prostate cancer 
The diagnosis of prostate cancer is currently based on the quantification of prostate 
specific antigen (PSA) levels in serum (Stampfer et al., 2014, Placer and Morote, 2011). 
In the normal prostate, PSA functions as a serine protease and is responsible for 
maintaining the fluidity of seminal fluid (Lilja and Abrahamsson, 1988). A PSA 
concentration of less than 4 ng/ml is considered to be normal, whereas PSA of more 
than 4 ng/ml usually requires further investigation, which involves a biopsy and digital 
rectal examination (DRE). However, PSA test might give false-positive or false-negative 
result. A false-positive test result occurs when a man’s PSA level is elevated but cancer 
is not present. A false-negative test result occurs when detected PSA level is low but 
the patient actually has prostate cancer. Majority of men with an elevated PSA level do 
not have prostate cancer; increased PSA level might also be a result of prostatitis or 
urinary tract infection. Only about 25% of men undergoing prostate biopsy due to 
elevated PSA level turn out to have prostate cancer (National Cancer Institute).  
During prostate cancer progression, the characteristic morphology of the gland begins 
to degrade and the basement membrane is eventually destroyed (Gleason, 1966). 
Following biopsy, the prostate tissue is histologically analysed and graded according to 
the Gleason tumour grading system (Figure 1.9) (Gleason, 1966). The Gleason grading 
system is based on the degree of glandular differentiation and 5 grades are identified; 
grade 1 represents normal, differentiated histology and grade 5 represents the least 
differentiated pattern. The Gleason grading system was recently updated and it has 
been proposed that Gleason grades 2 + 4 should be rarely diagnosed on needle biopsy 
and should be replaced with 3 + 3 (Epstein, 2010).    
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Figure 1.9. Gleason grading system for prostatic adenocarcinoma.   
The original (A) and modified (B) Gleason grading system describing architectural features 
divided into 5 histological patterns of decreasing differentiation, with pattern 1 representing 
the most differentiated and pattern 5 being the least differentiated. Adapted from (Gleason, 
1966, Epstein, 2010).  
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1.2.4.3. Current strategies for treatment of prostate cancer  
The treatment strategy for patients with prostate cancer depends on the stage of 
disease at the time of the diagnosis and most importantly whether the cancer is 
confined to the prostate or it has spread. The different treatment options can include: 
 Watchful waiting  
 active surveillance 
 Radical prostatectomy 
 Radiotherapy 
 Androgen deprivation therapy (ADT) 
 Chemotherapy 
 
1.2.4.3.1. Organ-confined prostate cancer 
Patients diagnosed with small volume, low Gleason grade tumours, which are still 
confined to the prostate can be offered active surveillance rather than aggressive 
treatment options.  
However, the most common treatment for organ-confined tumours is total surgical 
removal of the prostate – radical prostatectomy. It has been shown that this method 
of treatment reduces disease-specific mortality, risk of metastasis and local 
progression (Bill-Axelson et al., 2005). Although radical prostatectomy is a most 
common treatment for early stage prostate cancer, there are potential side effects, 
including urinary impotence and sexual dysfunction (Catalona et al., 1999). The risk of 
those side effects was reduced after introduction of nerve-sparing surgery (Walsh, 
2007).  
An additional treatment option for localised prostate cancer is radiotherapy, which 
involves applying ionising radiation directly to the tumour (brachytherapy) or indirectly 
by using external beam radiotherapy (Duchesne, 2011). Brachytherapy involves 
implantation of small radioactive seeds, which allows direct targeting of the cancerous 
tissue while surrounding healthy tissue only gets a small amount of radiation. 
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1.2.4.3.2. Metastatic prostate cancer 
The treatment of prostate cancer, which has spread outside the prostate gland, usually 
involves androgen deprivation therapy (ADT). ADT blocks testosterone-driven 
proliferation of prostate cancer cells, which induces apoptosis in the majority of cancer 
cells. Prostate tumours initially respond well to androgen ablation therapy and a 
reduction of tumour volume is observed. However, in most cases, ADT ultimately fails 
and castration resistant prostate cancer (CRPC) emerges, which is inevitably fatal 
(Feldman and Feldman, 2001). The median survival for patients with CRPC is 
approximately 18 – 24 months (Tannock et al., 2004, Taichman et al., 2007).    
There is evidence to suggest that the mechanisms of resistance to ADT can be acquired 
via: 
 Point mutations in the AR ligand binding domain (Veldscholte et al., 1992) 
 Amplification of the AR gene and consequent overexpression (Visakorpi et al., 
1995) 
 Activation of the IL-6 pathway (Hobisch et al., 1998) 
 Changes in AR co-activators (Culig and Santer, 2012) 
 Crosstalk with the PI3K/AKT pathway (Carver et al., 2011) 
 Autonomous intratumoural androgen biosynthesis (Chang et al., 2011) 
 Altered expression of AR transcriptional cofactors such as FOXA1 (Gerhardt et 
al., 2012) 
 AR splice variants lacking the ligand binding domain (Sun et al., 2010) 
Recently novel therapeutic agents, such as abiraterone and enzalutamide have 
demonstrated improved overall survival in metastatic castration-resistant prostate 
cancer (Esch et al., 2014). A summary of the most recent treatment strategies for 
prostate cancer is presented in Table 1.1.  
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Table 1.1. A list of new treatments for CRPC prostate cancer. (Adapted from Maitland N.J., 
Prostate cancer. Diagnosis and clinical management; 2014).  
Treatment Disease 
stage 
Median / 
Mean 
survival 
[months] 
Placebo / 
Standard of Care 
(SOC) comparator 
[months] 
Therapeutic 
advantage 
[months] 
Docetaxel 
+prednisone 
+ADT 
1st line 
mPC 
57.6 44 13.6 
Docetaxel 1st line 
mCRPC 
18.9 16.4 2.5 
Abiraterone CRPC 14.8 11.2 3.6 
Provenge  CRPC 25.8 21.7 4.1 
MDV3100 
(Enzalutamide) 
1st line 
mCRPC 
32.4 30.2 2.2 
MDV3100 
(Enzalutamide) 
2nd line 
mCRPC 
18.4 13.6 4.8 
Radium-223 
chloride 
mCRPC 
(Bone 
metastasis) 
14 11 3 
mPC – metastatic prostate cancer 
mCRPC – metastatic castration resistant prostate cancer 
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1.2.4.4. Prostate cancer stem cells 
The origin of prostate cancer is still controversial. It has been suggested that the 
initiating cell of a prostate cancer would be a luminal cell, because terminally 
differentiated luminal cells constitute the majority of cells in the tumour bulk 
(Signoretti et al., 2000). However, evidence has been accumulating to support the 
cancer stem cell theory of tumour initiation. A cancer stem cell (CSC) is defined as a 
cell within the tumour that is able to self-renew and initiate tumour development in 
immunocompromised mice (Li et al., 2009). Additional characteristics of cancer stem 
cells include: 
 Resistance to chemotherapy and radiotherapy 
 Ability to regenerate the tumour after treatment 
 Asymmetrical division 
 Quiescence or slow proliferation 
 Extensive proliferative potential 
 Cell colony formation in vitro  
 Matrix invasion 
(Tindall, Reya et al., 2001, Vogelstein and Kinzler, 1993). 
Cancer stem cells have been identified in a number of cancers, including acute myeloid 
leukaemia (Bonnet and Dick, 1997), breast (Al-Hajj et al., 2003), brain (Singh et al., 
2003), multiple myeloma (Matsui et al., 2004), lung (Eramo et al., 2008) and many 
others.  
Human prostate stem-like cells have been identified and isolated from prostate cancer 
biopsies based on the expression of cell surface markers CD44+α2β1
hiCD133+ (Collins et 
al., 2005). The prostate CSCs have been shown to constitute a small cell population 
(0.1%) within the tumour, which have a basal phenotype and do not express the 
androgen receptor (Collins et al., 2005). Moreover, under differentiating conditions, 
luminal cells expressing androgen receptor (AR), cytokeratin 18 (CK18) and prostatic 
acid phosphatase (PAP) can be derived from prostate CSCs. It has also been shown that 
fewer than 100 cells were required to initiate tumour growth in immunocompromised 
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mice, indicating that this basal phenotype fraction of cells has indeed very high tumour 
initiation potential (Maitland et al., 2011).   
 
1.2.5. Models of prostate cancer 
1.2.5.1. Prostate epithelial cell lines 
Prostate epithelial cell lines are the most commonly used model for studying prostate 
cancer. Using cell lines in research has several advantages, including easy maintenance 
and manipulation as well as extended potential to proliferate in culture. The most 
commonly used prostate cancer cell lines include LNCaP cells, derived from lymph 
node metastasis (Horoszewicz et al., 1983), PC3 derived from bone metastasis (Kaighn 
et al., 1979) and DU-145 from brain metastasis (Stone et al., 1978).  
However, cell lines do not accurately represent human tumours. Additionally, it has 
been shown that long-term culture of cells in media with the addition of serum, is very 
likely to induce chromosomal changes (Izadpanah et al., 2008). Therefore, different 
models, such as primary cultures derived from patient biopsies should be considered.  
 
1.2.5.2. Primary prostate epithelial cultures 
Primary cultures derived from prostate cancer tumours and from benign prostatic 
hyperplasia more accurately represent the heterogeneity and complexity of the human 
disease. Moreover, growing primary cells on collagen I-coated plates and in the 
presence of feeder cells mimics the tumour-matrix/stroma interactions. However, 
primary cultures’ limited lifespan in vitro can be a serious limiting factor for performing 
experiments.      
 
1.2.5.3. Mouse models 
The significant role of PTEN loss in prostate cancer progression has influenced the 
development of genetically engineered mice models based on PTEN gene inactivation 
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(De Velasco and Uemura, 2012). However, it has been shown that homozygous 
deletion of PTEN is embryonic lethal, whereas heterozygous PTEN knock-out mice 
develop PIN, but do not progress to malignant adenocarcinoma (Di Cristofano et al., 
1998, Podsypanina et al., 1999). This indicated that inactivation of one allele of PTEN 
was sufficient to induce tumorigenesis, but not prostate cancer progression.   
Several animal models have shown evidence of collaboration between PTEN 
haploinsufficiency and inactivation of other tumour suppressor genes in promoting 
prostate cancer progression (Kwabi-Addo et al., 2001).  
Development of conditional gene targeting by the Cre-LoxP system has expanded the 
opportunities for transgenic mouse modelling research. The main advantage of the 
system is that in the conditional knock-out mice a genetic mutation can be induced in 
specific tissue without affecting other cell types (De Velasco and Uemura, 2012, Anton 
and Graham, 1995, Kanegae et al., 1995) .  
Two of the most frequently used inducible promoters for conditional targeting of the 
mouse prostate include PSACreERT2 and Nkx3.1CreERT2 and are both inducible with 
tamoxifen (Ratnacaram et al., 2008). Importantly, it has been demonstrated that 
prostate-specific conditional PTEN knock-out mice show many similar features to 
human prostate cancer, including histopathological and molecular similarities (Berquin 
et al., 2005)    
 
1.3. The PI3K/AKT/mTOR pathway over-activation in human cancers 
The phosphatydidyl inositol-3-OH kinases (PI3Ks) are a family of proteins involved in 
many cellular processes including: growth, metabolism, proliferation and glucose 
homeostasis. There are three classes in the family: class I, which is divided in to IA and 
IB, class II and class III (Cantley, 2002). Members of class IA are heterodimers consisting 
of a regulatory subunit, with three isoforms: p85α, p85β and p55γ, and a catalytic 
subunit p110 also with three isoforms: α, β and δ. Class IB are also heterodimers which 
consist of p101 – regulatory subunit and a p100γ catalytic subunit (Chalhoub and 
Baker, 2009). PI3K IA are activated by receptor tyrosine kinases (RTKs) and PI3K IB, by 
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G-protein-coupled receptors (GPCRs), which generate lipid second messenger 
phosphatidylinositol (3-5)-triphosphate (PIP3) from phosphatidylinositol 4,5-
biphosphate (PIP2) (Figure 1.10) (Carracedo and Pandolfi, 2008, Meric-Bernstam and 
Gonzalez-Angulo, 2009). PTEN directly opposes the activity of PI3Ks by 
dephosphorylating PIP3 into PIP2 (Chalhoub and Baker, 2009). PIP3 recruits proteins, 
containing pleckstrin homology (PH) domains, such as AKT and phosphoinositide-
dependent kinase 1 (PDK1), to the cell membrane. After conformational change AKT 
gets phosphorylated by constitutively active PDK1 at Threonine 308 and by 
mammalian target of rapamycin complex 2 (mTORC2) at Serine 473 leading to its full 
activation (Sarker et al., 2009). Following activation, AKT translocates from the cell 
membrane to the cytoplasm and the nucleus and phosphorylates downstream targets, 
including the glycogen synthase kinase 3 β (GSK3 β), the tuberous sclerosis 2 (TSC2) 
tumour suppressor, FKHR and FKHRL transcription factors and many others 
(Vanhaesebroeck et al., 2012, Sarker et al., 2009). AKT signalling results in inhibition of 
apoptosis through phosphorylation of pro-apoptotic proteins, such as BAD, MDM2 and 
proteins from the Forkhead family, it also activates proliferation through inactivation 
of p27 and GSK3 (del Peso et al., 1997, Brunet et al., 1999, Carracedo and Pandolfi, 
2008, Sano et al., 2003). Additionally, AKT regulates growth, protein translation 
(through regulation of mTORC1) and metabolism (by increasing rate of glucose 
catabolism) (Sano et al., 2003, Cross et al., 1995). 
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Figure 1.10. The PI3K/AKT/mTOR signalling network. 
Activation of the PI3K pathway leads to phosphorylation of AKT and activates a cascade of 
phosphorylation events which result in increase of survival, proliferation and inhibition of 
apoptosis. Additionally, PI3K/AKT pathway interacts with androgen receptor (AR) signalling; 
upon binding of androgens, AR (which is normally bound to heat shock protein 90 (HSP-90) in 
the cytoplasm) dissociates from HSP-90, which allows phosphorylation of AR at multiple sites. 
AR-androgen complex translocates to the nucleus, binds to androgen response elements on 
promotors of target genes, leading to transcription. Arrows represent activation and bars 
represent inhibition. Taken from (Sarker et al., 2009). 
 
 
 
42 
 
The PI3K pathway has been found to be up-regulated in many human cancers, 
including glioblastoma, breast, ovarian, lung and prostate cancer (Vivanco and 
Sawyers, 2002, Engelman, 2009, Courtney et al., 2010). PI3K can get activated at the 
cell membrane by a number of receptor tyrosine kinases, such as epidermal growth 
factor receptor (EGFR), insulin-like growth factor receptor (IGFR) and platelet derived 
growth factor receptor (PDGFR) (Rameh and Cantley, 1999).  
The PI3K pathway is constitutively activated, and aberrant PI3K signalling is estimated 
to be present in >30% of human cancers (Shaw and Cantley, 2006). It has been 
proposed by Carnero et al (Carnero et al., 2008) that possible biological events leading 
to PI3K pathway increased activation include: 
 amplification of receptor tyrosine kinases 
 amplification of PI3K 
 activating mutations in the PIK3CA gene coding the 
p110α catalytic subunit 
 overexpression of AKT 
 loss or inactivating mutations of the tumour suppressor 
gene PTEN  
 constitutive recruitment and activation of mutant forms 
of the Ras oncogene 
Additionally, it has been shown that in prostate cancer the PI3K and androgen receptor 
signalling pathways regulate each other by reciprocal negative feedback, such that 
inhibition of one activates the other (Carver et al., 2011). Prostate cancer is dependent 
of androgens such as testosterone which activates AR signalling. The AR is a member 
of the steroid hormone receptor family which in the absence of androgens is 
predominantly inactive and localized in the cytoplasm bound to heat shock proteins 
(Figure 1.10). Upon ligand binding AR undergoes conformational changes, dimerization 
and translocates into the nucleus. In the nucleus, AR binds to androgen response 
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elements on promotors of target genes, leading to transcription (Bennett et al., 2010, 
Knudsen and Penning, 2010, Sarker et al., 2009).  
There is evidence indicating that AR signalling continues to contribute to progression 
of CRPC after failure of ADT treatment despite low levels of androgen. A variety of 
possible mechanisms have been proposed to explain this phenomenon (see page 35). 
However, it has also been shown that activation of the PI3K pathway occurs in prostate 
tumours with repressed androgen signalling, which might be responsible for castrate-
resistant phenotype (Carver et al., 2011). Carver and colleagues have demonstrated 
that inhibition of the PI3K pathway restores AR signalling in PTEN-deficient prostate 
cells trough a relief of negative feedback to HER kinases. They have also shown that a 
blockade of AR relieves feedback inhibition of AKT through reduced levels of FKBP5 
which decrease stability of the phosphatase PHLPP. They have demonstrated that a 
combined inhibition of both pathways using an AR blocker MDV3100, that impairs AR 
translocation at the nucleus and binding to DNA and a PI3K/mTOR inhibitor BEZ235 
resulted in a decrease in cell number and activation of apoptosis in PTEN-negative 
LNCaP cells (Carver et al., 2011).  
However, prostate basal cells, unlike luminal cells, do not express high levels of AR and 
are not dependent on androgens for survival (Maitland et al., 2011, Lilja and 
Abrahamsson, 1988, Sar et al., 1990, Kyprianou and Isaacs, 1988, Bonkhoff and 
Remberger, 1993). Therefore androgen signalling was not investigated in this study.  
 
1.3.1. PTEN  
The tumour suppressor gene PTEN, which negatively regulates AKT, is the second 
(after p53) most frequently mutated gene in human cancers (Yilmaz and Morrison, 
2008). PTEN has been implicated in multiple cancers through mutation, homozygous 
deletion, loss of heterozygosity, or epigenetic loss of expression (Mehrian-Shai et al., 
2007). It has been shown that PTEN mutations consist of 49% frameshift mutations, 
30% missense mutations and 15% nonsense mutations. Among the cancers most 
commonly affected by PTEN abnormalities are glioblastoma, prostate and endometrial 
tumours, with frequencies approaching 50% (Sulis and Parsons, 2003).   
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A cluster of six phosphorylation sites (Thr366, Ser370, Ser380, Thr382, Thr383 and 
Ser385), involved in PTEN tumour suppressor function, modulating stability and 
subcellular distribution, has been identified at the C-terminus of PTEN (Figure 1.11 A). 
It has been shown that mutation of the Ser380, Thr382 and Thr383 destabilizes PTEN 
and increases its phosphatase activity, compared to wild-type PTEN (Vazquez et al., 
2000). PTEN is tightly regulated at the transcriptional level, and can be activated by 
EGR1, IGF2, PPARγ, p53 and inhibited by NFκB activation. PTEN mRNA is post-
transcriptionally regulated by miRs (miR21, miR221/222 and miR25) (Figure 1.11). 
PTEN protein is regulated by post-translational modifications, including 
phosphorylation and ubiquitination (Figure 1.11 B) (Zhang and Yu, 2010, Salmena et 
al., 2008, Wang and Jiang, 2008, Carracedo and Pandolfi, 2008). It has been proposed 
that PTEN is normally maintained in a phosphorylated, inactive state and that its 
activation can be mediated through dephosphorylation of Ser380, Thr382 and Thr383 
(Salmena et al., 2008). PTEN biological function includes PIP3 dephosphorylation in the 
membrane, regulation of the cell cycle through CHK1 and maintaining chromosomal 
stability by association with centromeres in the nucleus (Figure 1.11 B) (Zhang and Yu, 
2010). 
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Figure 1.11. Structure and regulation of PTEN. 
Schematic representation of PTEN structure (A), function and regulation (B). 1 – PTEN 
transcription is activated by EGR1, IGF2, p53 etc. and inhibited by MEK-mediated NF-κB 
activation; 2 – PTEN is post-transcriptionally regulated by miRs, including miR21, niR221/222 
and miR25; 3 – phosphorylation of C-terminal domains of PTEN lead to ‘closed’ state of the 
protein and therefore influencing its activity and stability ; 4 – NEDD4-1 is an E3 ligase of PTEN, 
which mediates its mono- and poly-ubiquitination; 5 – HAUSP de-ubiquitinates PTEN in the 
nucleus and leads to PTEN nuclear exclusion; 6 – at the cell membrane PTEN dephosphorylated 
PIP3 and subsequently inhibits PI3K pathway; 7 – PTEN regulates cell cycle; 8 – PTEN associates 
with centromeres in the nucleus and maintains chromosome stability. Taken from (Zhang and 
Yu, 2010). 
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1.3.1.1. PTEN haploinsufficiency in prostate cancer 
It is estimated that pathway up-regulation occurs in 30-50% of primary prostate 
cancers, and its aberrant signalling has also been detected in prostate cancer cell lines 
and xenografts (Morgan et al., 2009). The PTEN gene encodes a dual-specificity 
phosphatase that has activity against lipid and protein substrates (Vivanco and 
Sawyers, 2002). Its tumour suppressive property is attributed to its lipid phosphatase 
activity against phosphatidylinositol (3-5)-triphosphate (PIP3). PTEN dephosphorylates 
PIP3, which inhibits activation of the downstream effector AKT, leading to inhibition of 
cell survival and proliferation (Mehrian-Shai et al., 2007).  
It has been shown by Kremer et al (2006), in immunohistochemistry experiments, on 
prostate tissue that the level of PTEN expression was lower in prostate intraepithelial 
neoplasia (PIN) and prostate cancer compared to normal prostate tissue (Kremer et al., 
2006). Decreased levels of PTEN have also been found to be significantly associated 
with prostate cancer progression. Kinkade and colleagues (2008) investigated the 
expression of PTEN in BPH, PIN, low and high Gleason score prostate cancers. They 
found that levels of PTEN protein were reduced during prostate cancer progression in 
59% of cases (Kinkade et al., 2008).  
It has been shown by Sharrard and Maitland (2000) that there are several splice 
variants of PTEN present in prostate cell lines, mostly involving deletions from the full-
length coding sequence (Figure 1.12) (Sharrard and Maitland, 2000).  
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Figure 1.12. Partial genomic structure of PTEN gene.  
The exons are shown to scale as solid boxes. An open box at the end of exon 8 indicates an 
alternatively spliced segment of intron H forming the 3’ end of PTEN- Δ. The in-frame stop 
codons are marked by asterisks. Taken from (Sharrard and Maitland, 2000); 
 
Two of the model cell lines for metastatic prostate cancer, LNCaP and PC3, were 
shown to lack expression of the PTEN protein; LNCaP cells have a two-base pair 
deletion in codon 6, and PC3 cells have a deletion at the 3’ end of the gene (Sharrard 
and Maitland, 2007). 
 
1.3.2. AKT kinase 
There are three members of the AKT family: AKT1, AKT2 and AKT3, which are broadly 
expressed in most tissues (Zinda et al., 2001). AKT1 (also called protein kinase B) is one 
of the downstream effectors of PIP3, activated by phosphorylation at threonine 308 by 
phosphoinositide-dependent kinase 1 (PDK1) and at serine 473 by the rapamycin-
insensitive mTOR complex (mTORC2) (Guertin et al., 2009). Activated AKT moves from 
the cell membrane to the cytoplasm and the nucleus, and phosphorylates a number of 
downstream targets, including Forkhead family of transcription factors (FOXO), 
glycogen synthase kinase 3 (GSK3) and many other proteins involved in cell survival, 
proliferation and cellular growth (Figure  1.13) (Jiang and Liu, 2008).  
AKT-mediated phosphorylation can also modulate cell function by enhancing the 
activity of proteins such as MDM2, which promotes degradation of the tumour-
suppressor p53 and the nuclear factor-kappa B (NF-κB) (Chalhoub and Baker, 2009). 
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Figure 1.13. AKT kinase signalling. 
Upon activation of the PI3K pathway AKT kinase gets phosphorylated at Thr308 by PDK1 and at 
Ser473 by mTORC2. Fully active AKT phosphorylates multiple downstream substrates including 
pro-apoptotic proteins BAD and BAX protecting cells from apoptosis, GSK3 which leads to 
activation of glycogen synthase and cyclin D1. AKT phosphorylates TSC1 and TSC2, tumour 
suppressors, which are negative regulators of mTORC1 complex leading to increased ribosome 
biogenesis and protein translation. The main outcomes of AKT activity are  increase in survival 
and proliferation, inhibition of apoptosis and cell cycle progression (Sarris et al., 2012).  
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1.3.3. mTOR kinase 
Mammalian target of rapamycin (mTOR) is a serine-threonine kinase that exists in two 
distinct intracellular complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2) 
(Engelman, 2009). Both mTOR complexes have distinct functions and are activated in 
response to different stimuli (Figure 1.14) (Laplante and Sabatini, 2012). 
 
Figure 1.14. Activation and function of mTORC1 and mTORC2. 
The mTORC1 responds to a range of intracellular and extracellular signals, including: growth 
factors, amino acids, stress and energy levels. It controls protein and lipid synthesis and 
autophagy. mTORC2 is mainly responsive to growth factors and its major function is to 
regulate cell survival downstream from AKT. Adapted from (Laplante and Sabatini, 2012). 
 
It has been shown that many cancer-promoting lesions activate the mTORC1 pathway 
(Sabatini, 2006). In response to growth factors and nutrients, mTORC1 regulates cell 
growth through downstream effectors, such as the regulators of translation, namely  
eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and ribosomal S6 
kinase 1 (S6K1). Several negative feedback loops have been detected within the PI3K 
pathway, for example S6K1 represses the PI3K/AKT pathway by inhibiting insulin 
receptor substrate 1 (IRS1) and 2 (IRS2), therefore an active mTORC1 pathway can 
suppress PI3K/AKT signalling (Sparks and Guertin, 2010, Sabatini, 2006). S6K1 is also 
responsible for inhibition of platelet-derived growth factor receptor (PDGFR), which 
similarly to IRS1 and IRS2 also signals through PI3K, thus creating functionally similar 
feedback loop (Zhang et al., 2007). Moreover, it has been shown that inhibition of 
mTORC1 also leads to MAPK pathway activation through a PI3K-dependent feedback 
loop (Carracedo et al., 2008, Efeyan and Sabatini, 2010). The importance of negative 
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feedback loops has been demonstrated in clinical trials with rapamycin; it has been 
shown that mTORC1 inhibitor, rapamycin, increases AKT activation in certain cancers 
including prostate, breast and colorectal carcinoma (O'Reilly et al., 2006). mTORC1 has 
been also shown to promote cell growth by inhibition of autophagy and to negatively 
regulate the biogenesis of lysosomes, which have the ability to degrade a majority of 
cellular components (Laplante and Sabatini, 2012). 
Complex mTORC2 consists of mTOR, GβL, rictor (rapamycin-insensitive companion of 
mTOR) and mSin1 (mitogen-activated-protein-kinase-associated protein 1) and it has 
been shown that it directly phosphorylates AKT at serine 473 (Sarbassov et al., 2006b). 
mTORC2 does not respond to the nutritional status of the cell, but it is activated in 
response to growth factors such as insulin (Laplante and Sabatini, 2012).   
It has been reported by Kremer and colleagues (2006) that the mTOR pathway is 
activated in advanced prostate cancer. The results of their investigation showed that 
expression of mTOR signalling markers increased in PIN and prostate cancer in 
comparison to normal prostate (Kremer et al., 2006). Additionally, it has been shown 
by Guertin et al (2009) that the development of invasive prostate cancer, induced by 
PTEN loss in mice requires mTORC2 activity. They have also shown that rictor, which is 
involved in mTORC2 complex, was required for PC3 cells to form tumours as xenografts 
(Guertin et al., 2009). These studies emphasise mTORC2’s role in promoting 
tumourigenesis, therefore indicating that mTOR might be a good target for anti-cancer 
therapy (Laplante and Sabatini, 2012). 
 
1.4. Ras/MEK/ERK pathway  
The Ras/MEK/ERK pathway is responsible for regulation of many cellular processes 
including proliferation, differentiation, development, survival and also apoptosis (Shaul 
and Seger, 2007). The ability to regulate such variety of cellular processes is achieved 
through a range of mechanisms directing MEK-ERK signals to appropriate downstream 
locations. Integration and direction of signals is mediated through changes in 
subcellular localization, strength and length of signals, interaction with specific 
scaffolds and presence of multiple members of the pathway cooperating in 
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transduction of the signals (Shaul and Seger, 2007, Torii et al., 2004, Yoon and Seger, 
2006).  
The pathway signalling is usually initiated by activation of small G proteins, such as Ras. 
Transmission of signals continues through recruitment to the plasma membrane and 
activation of Raf kinases, followed by activation of MAPK/ERK kinases (MEKs) 
(Wellbrock et al., 2004, Ahn et al., 1991). There are three highly homologous isoforms 
of MEK kinases: MEK1, its alternatively spliced inactive form MEK1b and MEK2. MEKs 
are activated by phosphorylation of two serine (Ser) residues in their activation loop 
(Alessi et al., 1994). However, MEKs’ activity is also regulated by additional 
phosphorylation and dephosphorylation processes. For example phosphorylation of 
Ser386 of MEK1 (by ERKs) can either inhibit or activate ERKs activity. Downregulation 
of MEKs activity is achieved by rapid dephosphorylation of phospho-Ser218 (pSer218) 
and pSer222 by the protein Ser/Thr phosphatase PP2A (Sontag et al., 1993). Activated 
MEKs phosphorylate the regulatory tyrosine (Tyr) and threonine (Thr) residues the ERK 
proteins, ERK1 and ERK2, which leads to their activation (Seger et al., 1992). ERK1 and 
ERK2 proteins are evolutionary conserved products of the two genes erk1 and erk2 
(Boulton et al., 1991). The inactivation of ERKs is achieved by dephosphorylation of 
one or both regulatory Tyr and Thr residues, which can be mediated by either protein 
Ser/Thr phosphatases such as PP2A, protein Tyr phosphatases or dual specificity 
phosphatases MAPK phosphatases (MKPs) (Alessi et al., 1995b, Pulido et al., 1998). 
Additionally, ERKs’ activity is also mediated through their involvement in multiple 
feedback loops including inhibitory phosphorylation of the upstream exchange factor 
SOS, Rafs and MEKs (Dougherty et al., 2005, Shaul and Seger, 2007). It has been shown 
that upon stimulation, ERKs phosphorylate large number of substrates, which are 
localized in cytoplasm and also in the nucleus (Yoon and Seger, 2006). It has also been 
demonstrated that ERKs phosphorylate and activate several transcription factors 
including p53, Ets1/2, c-Fos and Elk1 (Shaul and Seger, 2007).  
ERK1 and ERK2 are very similar proteins with about 70% similarity between them 
(Boulton et al., 1991). They are both expressed in all types of tissues, they share 
cellular localization, substrates and similar activation kinetics, indicating similar 
functions of the two isoforms (Shaul and Seger, 2007, Boulton et al., 1991). However, it 
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has been demonstrated that differences exist between ERK1 and ERK2. It has been 
shown that ERK1 participates in MEKs signalling during G2M phase and ERK2 seems to 
be essential during the G1 phase of the cell cycle (Shaul and Seger, 2007, Liu et al., 
2004). Moreover, ablation of ERK1 has been shown to promote cell proliferation in 
Ras-dependent proliferation in fibroblasts, whereas ERK2 knockdown has been shown 
to block this effect, which indicates that ERK1 and ERK2 are not functionally redundant 
molecules (Vantaggiato et al., 2006).      
 
1.5. Cross-talk between the PI3K/AKT/mTOR and the Ras/MEK/ERK 
pathway in prostate cancer 
The PI3K/AKT/mTOR and the RAS/MEK/ERK pathways are the two most frequently 
over-activated pathways, with mutated components, that promote cancer progression 
by increasing survival of the cancer cells (Yuen et al., 2012).  
The RAS/MEK/ERK signalling cascade has been shown to be frequently activated in 
advanced prostate cancer, which is often coordinated with aberrant activity of  
PI3K/AKT/mTOR signalling (Gioeli et al., 1999, Kinkade et al., 2008). It has been 
demonstrated that combinatorial inhibition of these pathways inhibits CRPC in 
Nkx3.1;Pten mutant mice (Kinkade et al., 2008). 
The PI3K and the ERK pathways are known to interact at multiple points, which can 
lead to cross-activation or cross-inhibition as well as pathway convergence (Figure 
1.15) (Mendoza et al., 2011).  
In case of cross-activation, a member of one pathway positively regulates an upstream 
component of another pathway resulting in increased activity of that pathway. For 
example, Ras-GTP can directly bind and allosterically activate PI3K; an over-activated 
ERK can also phosphorylate TSC2 at sites distinct from those phosphorylated by AKT, 
leading to increased activation of mTORC1 (Rodriguez-Viciana et al., 1994, Zoncu et al., 
2011).   
Cross-inhibition takes place when a member of one pathway negatively regulates an 
upstream component of another pathway, thereby inhibiting the other pathway’s 
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signalling. For example, during strong IGF1 stimulation, AKT is able to inhibit ERK 
activation by phosphorylating inhibitory sites of the regulatory domain of RAF 
(Zimmermann and Moelling, 1999).  
A phenomenon of pathway convergence takes place when members of two or more 
signalling pathways act directly on the same protein or complex. For example, the AGC 
kinases, namely RSK, AKT and S6K often phosphorylate the same substrates, which 
include FOXO3A and c-Myc transcription factors, BAD and GSK3, to promote cell 
survival, proliferation and motility (Yang et al., 2008, Manning and Cantley, 2007).   
Inhibition of only one pathway has proven not to be sufficient for treatment of cancer 
due to the existence of feedback loops and cross-talk between pathways (Grant, 2008, 
Turke et al., 2012, Yuen et al., 2012). Single agent inhibition of PI3K or MEK kinase in 
tumours driven by activated or amplified RTKs results in a compensatory increase in 
activity of ERK or AKT, respectively (Turke et al., 2012). Therefore a combined targeting 
of the PI3K/AKT/mTOR and the Ras/MEK/ERK pathways has been proposed as an 
alternative approach to target tumour cells, in a range of different cancers, including 
multiple myeloma (MM), melanoma and prostate cancer (Steinbrunn et al., 2012, 
Gioeli et al., 2011, Kinkade et al., 2008).  
In multiple myeloma inhibition of the PI3K pathway alone was shown to induce 
apoptosis in cell lines and in primary MM samples. However, a combined blockade of 
PI3K and MAPK pathway resulted in significantly enhanced cell death in the majority of 
primary samples (Steinbrunn et al., 2012). Moreover, combination of the mTOR 
inhibitor, rapamycin and MEK inhibitor, PD325901, induced growth inhibition of 
androgen-responsive (CWR22Rv1 and CASP 2.1) and androgen-independent (CASP 1.1) 
prostate cancer cell lines (Kinkade et al., 2008, Gioeli et al., 2011).   
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Figure 1.15. The PI3K/AKT/mTOR and Ras/MEK/ERK pathways interactions. 
Activated receptor tyrosine kinases (RTKs) recruit and activate PI3K, which leads to membrane 
recruitment and activation of PDK1 and AKT. PDK1 together with mTORC2 phosphorylate AKT, 
which in turn triggers a downstream cascade of phosphorylation events. The mammalian 
target of rapamycin is present in two distinct complexes: mTORC1 and mTORC2. Activated 
RTKs can also activate Ras and subsequently Raf, MEK1/2 and ERK1/2. ERK1/2 can in turn 
phosphorylate a number of transcription factors and other signalling proteins leading to 
increased cell survival. Inhibition of mTORC1, and subsequently S6K, can lead to a relief of 
inhibitory activity of S6K on RTKs therefore increasing signalling through PI3K or Ras.   
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1.6. Development of the PI3K/AKT/mTOR and the Ras/MEK/ERK pathway 
inhibitors 
The main negative regulator of PI3 kinase activity is the tumour suppressor PTEN, 
which dephosphorylates PIP3 to PIP2. In advanced prostate cancer, PTEN is frequently 
lost and therefore the PI3K signalling pathway becomes over-activated. The first 
generation of pan-PI3K inhibitors: LY294002 and wortmannin, which inhibit the p110 
catalytic subunit, were shown to be active in prostate cancer cell lines. However, 
because of their high toxicity and poor pharmaceutical properties they have been 
restricted to preclinical studies (Yap et al., 2008). Treatment of LNCaP, PC3 and DU145 
cells with LY294002 caused cell cycle arrest, decreased invasive properties and 
sensitized the cells to radiation (Shukla et al., 2007, Gottschalk et al., 2005). 
Wortmannin, which is a fungicide originally isolated from soil, is an irreversible 
inhibitor of PI3K (Powis et al., 1994). It has been demonstrated that treatment of 
LNCaP and PC3 cells decreased phospho-AKT levels, and also induced apoptosis and 
radiosensitized DU145 cells (Lin et al., 1999, Seol et al., 2005). 
 
1.6.1.1. AKT kinase inhibitors 
AKT kinase phosphorylates up to 100 substrates and is involved in regulating many 
cellular processes, such as proliferation (by inhibition of GSK3 and p27), apoptosis (by 
inhibiting of FOXO proteins and pro-apoptotic proteins BAD and MDM2), metabolism 
and survival (Crowell et al., 2007, Carracedo and Pandolfi, 2008). AKT-specific 
inhibitors include: 
- agents that target plekstrin homology domain  
- the ATP-binding pocket molecules 
- allosteric inhibitors  
- pseudosubstrates (Crowell et al., 2007) 
Perifosine is a plekstrin homology domain inhibitor, which has been shown to inhibit 
growth and induce cell cycle arrest of PC3 cells and also differentiation of PC3 and 
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LNCaP cells through activation of the GSK3β pathway (Floryk and Thompson, 2008). 
GSK690693 is an example of an ATP competitive kinase domain inhibitor, which 
prevents substrate phosphorylation by AKT. It has been demonstrated that GSK690693 
inhibits proliferation of PC3 and DU145 cells in vitro and also inhibits growth of LNCaP 
tumours in vivo (Rhodes et al., 2008). However, due to lack of oral bioavailability it was 
withdrawn from development in phase I trials. MK-2206 is an allosteric inhibitor of AKT 
that binds to the region, which interacts with the PH and kinase domains, and prevents 
translocation of AKT to the cell membrane and its activation. It has been shown that 
MK-2206 in combination with RTK inhibitors (erlotinib and lapatinib) inhibited cell 
proliferation in breast cancer cell lines and caused tumour regression in xenograft 
models of breast and ovarian cancer (Hirai et al., 2010). Moreover, a combination of 
MK-2206 with different chemotherapeutic agents such as topoisomerase inhibitors 
(doxorubicin, camptothecin), antimetabolites (gemcitabine, 5-fluorouracil), anti-
microtubule agents (docetaxel) and DNA cross-linker (carboplatin) resulted in 
induction of apoptosis and reduced levels of phospho-S6 in breast cancer cell line 
HCC70 (Hirai et al., 2010).   
 
1.6.1.2. mTOR kinase inhibitors 
The first generation of mTOR inhibitors are derivatives of rapamycin – “rapalogs” that 
specifically inhibit the mTORC1 complex, examples include RAD001 (everolimus), CCI-
779 (temsirolimus) and ridaforolimus (Meric-Bernstam and Gonzalez-Angulo, 2009). 
The mechanism of action of rapamycin involves FK506-binding protein (FKBP12) which 
targets the FKBP12-rapamycin-binding domain adjacent to the catalytic site of the 
mTOR protein (Choi et al., 1996). A number of studies have shown that mTORC2 is 
rapamycin insensitive, however, it has also been shown that long-term exposure to 
rapamycin can also inhibit mTORC2 and that it is tissue specific (Sarbassov et al., 
2006a). Rapamycin treatment decreased levels of phosphorylated substrates of mTOR 
(S6K and 4EBP1) and also induced cell cycle arrest in PC3 and DU145 cells (Gao et al., 
2003). It has been demonstrated that temsirolimus and everolimus both inhibited the 
growth of PC3 and DU145 cells in a dose-dependent manner in vitro, and reduced 
tumour volumes in PC3 and DU145 xenografts (Wu et al., 2005).  
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The second generation of mTOR inhibitors targeting the ATP site of the kinase domain 
of mTOR, are able to block both mTORC1 and mTORC2 complexes (Vilar et al., 2011). 
Some of these second generation compounds have dual activity against PI3K and 
mTOR, which is due to the fact that their catalytic domains are structurally similar 
(Courtney et al., 2010). Dual PI3K-mTOR inhibitors disable both inputs to AKT:  PI3K-
PDK1 and mTORC2, and may bypass feedback loops. An example of dual PI3K-mTOR 
inhibitors is NVP-BEZ235. NVP-BEZ235 has been shown to reversibly block the p110α 
catalytic subunit of PI3K and mTOR (Maira et al., 2008). Treatment with NVP-BEZ125 
has resulted in a significant decrease in phosphorylation levels of mTORC1 substrates, 
S6K1 and 4E-BP1, and mTORC2 target AKT, and higher antiproliferative effect than 
everolimus in BT474 breast cancer cells and in xenografts derived from them (Serra et 
al., 2008).  However, this broad inhibition can also be toxic to normal cells (Janes et al., 
2010).  
 
1.6.1.3. MEK inhibitors 
A number of MEK inhibitors have been developed and are currently being tested for 
the treatment of cancer (clinicaltrials.gov). Both MEK1 and MEK2 have unique inhibitor 
binding sites located on a hydrophobic pocket adjacent to the ATP-binding site, which 
allows a design of highly specific compounds (Ohren et al., 2004). Additionally, specific 
targeting of MEK1/2 is possible due to the fact that ERK1 and ERK2 are the only well-
described downstream targets (Chappell et al., 2011).  
The first MEK inhibitor to enter clinical trials was PD-184352. However, despite being 
able to inhibit phospho-ERK in patients, phase II clinical trials performed on patients 
with wide range of solid tumours did not show expected efficacy, which was probably 
due to its high metabolism (Sebolt-Leopold, 2008). An improved MEK inhibitor, 
PD0325901, showed higher bioavailability and increased potency against MEK as well 
as greater metabolic stability (Sebolt-Leopold, 2008, McCubrey et al., 2012a).  
Selumetinib (AZD6244) has been shown to be a potent, selective and ATP-
uncompetitive inhibitor of MEK1/2 kinases (Davies et al., 2007). It has been suggested 
that binding of the AZD6244 inhibitor may lock MEK1/2 kinases in an inactive 
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conformation, which would not prevent binding of ATP and substrate. However, it has 
been confirmed that despite increased phospho-MEK1/2 levels, the activity of ERK 
remained at comparable level to vehicle control (Davies et al., 2007).     
It has been shown that MEK1/2 inhibitor, AZD6244, induced G1/S cell cycle arrest in 
colon and melanoma cell lines and also increased caspase-3 and caspase-7 expression 
(McCubrey et al., 2012a). Importantly, it has been demonstrated that AZD6244 
showed higher efficiency in suppressing the tumour growth of pancreatic cancer in 
immunocompromised mice than standard chemotherapeutic drug, gemcitabine. 
However, once the treatment was discontinued, the tumours reappeared (McCubrey 
et al., 2012b).  
 
1.6.2. Preclinical assessment of the candidate compounds 
The development of successful treatment strategy for advanced prostate cancer has 
been challenging due to heterogeneity of the disease. A large number of prospective 
therapeutics are currently being tested in clinical trials. However, in order to identify 
and validate an effective drug, relevant preclinical models of prostate cancer are 
needed (De Velasco and Uemura, 2012). 
A combined approach of cell culture in vitro and animal studies is essential in 
predicting the efficacy of novel anti-cancer treatments in human clinical trials 
(HogenEsch and Nikitin, 2012). The use of well characterised cell lines enables 
determination of the efficacy, pharmacodynamics and mechanism of action of novel 
drugs in highly controlled, reproducible conditions. However, it has been 
demonstrated in a number of studies that gene expression and DNA methylation 
patterns in cancer cell lines are significantly different from human primary tumours 
and xenografts derived from them (Houshdaran et al., 2010, Hennessey et al., 2011).    
 It has been reported by pharmaceutical companies that less than 1% of drugs entering 
drug development process succeeds in achieving drug approval (Kola and Landis, 2004, 
De Velasco and Uemura, 2012). The drug development process (Figure 1.16) consists 
of: 
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 Drug research 
 Preclinical assessment based on cell cultures and animal studies 
 Clinical trials:  
o Phase I, healthy volunteers  
o Phase II, determining drug safety and dosing in patients 
o Phase III, testing efficacy and adverse events in patients 
 Evaluation and approval 
 Phase IV studies 
The process of drug approval takes on average 12 years and costs over 1 billion 
pounds. The most common reason for drug failure is lack of efficacy in Phase II and 
Phase III trials, which has been attributed to unpredictable preclinical models (De 
Velasco and Uemura, 2012, Suggitt and Bibby, 2005).   
 
 
Figure 1.16. Drug development process. 
A schematic representation of an approval process of a new drug. Taken from (http://venture-
pharmaceuticals.com/what-is-drug-development/olddrugs2/). 
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1.7. Compounds used in this study 
The inhibitors used in this study include AKT inhibitor AZD7328 (AKTi), mTOR inhibitor 
Ku-0063794 (mTORi), MEK1/2 inhibitor AZD6244 (MEKi) and an additional MEK1/2 
inhibitor RO-5126766 (RO-512). AKT and mTOR inhibitors are pro-compounds, which 
have not been tested in the clinical trials. Whereas, both MEK1/2 inhibitors are 
currently undergoing clinical assessment in either Phase I (RO-512) or Phase II (MEKi). 
Table 1.2. A list of inhibitors used in this study. 
Compound Target Type of 
inhibition 
Clinical Trial References 
AKT inhibitor 
AZD7328 
AKT1 
AKT2 
AKT3 
ATP-
competitive 
N/A (Dickstein et al., 
2012) 
mTOR 
inhibitor 
Ku-0063794 
mTORC1 
mTORC2 
ATP-
competitive 
N/A (Garcia-Martinez 
et al., 2009) 
MEK1/2 
inhibitor 
AZD6244 
MEK1 
MEK2 
Non-ATP 
competitive 
Currently in 
Phase II 
(Davies et al., 
2007) 
MEK1/2 
inhibitor 
RO-5126766 
MEK1 
MEK2 
Non-ATP 
competitive 
Phase I study 
completed 
(Ishii et al., 2013) 
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1.8. Aims of research 
 
There is no effective cure for advanced prostate cancer. Current treatment strategies 
based on androgen deprivation therapy and chemotherapy fail in the majority of 
prostate cancer patients. Therefore, there is an urgent need for new therapeutic 
approaches. A number of studies have demonstrated that the PI3K/AKT/mTOR 
signalling pathway is over-activated in advanced prostate cancer and its activity is 
correlated to enhanced tumour growth and emergence of castration resistant prostate 
cancer (CRPC) (Kinkade et al., 2008, McMenamin et al., 1999). Therefore targeting of 
the pathway might be an effective treatment for patients with advanced prostate 
cancer and potentially for patients with CRPC.     
The main aim of this project was to investigate the PI3K/AKT/mTOR signalling in 
prostate cancer and to determine the effect of novel small molecule inhibitors on the 
signal transduction within the pathway. 
The objectives of the research were to: 
- determine the PI3K/AKT/mTOR pathway activity in prostate cell lines in 
comparison to clinical tumour samples from prostate cancer patients 
 
- explore the effect of inhibition of AKT and mTOR kinase on proximal and distal 
signalling molecules of the pathway in prostate cell lines and in primary 
prostate cultures 
 
- determine cell fate of cancer stem-like cells following therapeutic intervention 
in primary tumour cultures   
 
- investigate the role of the PI3K/AKT/mTOR pathway activity on tumour 
outgrowth and tumour initiation frequency using ‘near-patient’ xenograft 
models of prostate cancer 
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Chapter 2 
Materials and 
methods 
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2. MATERIALS AND METHODS 
2.1. Mammalian cell culture 
2.1.1. Maintenance of cell lines 
Human prostate cell lines used in the experiments included: BPH1, P4E6, LNCaP and 
PC3 cells (Table 2.1). All cell lines were purchased from American Type Culture 
Collection (ATCC, USA), or the European Collection of Animal Cell Culture (ECACC, UK), 
except for P4E6, which were derived in our laboratory (Maitland et al., 2001). BPH1 
and LNCaP cells were cultured in Roswell Park Memorial Institute-1640 (RPMI) 
(Invitrogen) supplemented with 5% or 10% Foetal Calf Serum (FCS) (PAA), respectively, 
and 2 mM L-Glutamine (Invitrogen). PC3 cells were cultured in Ham’s F-12 medium 
(Lorza) supplemented with 7% FCS and 2 mM L-Glutamine. P4E6 cells were cultured in 
Keratinocyte Serum-Free Medium (KSFM) (Invitrogen) supplemented with 2% FCS, 2 
mM L-Glutamine, 5 ng/ml Epidermal Growth Factor (EGF), 50 μg/ml bovine pituitary 
extract (Invitrogen). All cell lines were cultured in T25 or T75 cell culture flasks 
(Corning) at 37°C in 5 % CO2.  
 
Table 2.1. Human prostate cell lines. 
Cell 
line 
Description Growth 
medium 
Reference 
BPH1 Derived from Human benign prostate 
hyperplasia immortalised with SV-40  
RPMI + 5% FCS (Hayward et al., 
1995) 
P4E6 Human prostatic cell line derived from early 
stage, well differentiated prostate cancer; 
Immortalised with retrovirus HPV16 E6 
KSFM + 2% FCS (Maitland et al., 
2001) 
LNCaP Androgen-dependent human prostate cancer 
cell line, derived from lymph node metastasis 
RPMI + 10% 
FCS 
(Horoszewicz et 
al., 1983) 
PC3 Androgen-independent human prostate 
cancer cell line, derived from bone metastasis 
HAMS F12 + 7% 
FCS 
(Kaighn et al., 
1979) 
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2.1.2. Isolation and culture of primary epithelial cells 
Prostate tissue was obtained from patients undergoing radical prostatectomy or 
transurethral resection of the prostate, with informed patient consent and approval 
from the York Research Ethics Committee. All patient samples were anonymized.  
Patient tissues were chopped with a disposable scalpel (Swann Morton) and digested 
with 200 IU/mg collagenase (Lorne Laboratories) dissolved in 2.5 ml Keratinocyte 
Serum-Free Medium (KSFM with 5 ng/ml human EGF and 50 µg/ml bovine pituitary 
extract supplements (Invitrogen)) and 5 ml Roswell Park Memorial Institute-1640 
medium (RPMI, Invitrogen), supplemented with 100 IU/ml antibiotic/antimycotic 
solution containing 100 IU/ml Penicillin, 100 μg/ml Streptomycin, and 0.25 μg/ml 
Fungizone (ABM, Invitrogen) and 2 mM L-Glutamine (Invitrogen) overnight at 37°C, 
with shaking at 80 RPM. The digested tissue was then triturated by passing through a 5 
ml pipette and 21G blunt needle (Kendall Tyco Healthcare) and centrifuged at 2000 
RPM for 10 min to sediment cells. Two washing steps with PBS were performed to 
wash out the collagenase; the supernatant was removed, 10 ml PBS was added, the 
cell pellet was re-centrifuged at 2000 RPM for 10 min and the procedure repeated. 
Organoids were separated from the stromal cells by differential centrifugation at 800 
RPM for 1 minute. The pellet consisting of the acini-containing epithelial cells were 
treated with 5 ml 0.05% trypsin-EDTA for 30 min at 37°C in an orbital shaker at 80 
RPM. Trypsin-EDTA was inactivated with R10 medium, and epithelial cells centrifuged 
at 1500 RPM for 3 min.  
 
2.1.2.1. Isolation of subpopulations from primary prostate 
epithelial cells 
Primary prostate epithelial cultures were grown on collagen I-coated plates and then 
harvested using 0.05% trypsin-EDTA. Collagen I-coated 10 cm dishes were blocked with 
0.3% bovine serum albumin (BSA) in PBS, (denatured by heating at 80°C for 5 minutes) 
for 1 hour at 37°C before the cell suspension was added. To isolate CB cells (40min+ 
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fraction) a suspension of cells was incubated (on the blocked plates) for 40 minutes at 
37°C and the non-adherent cells collected by washing the plates with PBS. The 
adherent cells (stem cells and TA cells) were collected by 0.05% trypsin-EDTA. Trypsin 
was neutralized with R10 or D10 medium, and the suspension of cells was washed in 
PBS before resuspending in stem cell medium. Stem cells were then isolated by 
selecting for CD133 by MACS cell sorting according to the manufacturer’s instructions 
(Miltenyi Biotec). Briefly, the cells were resuspended in 300 μl magnetic-activated cell 
sorting (MACS) buffer (2 mM EDTA, 0.5% (v/v) FCS in PBS), 100 µL FcR blocking reagent 
(Miltenyi Biotec) and 100 µL CD133 beads (Miltenyi Biotec) at 4C for 30 min. Cells 
were then washed with MACS buffer, centrifuged at 1500 RPM for 5 minutes, 
resuspended in 500 μl MACS buffer and added to a pre-prepared MS column. The 
column was washed three times with 3 ml MACS buffer to collect the CD133- fraction, 
followed by collection of CD133+ cells which were eluted from the beads with a 
plunger. To increase the purity of the CD133+ population from 70-75% to 95%, the 
procedure was repeated by passing the CD133+ cells over a second MS column. Three 
populations of cells were isolated: α2β1
low cells (committed basal), α2β1
high CD133- 
(transit amplifying) and α2β1
high CD133+ (stem cells) and resuspended in SCM for 
further use.  
 
2.1.3. Preparation of feeder cells by Irradiation  
Mouse STO fibroblasts were trypsinized and centrifuged at 1500 RPM for 3 minutes, 
they were then resuspended in 10 ml SCM per 100 cm2 of culture surface and treated 
with a radiation dose of 60 Gy. Radiation-inactivated STO cells were resuspended in 
KSFM medium (with 5 ng/ml human EGF and 50 µg/ml bovine pituitary extract 
supplements) (Invitrogen) and stored at 4°C for up to 5 days before use. This 
procedure was routinely performed by Mrs. Caty Hyde.  
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2.1.4. Determination of live cell number using a haemocytometer 
Trypan Blue exclusion was used to determine viable cells by adding 0.4% Trypan Blue 
Stain (Sigma) to a suspension of cells in a  1:1 ratio. Total cell number (blue and non-
stained cells) and live cell number (non-stained cells) were counted using a 
haemocytometer (Neubauer).   
 
2.1.5. Determination of viable cell number using the Vi-Cell cell 
viability analyser 
Trypsinized cells were centrifuged at 1500 RPM for 3 minutes and cell pellets were 
resuspended in 500 μl PBS and analysed on a Vi-Cell Cell Viability Analyser (Beckman 
Coulter). The average number of total and viable cells was determined from 50 images.  
 
2.1.6. Determination of proliferation using MTS assay 
The CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega) was used 
to determine changes in the proliferation of viable cells following treatment. Cells 
were seeded onto 24-well plates and once plated (24 hours later) an MTS reagent 
(tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt) was added at 70 μl per well, where it was 
then bioreduced by cells into a formazan product during a 2-hour incubation at 37°C at 
5% CO2. The absorbance of the formazan was measured at 490 nm directly from the 
plates on the microplate reader POLARstar Optima (BMG Labtech). The quantity of 
formazan product is directly proportional to the number of living cells in culture.    
 
2.2. Transfection of cell lines with siRNA 
DharmaFECT 2 transfection reagent (Thermo Scientific) was used to transfect cell lines 
with scrambled (Ambion, ID:4390843), PTEN (Cell Signaling Technology, #6538) and 
GAPDH-Cy3 conjugated siRNA (Life Technologies, ID:AM4649). BPH1 and P4E6 cells 
were seeded onto 6-well plates 24 hours prior to transfection. A 50 μM working stock 
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siRNA solution was prepared in RNase-free double distilled water (ddH2O). In separate 
tubes siRNA (tube 1) and DharmaFECT 2 (tube 2) were diluted into OptiMEM reduced 
serum medium (Fisher Scientific Ltd) in a polystyrene tube, gently pipetted to mix and 
incubated at room temperature for 5 min. Tubes 1 and 2 were combined, gently mixed 
by pipetting and incubated at room temperature for 20 min. R10 (BPH1) or K2 (P4E6) 
culture medium was added to the mix and the mixture was added to the cells. The final 
concentration of siRNA was 20 nM. The cells were incubated with siRNA solution for 72 
h and 96 h, and then they were collected for mRNA and protein analysis.   
 
2.3. Treatment of mammalian cells with inhibitors 
2.3.1. Treatment of cell lines with AKT and mTOR inhibitors 
Cell lines were seeded onto 6-well plates or 10 cm dishes 24 hours prior to treatment. 
Cells were treated with increasing concentrations (0.01 μM to 50 μM) of AKT and 
mTOR inhibitors dissolved in dimethyl sulfoxide (DMSO) either alone or in combination 
for up to 72 hours. The vehicle control was made up in DMSO and did not exceed 0.5%.  
 
2.3.2. Treatment of primary cultures with AKT, mTOR and MEK 
inhibitors 
Primary cells were seeded onto collagen I-coated 10 cm dishes, 24 hours prior to 
treatment. Cells were treated with increasing concentrations (0.1 μM to 50 μM) of 
AKT, mTOR or MEK inhibitors either alone or in combination: AKT + MEK and AKT + 
mTOR for up to 72 hours. Control cells were treated with DMSO, as above. 
 
2.4. Isolation and analysis of cell RNA 
2.4.1. RNA extraction 
RNA extraction was performed using RNeasy Mini kit (Qiagen) according to the 
manufacturer’s protocol. Cells were resuspended in 350 μl RTL buffer and the lysate 
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was added onto a Shredder column and centrifuged at 13 000 RPM for 2 minutes to 
remove cell debris. An equal volume of 70% ethanol was added to the flow through 
and the suspension was added to a binding column. RNA was eluted from the binding 
column by washing three times with RNase-free water. RNA concentration was 
measured using a Nanodrop spectrophotometer and the RNA stored at -80°C.  
 
2.4.2. cDNA synthesis 
Total RNA (~1 μg) was reverse transcribed using 1 μl RNase OUT (Invitrogen) and 1 μl 
Oligo (dT)12-18 (Invitrogen) in a total volume of 9.5 μl and heated to 70°C for 10 min. 
The Reaction mix, consisting of 4 µl, 5 x First strand buffer (Invitrogen), 2 µl of 0.1 M 
DTT (Invitrogen), 2 µl of 10 mM dNTPs (Invitrogen), 0.5 µl RNase OUT and 1 µl of 
Superscript II enzyme (Invitrogen), was added to the mixture and incubated at 45°C for 
2 hours. Complementary DNA (cDNA) was purified by ethanol (EtOH) precipitation, by 
the addition of 15 µl of 3 M NaCl and 120 µl of 100% EtOH and stored at -80°C, for 30 
min. Samples were centrifuged at 13,000 RPM for 10 min in a benchtop centrifuge and 
the supernatant removed. The pelleted cDNA was washed in 100 µl of 70% EtOH and 
re-centrifuged at 13,000 RPM for 5 min. The supernatant was removed; the pellet was 
dried and then resuspended in 30 µl DEPC-treated ddH2O. Synthesized cDNA was 
stored at -20°C. 
 
2.4.3. Reverse Transcription polymerase chain reaction  (RT-PCR) 
Reverse transcription polymerase chain reaction (RT-PCR) was performed using a 1 in 
10 dilution of cDNA synthesized using the method described in section 2.4.2. PTEN 
primers, forward: 5' GAGGATGGATTCGACTTAGA 3' and reverse: 5’ 
CCTTTTTGTCTCTGGTCCTTAC 3’, flanking the region between exon 1 and 5 of the PTEN 
coding sequence were previously described in (Sharrard and Maitland, 2007). cDNA 
was added to a PCR reaction mix containing: 2.5 μl  10 μM forward and reverse 
primers, 1.5 μl 25 mM MgCl2 (Promega), 0.2 μl 25 mM dNTPs, 5 μl 5 x Go Taq Buffer 
(Promega), 0.2 μl 5 U/μl GoTaq polymerase (Promega). cDNA integrity was confirmed 
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using GAPDH primers, forward: 5’ CCTCCCGCTTCGCTCTCT 3’ and reverse: 5’ 
GCTGGCGACGCAAAAGA 3’. The standard PCR programme was used: 
94°C for 2 minutes 
94°C for 30 seconds 
60°C for 30 seconds                     25 cycles 
72°C for 30 seconds 
72°C for 2 minutes 
The reaction was carried out using a GeneAmp PCR System 9700 thermal cycler 
(Applied Biosystems). 
PCR products were visualized on a 1% (w/v) agarose (Invitrogen) gel together with a 
100 base pair (bp) marker (Invitrogen) to assess product sizes using GeneGenious UV 
transilluminator (Syngene).  
 
2.4.4. Quantitative RT- PCR (qRT-PCR) 
RNA was extracted from cells as described in section 2.4.1. and cDNA synthesis was 
performed as described in section 2.4.3. Quantitative RT-PCR was performed in a total 
volume of 20 μl per well using 2 μl 1 in 10 dilution cDNA, 1 x TaqMan PCR mastermix 
(AB Applied Biosystems), 1 x TaqMan gene expression assay (AB Applied Biosystems). 
Samples were run in triplicate on a C1000 Thermal Cycler (CFX96 Real Time System, 
Biorad). Gene expression levels were normalized to the housekeeping gene human 
ribosomal protein, large, P0 (RPLP0).  
 
2.5. Protein expression analysis 
2.5.1. SDS-PAGE and Western blotting 
2.5.1.1. Preparation of whole cell lysates 
 
70 
 
Adherent and non-adherent cells were harvested, centrifuged at 1500 RPM for 3 
minutes and resuspended in 120 μl Cytobuster protein extraction reagent (Novagen) 
with the addition of protease inhibitor cocktail (Roche) and phosphatase inhibitor 
cocktail (Roche). The cells were incubated at room temperature for 5 minutes, then 
centrifuged at 13 000 RPM for 5 minutes and the supernatant was collected and stored 
at -80°C for further analysis.    
 
2.5.1.2. Determination of protein concentration using the 
Bicinchoninic acid (BCA)  assay 
Whole cell protein lysates were quantified using the Bicinchoninic acid assay (BCA) 
protein assay kit (Thermo Scientific), according to manufacturer’s instructions. Briefly, 
10 µl of BSA standards, or unknown samples, were pipetted in triplicate into a 96 well 
plate. 200 µl working reagent was added to each well, and the plate was incubated at 
37°C for 30 min. The absorbance was read at 562 nm on a POLARstar OPTIMA 
microplate reader (BMG Labtech). A standard curve of BSA samples was prepared to 
determine the protein concentration of the test samples.  
 
2.5.1.3. SDS-PAGE gel electrophoresis 
20 μg protein lysate (in a volume of 30 μl) was added to 4 x SDS loading buffer (10% 
(v/v) glycerol, 62.5 mM Tris-HCl pH 6.8, 1% (w/v) SDS, 65 mM DTT and bromophenol 
blue to colour), and heated to 100°C for 10 min in a Grant QBD2 heating block (Grant). 
The samples were then centrifuged for 15 seconds to collect the contents. Samples 
were loaded onto 10% Tris-SDS acrylamide gels using the mini-PROTEAN Tetra Cell 
system (Biorad). Precision plus kaleidoscope (Biorad) and biotinylated (Cell Signaling 
Technology) protein markers were used to determine molecular weights of the 
separated proteins. Gels were run at 80 volts (V) for approximately 2 hours in SDS 
running buffer (25 mM Tris, 0.19 M Glycine, 3.5 mM SDS).  
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2.5.1.4. Western blotting 
Resolved proteins were immediately transferred onto Immobilon-P membrane 
(Millipore) pre-treated with methanol at 60 V for 2 hours (or 40 V overnight at 4°C) in 
transfer buffer (48 mM Tris, 39 mM Glycine, 10% (v/v) Methanol). Membranes were 
air-dried for storage, re-wet using methanol and washed three times with 0.1% Tris-
buffered saline – Tween 20 (TBS-T: 150 mM NaCl, 50 mM Tris/HCl, pH 7.5, 0.1% (v/v) 
Tween20). Membranes were then blocked with 10% blocking reagent (Roche) 
prepared in TBS-T for 1 hour at room temperature, followed by incubation with 
primary antibodies (Table 2.2) at 4°C for 2 hours or overnight. Membranes were 
washed three times with TBS-T, then blocked with 10% blocking reagent for 30 
minutes, followed by incubation with peroxide-labelled secondary antibodies for 1 
hour at room temperature. Membranes were washed three times with TBS-T and 
chemiluminescent detection was performed using the BM Chemiluminescence Blotting 
Substrate (POD) system (Roche). Labelled proteins were visualised using ECL Hyperfilm 
(Amersham) and manually processed using Kodak GBX developer and fixer solutions 
(SLS).   
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Table 2.2. List of antibodies used in western blotting experiments. 
Antibody Clone Species/ 
Isotype 
Working 
dilution 
Manufacturer Catalogue 
number 
AKT (pan) C67E7 Rabbit IgG 1:1000 Cell Signaling 
Technology 
4691 
Phospho-AKT 
(Thr308) 
C31E5E Rabbit IgG 1:1000 Cell Signaling 
Technology 
2965 
Phospho-AKT 
(Ser473) 
D9E 
XPTM 
Rabbit IgG 1:2000 Cell Signaling 
Technology 
4060 
Cleaved caspase – 3 
(Asp175) 
N/A Rabbit 
polyclonal 
1:1000 Cell Signaling 
Technology 
9661 
Cleaved PARP 
(Asp214) 
N/A Rabbit 
polyclonal 
1:1000 Cell Signaling 
Technology 
9541 
4E-BP1 N/A Rabbit 
polyclonal 
1:1000 Cell Signaling 
Technology 
9452 
Phospho-4E-BP1 
(Thr37/46) 
236B4 Rabbit IgG 1:1000 Cell Signaling 
Technology 
2855 
LC3 B N/A Rabbit 
polyclonal 
1:3000 abcam ab51520 
p44/42 MAPK 
(ERK 1/2)  
137F5 Rabbit IgG 1:1000 Cell Signaling 
Technology 
4695 
Phospho-p44/42 
MAPK (ERK 1/2) 
(Thr202/Tyr204) 
D13.14.
4E XPTM 
Rabbit IgG 1:2000 Cell Signaling 
Technology 
4370 
PRAS40 D23C7 
XPTM 
Rabbit IgG 1:1000 Cell Signaling 
Technology 
2691 
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Phospho-PRAS40 
(Thr246)  
C77D7 Rabbit IgG 1:1000 Cell Signaling 
Technology 
2997 
PTEN D4.3 
XPTM 
Rabbit IgG 1:1000 Cell Signaling 
Technology 
9188 
S6 Ribosomal 
Protein  
5G10 Rabbit IgG 1:1000 Cell Signaling 
Technology 
2217 
Phospho-S6 
Ribosomal Protein 
(Ser235/236) 
N/A Rabbit 
polyclonal 
1:1000 Cell Signaling 
Technology 
2211 
β – actin  AC-40 Mouse IgG 1:5000 Sigma A4700 
Anti-rabbit IgG 
HRP linked 
N/A N/A 1:5000 Cell Signaling 
Technology 
7074 
Sheep – anti – 
mouse IgG POD 
N/A N/A 1:5000 Boehringer 1500686 
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2.5.1.5. Stripping western blots 
The membranes were stripped in stripping buffer (20 mM Tris-HCl pH 6.8, 0.1% (w/v) 
SDS and 20 mM DTT) for 30 min at 55°C, with shaking and washed three times in 0.1% 
TBS-T. The membranes were blocked and re-stained, as detailed above, with β-actin 
antibody as an internal control to ensure equal loading of protein and to obtain 
quantitative protein expression intensities using Image J software (National Institutes 
of Health, http://rsbweb.nih.gov/ij/). 
 
2.5.2. Flow cytometry 
2.5.2.1. Detection of intracellular antigens 
For detection of intracellular antigens either primary prostate cells or tumour cells 
from xenografts were used. Primary cells were harvested after treatment with the 
inhibitors using 0.05% Trypsin-EDTA and tumour xenografts were firstly depleted of 
mouse cells using the method described in section 3.1.3.1. Harvested cells were 
washed once with MACS buffer and stained with 1:1000 LIVE/DEAD Fixable Violet 
Dead Cell Stain (Invitrogen, L34955) for 15 to 30 minutes at 4°C. Cells were then fixed 
in 4% PFA (w/v) for 10 minutes at 37°C followed by permeabilisation with ice-cold 
100% Methanol while vortexing to prevent clustering of cells. After 30 minutes’ 
incubation on ice, cells were washed with 0.5% BSA, centrifuged at 1500 RPM for 3 
minutes and then labelled with primary antibodies (Table 2.3) for 1 hour at room 
temperature. Cells were then washed with 0.5% BSA and incubated with secondary 
antibody for 30 minutes at room temperature. Following staining, cells were washed 
once with MACS buffer, resuspended in 1 ml and analysed on the Cyan ADP flow 
cytometer (Dako Cytomation). Results were analysed using Summit v4.3 software.    
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Table 2.3. List of antibodies used in flow cytometry experiments. 
Antibody Clone Species / 
Isotype 
Working 
dilution 
Manufacturer Catalogue 
number 
CD24-PE 32D12 Mouse 
IgG1 
1:10 Miltenyi Biotec 130-098-
861 
CD44-FITC DB10
5 
Mouse 
IgG1 
1:10 Miltenyi Biotec 130-098-
210 
Phospho-AKT 
(Ser473) 
D9E 
XPTM 
Rabbit IgG 1:100 Cell Signaling 
Technology 
4060 
Phospho-S6 
(Ser235/236) 
N/A Rabbit IgG 1:50 Cell Signaling 
Technology 
2211 
Phospho-ERK1/2 
(Thr202/Tyr204) 
D13.1
4.4E 
XPTM 
Rabbit IgG 1:200 Cell Signaling 
Technology 
4370 
Anti-Rabbit Alexa 
Fluor 488 
N/A Goat 1:300 Invitrogen A-11034 
Cytokeratin 18 FITC 
conjugated (CK-18) 
CY-90 Mouse IgG 1:10 Sigma C8541 
 
The staining was analysed using the following gates: 1) FSlin/SSlin dot plot which 
depicts granularity and cell size, 2) pulse width to exclude doublets and cell debris and 
3) Violet 1 log histogram to exclude dead cells which were labelled with LIVE/DEAD 
stain. Additional gates were set to the secondary only control and the fluorescence 
was measured using FITC log histogram on the FITC (488nm) channel.   
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2.5.2.2. Cell cycle analysis 
Cell lines and primary prostate cells were used for cell cycle analysis following 
treatment. Cells were trypsinized, centrifuged and resuspended in 0.5 ml PBS. To fix 
cells, 2.5 ml ice-cold 70% Ethanol was added drop wise to the cell suspension while 
vortexing, to prevent clustering of cells. Cells were incubated on ice for 30 minutes, 
then centrifuged, washed with 5 ml PBS and centrifuged again before resuspending the 
cells in 400 μl PBS. 50 µl RNase A (1 mg/ml final concentration) and 50 µl propidium 
iodide (PI; 400 µg/ml final concentration) was added and cells were incubated at 37°C 
for 30 min. Cells were then placed on ice, analysed on a CyAn ADP flow cytometer 
(Dako Cytomation) and PI fluorescence was recorded in the PE channel. To prevent 
bleaching of the fluorescence, cells were protected from light where possible during 
the procedure. 
The results were analysed using the Summit v4.3 software. To select the cell 
population of interest a gate was set in an FSlin/SSlin (R1) histogram, which allowed 
exclusion of cell debris. Additional gates were set up in the PE channel and these 
included: cells in G0/G1 phases (R2), S phase (R3), G2M phases (R4) and also apoptotic 
cells (R5). For statistical significance, at least 20,000 events were collected.   
 
2.5.3. Immunofluorescence  
Immunofluorescence was performed in BD-Biocoat collagen I-coated 8-well chamber 
slides (BD Bioscience). Primary prostate cells were seeded at a density of 7.5 x 104 per 
well and incubated at 37°C at 5% CO2 for 24 hours before treatment. Cells were 
washed twice with PBS and fixed with 4% (w/v) PFA for 15 minutes at room 
temperature. Cells were washed twice with ice-cold PBS and then permeabilised with 
0.25% Triton X-100 in PBS for 10 minutes. Cells were washed a further three times with 
PBS, and then incubated with blocking buffer (10% (v/v) (goat) serum diluted in PBS 
containing 0.3 M glycine) for 30 minutes to block nonspecific binding of the secondary 
antibodies. Following blocking, the cells were incubated with primary antibody in 
blocking buffer at 4°C overnight (Table 2.4).  
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Cells were washed three times with PBS, incubated in blocking buffer for 30 minutes at 
room temperature and then incubated with a secondary antibody diluted in blocking 
buffer, for 1 hour at room temperature, and protected from light. After a final three 
washes with PBS, the chambers were removed from the slides, mounted in Vectashield 
containing DAPI (Vector laboratories) and glass cover slips added. Cover slips were 
sealed with clear nail varnish and stored at 4°C until analysis on a Nikon Eclipse TE300 
fluorescent microscope (Nikon). Secondary only antibodies, where the primary 
antibody was replaced with PBS, were used as controls. 
 
Table 2.4. List of antibodies used in Immunofluorescence 
Antibody Clone Species / 
Isotype 
Working 
dilution 
Manufacturer Catalogue 
number 
LC3 B N/A Rabbit 
polyclonal 
1:2000 abcam ab51520 
Cytokeratin 18 
FITC conjugated 
(CK-18) 
CY-90 Mouse IgG 1:100 Sigma C8541 
Anti-Rabbit 
Alexa Fluor 488 
N/A Goat 1:300 Invitrogen A-11034 
 
2.5.4. β-Galactosidase assay staining 
Cells were seeded onto 10 cm dishes and following treatment a β-Galactosidase assay 
(Cell Signaling, #9860) was performed as an indicator of senescence.  Briefly, cells were 
washed once with PBS and fixed for 15 minutes at room temperature, washed twice 
with PBS, and then incubated with β-Galactosidase staining solution, at pH 6.1, 
overnight at 37°C in a dry incubator. The staining results were analysed using an Evos 
XL transmitted light microscope (AMG) at 10x and 20x magnification.  
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2.6. Functional analysis 
2.6.1. Wound healing assay 
Following treatment of semi-confluent cells, a scratch was created in the cell 
monolayer with a 1 ml pipette tip. The cells were then washed with PBS and fresh 
medium was added to the wells. Cell migration into the wound was monitored over 
time and 10 x images were taken on an Evos XL transmitted light microscope (AMG) at 
0 hours, 2 hours  and 10 hours after wounding and the percentage of wound closure 
was calculated. The width of the wound at 0 and 10 hours was measured, the average 
(of 10 points) taken and the relative percentage wound closure at 10 hours with 
respect to 0 hours was calculated. 
 
2.6.2. Clonogenic recovery assay 
Primary prostate cancer cells were treated with AKTi and mTORi as described in 
section 2.3.2. Following treatment, the cells were selected for α2β1
hi/CD133+ (SC), 
α2β1
hi/CD133- (TA) and α2β1
low (CB) cells as described in section 2.1.2.1.  The sorted 
fractions were subsequently plated at 100 cells per well, diluted in 2 ml SCM, in a 6 
well collagen-I coated plate, in triplicate. Irradiated STOs were added (to a 
concentration that resulted in a confluent monolayer) and plates were incubated at 
37°C in 5% CO2. The number of STOs was evaluated following plating so that a 
confluent monolayer was achieved. Medium was changed every 2 days and STOs were 
added when required. When colonies greater than 32 cells (5 population doublings) 
started to appear, medium was removed and cells were washed with 1 ml PBS. The 
cells were then fixed with 2 ml crystal violet stain (1% (w/v) crystal violet, 10% (v/v) 
ethanol and 89% (v/v) PBS) and the number of colonies counted visually under the 10 x 
objective of a Leica DM IL LED microscope (Leica Microsystems). The percentage 
colony forming efficiency (CFE) was calculated, by dividing the number of colonies by 
the number of cells plated and multiplying by 100.  
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2.7. In vivo studies 
2.7.1. Generation and maintenance of xenografts 
Tissue from serially-transplantable Xenografts of primary prostate cancer, derived in 
our laboratory, was used in these experiments. Immune-compromised RAG2-/-γC-/- 
mice were used to generate the xenografts.   
 
2.7.1.1. Depletion of mouse endothelial and lineage positive 
blood cells 
15 mm3 tumours were removed from humanely euthanized mice and placed in 
transport medium (R10 + ABM + 10 nM DHT).  The tumour was then placed in a Petri 
dish, washed with PBS, and digested in 200 IU/ml collagenase. The collagenase was 
dissolved in 7.5ml of R10 and was filter sterilised prior to use. Tumour was finely 
chopped with a disposable scalpel and the tissue suspension was placed in an 
Erlenmeyer flask for digestion overnight in an orbital shaker at 37°C at 80 RPM. After 
overnight digestion, the cell suspension was transferred into a universal and further 
triturated by passing through a 21G blunt needle, followed by centrifugation at 1200 
RPM for 2 minutes. Collected cells were washed with 10 ml PBS and centrifuged for a 
further 2 minutes at 1200 RPM. The pellet was resuspended in 10 ml 0.05% 
Trypsin/EDTA and incubated at 37°C for 30 minutes, after which R10 was added to 
inactivate trypsin and cells were centrifuged at 1300 RPM for 5 minutes. The cell pellet 
was resuspended in 15 ml R10 and passed through a 40 μm cell strainer (BD 
Biosciences). In order to further separate viable cells from dead cells and tissue debris, 
density centrifugation was performed using Ficoll-Paque Plus (MP Biomedicals). 15 ml 
of Ficoll-Paque solution was slowly placed underneath the cell suspension and 
centrifuged at 1800 RPM for 30 minutes with the brake turned off. The cells at the 
interface of the Ficoll-Paque Plus and cell dissociation buffer were collected, an equal 
volume of R10 was added and the cell suspension centrifuged at 1300 RPM for 10 
minutes. The cell pellet was resuspended in 80 μl MACS buffer, 20 μl anti-mouse biotin 
antibody cocktail (Miltenyi Biotec), and 5 μl CD31 biotin antibody (AbD serotec) and 
incubated at 4°C for 10 minutes using MACSmix Tube Rotator. After the incubation, 60 
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μl MACS buffer and 40 μl anti-biotin Microbeads (Miltenyi Biotec) were added and 
cells were further incubated at 4°C for 15 minutes on the rotator. The cell suspension 
was washed with 4 ml MACS buffer, resuspended in 500 μl MACS buffer and added 
onto a pre-wetted LS column. The column was washed three times with 3 ml MACS 
buffer and the elute of LIN-CD31- cells was collected for further use.      
 
2.7.1.2. Ex vivo treatment and re-engraftment of prostate 
tumour cells 
Xenograft tumours were depleted of mouse endothelial and lineage positive blood 
cells as described in section 2.7.1.1. LIN-CD31- tumour cells were resuspended in D10 
medium placed into 10 cm collagen I – dishes and treated. Following treatment, the 
cells were counted and limiting dilutions prepared (10 000 cells to 1 cell). The required 
cell number was placed into a 1.5 ml Eppendorf tube and 2 x 105 irradiated STO cells 
were added. The cell suspension was centrifuged at 2000 RPM for 2 minutes. The cell 
pellet was resuspended in 50 μl Ice-cold Matrigel basement membrane complex (BD 
Biosciences) and kept on ice. The cells were injected subcutaneously, using a 1 ml 
insulin syringe (27G) (BD Biosciences) into both flanks of a Rag2-/-γC-/- mouse. The 
surgical procedures were carried out under general anaesthesia (2.5% Isoflurane 
(Abbott)) and prior to surgery mice were administered 4.5 mg/kg Rimadyl (Pfizer) as a 
local anaesthetic. Mice were monitored weekly for tumour growth. Once the tumours 
were detectable they were measured every 2-3 days using a digital calliper (Duratool 
DC150). Tumour volume (mm3) was calculated using the ellipsoidal formula: (length x 
width2)/2. Tumour initiation frequency was calculated using Extreme Limiting Dilution 
Analysis software available online at (http://bioinf.wehi.edu.au/software/elda/), which 
provided an estimate of frequency with 95% confidence intervals and includes the 
Pearson’s chi-square test for pairwise analysis to determine differences between 
treatment groups.  
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2.7.2. Preparation of Xenograft tumour tissue blocks and sections 
Prostate tissue from xenografts was fixed in 10% (v/v) formalin for at least 24 hours 
and then transferred to 70% ethanol. The tissue was then placed in an embedding 
cassette (Cell Path+ address) and submerged in fresh 70% ethanol for 10 minutes, 
followed by incubation in absolute ethanol for 10 minutes, which was repeated two 
more times. The cassette was then submerged into fresh isopropanol for two x 10 
minutes and submerged in fresh xylene (Fisher Scientific) for four times 10 minutes, 
after that the excess xylene was removed. The cassette was placed into Histoplast 
Paraffin at 60 - 65˚C (Thermo Scientific) for four x 15 minutes, followed by embedding 
in moulds with molten wax. The samples were allowed to set on a cold plate at -10˚C. 
Paraffin-embedded sections of tissues were prepared using APES-coated (2% 
(3’aminopropyl triehoxysilane) (v/v) (Sigma) in acetone) SuperFrost Plus slides (Merck), 
sections were cut using a microtome to a thickness of 5 µM. These procedures were 
carried out by Mrs. Caty Hyde.  
 
2.7.3. Haematoxylin & eosin (H&E) staining 
Tumour tissue sections embedded in paraffin, as described in section 3.7.4. dewaxed in 
xylene for two x 10 minutes and two x 1 minute, followed by rehydration with absolute 
ethanol at three x 1 minute and then one x 1 minute with 70% ethanol.   
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3. RESULTS I 
3.1. PTEN expression in human prostate cell lines 
The phosphatase and tensin homologue gene (PTEN) codes for a negative regulator of 
the PI3K/AKT/mTOR pathway and is the most frequently deleted tumour suppressor 
gene in prostate cancer (Bitting and Armstrong, 2013). 
PTEN expression was determined at the mRNA level in several human prostate cell 
lines including BPH1 (derived from benign prostatic hyperplasia), P4E6 (from well 
differentiated prostate cancer), LNCaP and PC3 (from metastatic prostate cancer). The 
results showed expression of PTEN in all cell lines apart from PC3 (Figure 3.1 A and B), 
suggesting that the PI3K axis might be over-activated in only those cells. However, 
western blotting, to determine protein expression, showed that PTEN is expressed in 
BPH1 and P4E6, but not in the metastatic cell lines, LNCaP and PC3 (Figure 3.1 C).  
To determine the PI3K/AKT/mTOR pathway activity in prostate cell lines, western 
blotting, of selected phospho-biomarkers, was performed. Phosphorylation levels of 
AKT (at Ser473) and ribosomal protein S6 (at Ser235/236) (indicative of AKT kinase and 
mTOR kinase activity, respectively) were analysed, as well as total AKT and total S6 
protein levels (Figure 3.1 C). As expected, the results demonstrate higher expression of 
phospho-AKT in the PTEN-negative cell lines in comparison to BPH1 and P4E6, 
suggesting higher activity of the PI3K/AKT pathway. Additionally, the presence of a 
double band in PC3 cells may indicate phosphorylation of AKT kinase at both Thr308 
and Ser473. However, phospho-S6 was mainly expressed in BPH1 and PC3 cells, 
indicating that mTOR kinase activity does not directly correlate with PTEN expression. 
Levels of total S6 varied between the cell lines, with the lowest expression in P4E6 and 
LNCaP, unlike total AKT, which was comparable across all analysed cell lines.  
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Figure 3.1. Expression of PTEN, AKT and S6 in human prostate cell lines.  
mRNA expression of PTEN was measured using RT-PCR (A) and qRT-PCR (B). Total RNA was 
extracted, followed by reverse transcriptase PCR and cDNA synthesis. GAPDH expression was 
assessed to confirm cDNA integrity. Protein expression of PTEN, phospho-AKT (S473), total 
AKT, phospho-S6 (S235/236) and total S6 was determined using western blotting (C). Whole 
cell lysates were prepared and 20 µg of protein was loaded per lane onto a 10% SDS gel, 
electrotransferred onto PVDF membranes and stained for the biomarkers indicated. Staining 
for β-actin was used as a loading control. ND – not detected. 
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3.2. Knock down of PTEN using siRNA 
To determine if the PI3K/AKT/mTOR pathway can be activated following knock down 
of PTEN expression, siRNAs to PTEN were used in the cell lines BPH1 and P4E6. PTEN 
knock down was confirmed at both the mRNA (Figure 3.2 A), by qRT-PCR, and protein 
level (Figure 3.3), by western blotting. Transfection efficiency for PTEN siRNA, 
determined by cy3-conjugated GAPDH siRNA, used at the same concentration (of 20 
nM), was 80-90% (Figure 3.2B). The results show that 24-hour treatment with siRNA 
resulted in approximately 70% knock-down of PTEN expression, in BPH1 cells and 
approximately 88% in P4E6 cells. The level of PTEN decreased further and reached over 
85% knock down after 96 hours, relative to non-selective siRNA, in both cell lines 
(Figure 3.2 A).  
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Figure 3.2. PTEN knock down in human prostate cell lines.  
BPH1 and P4E6 cells were treated with PTEN siRNA at 20nM or a scrambled control for up to 
96 hours. Subsequently total RNA was extracted, reverse transcribed and subjected to qRT-PCR 
and PTEN mRNA levels were determined (A). Transfection efficiency was determined using 
GAPDH cy3-conjugated siRNA at 20nM. (B) Phase contrast images (top panel) and 
immunofluorescent images (bottom panel) were taken at x40 magnification and show P4E6 
and BPH1 cells transfected with Cy3-conjugated GAPDH siRNA.  
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3.2.1. Phospho-AKT expression is increased following PTEN down 
regulation 
In order to determine if PTEN knock down was sufficient to activate the 
PI3K/AKT/mTOR pathway, expression of PTEN, phospho-AKT (Ser473) and phospho-S6 
(Ser235/236) proteins was determined by western blotting. The results showed a 
decrease in PTEN expression at 72h and 96h in BPH1 (89% and 99.8%, respectively) 
and P4E6 (87.3% and 97.4%, respectively) cells relative to controls (Figure 3.3 A and B). 
Moreover, a dramatic increase in expression of phospho-AKT was observed in both cell 
lines in response to PTEN knock down. In BPH1 cells phospho-AKT levels increased by 
97.9% at 72h and by 99.1% at 96h, and in P4E6 cells by 98.3% at 72h and by 91.8% at 
96h.  
Following PTEN knock down, the levels of phosphorylated ribosomal protein S6 
decreased in BPH1 cells by 38.3% (after 72h) and 70.7%  (after 96h) and in P4E6 cells 
by 88.7% and 100% after 72 and 96h, respectively (Figure 3.3 B).   
This result demonstrates that knock down of PTEN was sufficient to activate the PI3K 
pathway signalling.   
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Figure 3.3. Knock down of PTEN protein in BPH1 and P4E6 cells.  
BPH1 and P4E6 cells were treated with 20nM of PTEN siRNA (or a scrambled control) for up to 
96 hours; cell pellets were subsequently collected at four time points: 24h, 48h, 72h and 96h. 
Whole cell lysates were prepared, quantified and subjected to western blotting. Activation of 
the PI3K pathway was determined by analysis of phospho-AKT (Ser473) and phospho-S6 
(Ser235/236) expression following 72-hour and 96-hour incubation with PTEN siRNA (A). 
Quantification of protein expression was determined and was normalized to β-actin (B); ND – 
non detectable protein levels, C – control, KD – knock down;   
 
  
 
89 
 
3.2.2. Knock down of PTEN increases cell migration  
A wound healing assay was performed using PTEN siRNA-treated BPH1 cells in order to 
determine if knock down of PTEN influenced cell migration. Confluent monolayers of 
cells were wounded and the process of healing observed under phase contrast 
microscopy at x10 magnification. The width of the wound was measured at the 
beginning of the experiment (T0), after 2 hours and at the end of experiment – after 10 
hours of healing (T10). The rate of migration was calculated using the following 
equation (1-T10 /T0) x 100.  
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Figure 3.4. Wound healing assay following a PTEN knock-down in BPH1 cells.  
BPH1 cells were treated with a 20nM PTEN siRNA and non-selective (scrambled) siRNA for 72 
hours. The monolayer was then scratched and left to recover. Phase contrast images were 
taken at 0, 2 and 10 hours and the migration rate calculated. Single red arrows point at the 
wound and three arrows indicate where the wound used to be before it healed. The scale bar 
represents 400μm.  
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There was a significant difference (p = 7.8 x 10-9) in wound healing process between 
the scrambled control, where only 28.8% increase in wound closure was observed,  
and PTEN siRNA with nearly complete wound closure (98.8%) 10 hours after wounding. 
The result of the assay indicates that cells treated with PTEN siRNA have an increased 
rate of migration (by 3.4 fold) relative to control cells (non-selective siRNA) (Figure 
3.4).  
 
3.3. Treatment of cell lines with the AKT and mTOR inhibitors 
The efficacy of the AKT kinase inhibitor (AKTi) and the mTOR kinase inhibitor (mTORi), 
two ATP-competitive small molecule inhibitors, was tested in human prostate cell lines 
(BPH1, P4E6, LNCaP and PC3) over a wide range of concentrations (0.01 – 30 μM) and  
for up to 72 hours. Morphological and density changes following treatment with an 
AKT inhibitor and mTOR inhibitor were determined. 
Two PTEN-positive (BPH1 and P4E6) and two PTEN-negative (LNCaP and PC3) cell lines 
were treated with increasing concentrations of AKTi and mTORi. Phase contrast images 
were taken after 72 hours’ treatment, to determine the effect on morphology and 
density of the cells.  
A concentration of 10 μM of AKTi did not affect BPH1, P4E6 or PC3 cell morphology 
(Figure 3.5 and Figure 3.6), but a decrease of approximately 10% in PC3 cell density 
was observed (Figure 3.6). In contrast, changes in cell morphology were observed in 
LNCaP cells (following AKTi treatment at 1 μM) from an elongated to rounded shape 
(Figure 3.6). Following treatment with 10 μM AKTi almost all of the LNCaP cells 
detached from the dish (Figure 3.6, top panel - enlarged image).      
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Figure 3.5. Cell morphology and density changes after treatment with AKTi of BPH1 and P4E6 
cells.  
Phase contrast images showing BPH1 (right) and P4E6 cells (left) treated with 0.1, 1 or 10 μM 
of the AKT inhibitor for 72 hours. Vehicle control cells were treated with 0.1% DMSO. The scale 
bar represents 400 μm. 
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Figure 3.6. Cell morphology and density changes after treatment with AKTi of LNCaP and PC3 
cells.  
Phase contrast images showing LNCaP (right) and PC3 cells (left) treated with 0.1, 1 or 10 μM 
of the AKT inhibitor for 72 hours. Vehicle control cells were treated with 0.1% DMSO. The scale 
bar represents 400 μm.  
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Treatment with 10 μM mTORi (for 72 hours) resulted in a decrease in cell density in all 
cell lines analysed (Figure 3.7 and Figure 3.8). The highest drop in density was 
observed in LNCaP cells. Additionally, LNCaP cells were the only cell line which showed 
changes in morphology (from elongated to round shape) and detached from the dish 
(Figure 3.8, enlarged image). PC3 cells were also affected by treatment, but less so 
than LNCaP whereas BPH1 and P4E6 were the least affected - around 20-30% decrease 
in cell density, when treated with 10 μM mTOR inhibitor (Figure 3.7 and Figure 3.8). 
Concentrations of 0.1 and 1 μM of the compound did not affect morphology or density 
of any analysed cell lines.    
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Figure 3.7. Cell morphology and density changes after treatment with mTORi of BPH1 and 
P4E6 cells.  
Phase contrast images showing BPH1 (right) and P4E6 cells (left) treated with 0.1, 1 or 10 μM 
of the mTOR inhibitor for 72 hours. Vehicle control cells were treated with 0.1% DMSO. The 
scale bar represents 400 μm.  
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Figure 3.8. Cell morphology and density changes after treatment with mTORi of LNCaP and 
PC3 cells.  
Phase contrast images showing LNCaP (right) and PC3 cells (left) treated with 0.1, 1 or 10 μM 
of the mTOR inhibitor for 72 hours. Vehicle control cells were treated with 0.1% DMSO. The 
scale bar represents 400 μm.  
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3.3.1. AKTi and mTORi affects the viability of cell lines 
The AKT and mTOR kinases are crucial regulators of cell growth, proliferation and 
survival. An MTS assay, which gives an indication of a cells metabolic activity, which is 
indirectly proportional to cell number, was performed to investigate if AKTi and mTORi 
affect cell viability.  
Two PTEN-positive (BPH1 and P4E6) and two PTEN-negative (LNCaP and PC3) cell lines 
were treated with increasing concentrations (0.01 – 30 μM) of AKTi and mTORi, for up 
to 48 hours. Cell viability was assessed at 24 hours and 48 hours after treatment. The 
results showed a dose-dependent decrease in cell viability in all analysed cell lines 
(Figure 3.9). LNCaP cells were the most sensitive, to both inhibitors with an EC50 (50% 
viability effective concentration) of 0.5 μM (AKTi) and 0.9 μM (mTORi) (Figure 3.9 B). 
Although PC3 cells showed a similar sensitivity to the mTORi, they were 30 fold less 
sensitive to the AKTi (15.2 μM) (Figure 3.9 B). 
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Figure 3.9. Decrease in cell viability following incubation with AKTi and mTORi.  
An MTS assay was performed on a panel of prostate cell lines including BPH1, P4E6, LNCaP and 
PC3 cells treated (in triplicate) with increasing concentrations of AKTi and mTORi for 48 hours. 
(A) The results are expressed relative to vehicle control. (B) Summary of EC50s for all analysed 
cell lines. Vehicle cells were treated with 0.3% DMSO.   
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Although treatment with AKTi reduced viability of both PTEN-negative cell lines, the 
PTEN-positive cells lines (BPH1 and P4E6) were not affected by AKT inhibition. 
Moreover, the EC50 for the mTORi were approximately 5 – 10 fold higher for BPH1 and 
P4E6 in comparison to LNCaP and PC3 (Figure 3.9 B).  
Taken together, these results suggest that AKTi and mTORi’ ability to reduce cell 
viability is dependent on PTEN status.  
 
3.3.2. Cell migration decreased after treatment with AKTi and mTORi  
A wound healing assay was performed to determine if treatment with AKT and mTOR 
inhibitors affected cell migration. LNCaP and PC3 cells were grown in 6-well plates to 
confluence, and then a scratch was made in the cell monolayer and drug solutions 
subsequently added. Based on the EC50 for both cell lines, a concentration of 1 μM was 
chosen. Cells were treated with either 1 μM mTORi or 1 μM AKTi and control cells 
were treated with 0.01% DMSO. Images were taken at 0, 2, 24 and 96 hours after 
wounding. The rate of migration was calculated using the following equation (1-T24 or 96 
/T0) x 100. The data are presented as mean ± SD. 
The cancer cell line LNCaP showed a slower migration rate in comparison to PC3 cells 
and therefore the wound was left to heal for up to 96 hours. LNCaP cells treated with 1 
μM AKTi showed a 94.3% wound recovery rate relative to vehicle control, but this was 
not significant (p value = 0.64) (Figure 3.10 A). However, treatment with 1 μM mTORi 
significantly affected migration with a decrease of 23% relative to control (p value = 3.4 
x 10-5).  
The wound healing process was significantly faster in PC3 cells compared to LNCaP 
cells. However, treatment with 1 μM AKTi did not affect cell migration (Figure 3.10 B). 
In contrast, the mTORi – treated cells healed significantly slower, with a reduction in 
the rate of healing 28% less that vehicle control (p value = 0.006).  
Taken together, the results showed that 1 μM mTORi was sufficient to significantly 
inhibit cell migration in both cancer cell lines (Figure 3.10 C).  
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Figure 3.10. Migration rate of LNCaP (A) and PC3 (B) cells following incubation with AKT and 
mTOR inhibitors.  
Cell monolayer was wounded, 1 μM solution of AKTi and mTORi were added and phase 
contrast images were taken at 0h, 2h, 24h and 96h. Migration rates of the cells were calculated 
relative to the vehicle control (set as 100%) (C). Vehicle control cells were treated with 0.1% 
DMSO. The scale bar represents 400 μm. 
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3.3.3. Phospho-biomarker expression is decreased following treatment 
with AKT and mTOR inhibitors 
Cell lines were treated with increasing concentrations of the mTOR inhibitor (0.01 – 10 
µM) for 2, 24 and 72 hours, to determine the effect on proximal and distal biomarkers 
of the pathway, including AKT and S6. Phosphorylation of AKT was determined at 
Ser473 (mTORC2 substrate) and phosphorylation of ribosomal protein S6 was 
determined at Ser235/236 (an indirect substrate of mTORC1). The direct substrate of 
mTORC1, p70S6K, was not investigated in this analysis due to detection of nonspecific 
proteins by the antibody used to detect p70S6K.  
Following a 2-hour exposure to the mTOR inhibitor, PC3 cells showed a dose-
dependent decrease in phospho-AKT (88% inhibition at 3 μM) and phospho-S6 levels 
(60% inhibition at 1 μM) (Figure 3.11 A). However, when incubation with the drug was 
extended to 24 and 72 hours, the inhibitory effect was achieved mainly at the highest 
concentration (10 μM) (Figure 3.11 B and C); a 60% inhibition was observed for p-AKT 
at 24 hours and over 93% at 72 hours. A 50% inhibition of S6 phosphorylation was 
achieved at 0.1-0.3 μM concentration of the mTOR inhibitor at 24 hours and over 75% 
at 10μM following 72-hour incubation (Figure 3.11 C).     
  
 
103 
 
 
Figure 3.11. Changes in phospho-biomarker expression in PC3 cells following treatment with 
increasing concentrations of mTORi.  
Cells were treated with 0.01 – 10 μM mTORi for 2h (A), 24h (B) and 72h (C). Whole cell lysates 
were subsequently prepared and 20 μg of protein was loaded per lane onto a 10% SDS gel, 
electrotransferred onto PVDF membranes and stained with antibodies against phospho-AKT 
(Ser473), total AKT, phospho-S6 (Ser235/236), total S6 and β-actin (loading control). (D) 
Schematic illustration of the PI3K/AKT/mTOR pathway showing mTOR inhibition.    
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PTEN-positive cell lines, BPH1 and P4E6, as well as LNCaP (PTEN-negative), were also 
treated with increasing concentrations of mTORi, for 72 hours. Expression of 
downstream biomarkers, phospho-AKT and phospho-S6, were determined by western 
blotting. The results showed a dose-dependent decrease of phospho-AKT in BPH1 and 
LNCaP cells following treatment. The levels of phospho-AKT (mTORC2 substrate) 
decreased to 58% of control levels after treatment with 0.1 μM mTORi in BPH1 cells 
(Figure 3.12 A). Similarly, a concentration of 0.3 μM decreased phospho-AKT levels to 
47% in LNCaP cells (Figure 3.12 C). However, an unexpected dose-dependent increase 
in phosphorylation of S6, at Serine 235/236, was observed in P4E6 cells (Figure 3.12 B). 
A significant decrease in phospho-S6 expression in all of the cell lines was only 
observed after treatment with 10 μM mTORi.  
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Figure 3.12. Phospho-biomarker expression following treatment with mTORi.  
BPH1 (A), P4E6 (B) and LNCaP (C) cells were treated with 0.01 – 10 μM mTOR inhibitor for 72 
hours. Whole cell lysates were subsequently prepared and 20 μg of protein was loaded per 
lane onto a 10% SDS gel, electrotransferred onto PVDF membranes and stained with 
antibodies against phospho-AKT (Ser473), total AKT, phospho-S6 (Ser235/236), total S6 and β-
actin (loading control). Each cell line was treated at least twice and the representative blot was 
quantified using Image J software. 
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3.3.3.1. The efficacy of AKTi and mTORi differs across a panel 
of prostate cell lines  
The efficacy of AKTi and mTORi was determined in a panel of prostate cell lines using 
phospho-biomarkers expression by western blotting. Following a 72-hour incubation 
with the AKTi, a significant increase in phosphorylation of AKT at Serine 473 was 
detected in all the analysed cell lines (Figure 3.13 A). Additionally, an unexpected 
increase in the levels of phospho-PRAS40, an indicator of AKT kinase activity, was 
observed in P4E6 (4 fold increase) and in LNCaP cells (2 fold increase) relative to the 
vehicle control (Figure 3.13 A and B).  
Treatment with AKTi also resulted in a 20% decrease and 50% increase of phospho-ERK 
in P4E6 and LNCaP cells, respectively, whereas in PC3 phospho-ERK remained 
unchanged (Figure 3.13 A and B). Moreover, cleaved caspase-3, an indicator of 
apoptosis, was also detected in cells treated with AKTi.  
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Figure 3.13. Biomarkers expression in prostate cell lines following treatment with AKTi. 
P4E6, LNCaP and PC3 cells were treated with 1 μM AKTi for 72 hours. Following treatment, 
whole cell lysates were prepared and 20 μg of protein was loaded per lane onto a 10% SDS gel, 
electrotransferred onto PVDF membranes and stained with phospho-AKT (Ser473), total AKT, 
phospho-PRAS40 (Thr246), total PRAS40, phospho-ERK (Thr202/Tyr 204), cleaved caspase 3 
(Asp 175) and GAPDH (loading control) (A). Relative expression of the phospho-biomarkers was 
determined and quantified against the loading control GAPDH (B). A schematic representation 
of the pathway illustrating AKT inhibition (C). 
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Treatment with 1 μM mTOR inhibitor showed a decrease in phospho-S6 of 63% and 
phospho-4EBP1 of 12%, biomarkers downstream from mTORC1, in LNCaP cells relative 
to vehicle control (Figure 3.14 A). Additionally, PC3 cells showed a decrease in 
phospho-4EBP1 (21%) and phospho-ERK (40%), but there was no significant change in 
phospho-S6 expression (Figure 3.14 A and B). However, an unexpected pattern of 
biomarker expression was observed in PTEN-positive P4E6 cells. The immunoblotting 
results showed increased levels of all analysed biomarkers following 72-hour 
treatment with the mTOR inhibitor.      
The data shows that 1 μM concentration of the AKT and mTOR inhibitors achieved a 
sufficient inhibitory effect only in LNCaP cells.   
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Figure 3.14. Biomarkers expression in prostate cell lines following treatment with mTORi. 
P4E6, LNCaP and PC3 cells were treated with 1 μM mTOR inhibitor for 72 hours. Following 
treatment, whole cell lysates were prepared and 20 μg of protein was loaded per lane onto a 
10% SDS gel, electrotransferred onto PVDF membranes and stained with phospho-AKT 
(Ser473), total AKT, phospho-S6 (Ser235/236), total S6, phospho-4EBP1 (Thr37/46), phospho-
ERK (Thr202/Tyr 204), total ERK and GAPDH (loading control) (A). Relative expression of the 
phospho-biomarkers was determined and quantified against the loading control GAPDH (B). A 
schematic representation of the pathway illustrating mTOR inhibition (C). 
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3.3.4. LNCaP cells show G1 arrest after treatment with AKT and mTOR 
inhibitors 
Flow cytometry analysis for cell cycle distribution was performed to test whether AKT 
or mTOR inhibition affected cell cycle in prostate cell lines. Cells were treated with 
increasing concentrations of inhibitor for up to 72 hours. The results showed that the 
majority of LNCaP cells (87.5%) were in G0/G1 following treatment with 1 μM mTORi 
compared to 67.9% for the vehicle control. Similarly, after treatment with 1 μM AKT 
inhibitor, 84.3% of LNCaP cells were in G0/G1 relative to 76.5% for vehicle control 
(Figure 3.15 A). Moreover, treatment with 3 μM of AKTi resulted in G0/G1 arrest of 
96.9% of LNCaP cells (result not shown). 
Cell cycle distribution of PC3 as well as the PTEN-positive P4E6 cells – did not change 
after treatment with either inhibitor relative to vehicle control (Figure 3.15 B and C). 
However, a benign prostate cell line BPH1, showed a modest increase of 7.1% and 
4.1% in number of cells in S and G2M phase, respectively, after treatment with 1 μM 
mTORi (Figure 3.15 C). Moreover, after treatment with 3 μM AKTi, cell number in G2M 
phase increased by 8.6% relative to vehicle control (result not shown).  
Taken together, the data shows that G0/G1 phase arrest was only induced in LNCaP 
cells and this was achieved by both inhibitors at 1μM relative to vehicle control.  
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Figure 3.15. Flow cytometry cell cycle analysis using propidium iodide staining (PE) in 
prostate cell lines after 72 hour-treatment with AKTi and mTORi.  
Cell cycle profile for LNCaP cells (A) and PC3 cells (B) treated with 1 μM AKT inhibitor and 1 μM 
mTOR inhibitor. (C) Pie chart summary illustrating cell cycle distribution, following treatment 
with 1 μM mTORi relative to vehicle control (0.1% DMSO) in BPH1, P4E6, LNCaP and PC3 cells.  
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4. RESULTS II 
4.1. PTEN expression in primary prostate cell cultures 
Expression of PTEN was determined at the protein level in a number of prostate 
epithelial cultures. The results showed that expression of PTEN measured by western 
blotting varies between samples obtained from patients undergoing radical 
prostatectomies and does not seem to be Gleason grade dependent (Figure 4.1). The 
highest levels of PTEN were detected in H313/13 (BPH), H240/12 R (GL7) and H330/13 
(GL7) in comparison to the PTEN-positive BPH1 cell line. Surprisingly, the lowest 
expression of PTEN was detected in H278/13 (GL6) as well as in H359/13 (GL9) and 
H363/13 (GL9).  
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Figure 4.1. PTEN expression in primary prostate cultures. 
PTEN expression was measured in prostate epithelial cultures using western blotting. Whole 
cell lysates were prepared and 20 µg of protein was loaded per lane onto a 10% SDS gel, 
electrotransferred onto PVDF membranes and stained for PTEN. Cell lines PC3 and BPH1 were 
negative and positive control, respectively. Intensity of staining was measured using Image J 
software and normalized to β-actin (loading control).   
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4.2. Treatment of primary cell cultures with inhibitors  
Prostate epithelial cultures were treated with increasing concentrations of the AKT 
inhibitor (AKTi) and the mTOR inhibitor (mTORi) for up to 72 hours.   
 
 
Figure 4.2. Culture and treatment schedule of primary prostate epithelial cells. 
Prostate benign and malignant tissue was chopped with a scalpel and then digested with 
collagenase overnight in order to obtain a single cell suspension. This was followed by 
differential centrifugation to separate epithelial cells from stromal cells. The epithelia were 
cultured on collagen I-coated plates with inactivated STO feeder cells. Cultures were grown for 
2-4 weeks to reach confluence, when they were seeded onto fresh dishes without STOs, and 
treated 24 hours later with the inhibitors. Following 72 hours incubation with the inhibitors, 
cells were collected for analysis. Adapted from (Frame and Maitland, 2011)   
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4.2.1. Cell morphology changes following treatment with high 
concentrations of AKTi and mTORi 
The efficacy of the AKT and mTOR inhibitors was tested in prostate epithelial cultures 
including BPH, cancer and castration resistant prostate cancer (CRPC) (Figure 4.2). Cell 
cultures were treated with up to 25 μM concentrations of each inhibitor, for up to 72 
hours. Phase contrast images were taken after 72 hours’ treatment to determine the 
effect on the morphology and density of the cells.  
A concentration of 5 μM AKTi did not affect the cell morphology of H277/13 (BPH), 
H282/13 (GL7) or H271/13 (CRPC), but a decrease of approximately 15% in cell density 
was observed in H271/13 cells (Figure 4.3). However, a combined treatment of 5 μM 
AKTi with 5 μM mTORi reduced cell density by 10 to 15% in all treated cultures. 
Additionally, a small increase in a number of cells detached from the dish was 
observed in H271/13 following treatment with 5 μM mTORi in comparison to the 
vehicle control cells (Figure 4.3).   
There was no difference in BPH and cancer cell cultures’ susceptibility to the inhibitors 
over this concentration range.  
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Figure 4.3. Morphology and density of prostate epithelial cultures following treatment with 
AKTi and mTORi. 
A BPH (H277/13) (top row), cancer GL7 (H282/13) (middle row) and a CRPC (H271/13) cells 
(bottom row) were treated with 5 μM AKTi or mTORi as single agents or in a combination of 5 
+ 5. Phase contrast images of the cells were taken after 72 hour-treatment. Vehicle control 
cells were treated with 0.1% DMSO. Scale bar represents 400 μm.    
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Treatment with higher concentrations of the inhibitors (10 – 50 μM) caused dramatic 
morphological changes which were very specific for each inhibitor (Figure 4.4). 
Following a 72-hour exposure to 25 μM of AKTi, increased vacuolation of a Gleason 7 
primary culture (H282/12) was observed, suggestive of autophagy (Figure 4.4, left 
panel). In contrast, following treatment of the same cells with 25 μM of mTORi, 
membrane blebbing, indicative of apoptosis, was observed in a number of cells (Figure 
20, middle panel). Vehicle control cells (treated with 0.5% DMSO) did not show any 
morphological changes (Figure 4.4, right panel).  
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Figure 4.4. Cell morphology after exposure to high concentrations of AKTi and mTORi.  
Phase contrast images of primary cells (H282/12) from a Gleason 7 (4+3) prostate cancer, 
treated with 25 μM AKT inhibitor (left panel) and 25 μM mTOR inhibitor (middle panel) for 72 
hours. Increased vacuolization of AKTi-treated cells and membrane blebbing of mTORi-treated 
cells were observed (arrows). Control cells were treated with 0.5% DMSO. Scale bar represents 
400 μm.    
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Taken together, treatment with low concentrations (up to 5 μM) of the inhibitors did 
not change cell morphology, whereas high concentrations (25 μM) of AKTi and mTORi 
caused distinct morphology changes. Membrane blebbing might be an indication of 
apoptosis, whereas vacuolization might suggest an induction of autophagy which was 
investigated further (see section 4.2.3.).  
 
4.2.2. Cell viability is reduced in BPH and cancer after treatment with 
AKTi and mTORi  
A number of primary cells (derived from patients with BPH and cancer) were treated 
with increasing concentrations of AKTi and mTORi, either alone or in combination, to 
determine the effect on cell viability. The majority of samples showed a decrease in 
viability of approximately 30-40% following treatment with 3 μM of either inhibitor, 
whereas a decrease of up to a 50% was observed following treatment with a 
combination of 3 μM AKTi and 3 μM mTORi (Table 4.1 and Figure 4.5).  
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Table 4.1. Summary of primary samples viability following treatment with AKTi and mTORi. 
 
Sample Treatment
% Viability 
(relative to 
vehicle control)
3 μM AKTi 65%
3 μM mTORi 58%
3 μM AKTi + 3 μM mTORi 57%
3 μM AKTi 75%
3 μM mTORi 72%
3 μM AKTi + 3 μM mTORi 51%
3 μM AKTi 105%
3 μM mTORi 101%
3 μM AKTi + 3 μM mTORi 102%
3 μM AKTi 58%
3 μM mTORi 58%
3 μM AKTi + 3 μM mTORi 47%
3 μM AKTi 137%
3 μM mTORi 84%
3 μM AKTi + 3 μM mTORi 45%
3 μM AKTi 82%
3 μM mTORi 76%
3 μM AKTi + 3 μM mTORi 71%
3 μM AKTi 102%
3 μM mTORi 70%
3 μM AKTi + 3 μM mTORi 59%
3 μM AKTi 80%
3 μM mTORi 62%
3 μM AKTi + 3 μM mTORi 44%
3 μM AKTi 40%
3 μM mTORi 27%
3 μM AKTi + 3 μM mTORi 20%
H239/12 - GL9 (4+5)
H240/12 - GL7 (3+4)
24h
48h
72h
H233/12 L - Benign
H240/12 - GL7 (3+4)
H233/12 - GL8 (3+5)
H236/12 - GL8 (4+4)
H239/12 - GL9 (4+5)
H237/12 - GL7 (3+4)
H240/12 - GL7 (3+4)
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Figure 4.5. Cell viability following treatment with AKTi and mTORi. 
Primary cultures derived from BPH and cancer were treated with either 3 μM AKTi, 3 μM 
mTORi or a combination of 3 μM AKTi + 3 μM mTORi for 24 hours (A) and 48 hours (B).  
Following treatment, the cells were harvested, stained with Trypan blue and counted. 
Percentage of viable cells was calculated relative to the vehicle control (0.04% DMSO). 
Significant differences (p value < 0.05) in cell viability are indicated on the graphs.  
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However, there was variability in the response and some patients did not respond. This 
variability was observed with a matched normal and cancer sample (H233/12) in which 
the primary cells from the cancer biopsy showed little effect in contrast to the normal 
matched control (Figure 4.6). 
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Figure 4.6. Cell viability of matched benign and cancer cells after treatment with AKTi and 
mTORi.  
A primary cancer H233/12 (GL7 (4+3)) and matched benign cells were treated with either 3 μM 
AKTi, 3 μM mTORi or a combination of 3 μM AKTi + 1 μM mTORi or 1 μM AKTi + 3 μM mTORi 
or 3 μM AKTi + 3 μM mTORi for 24 hours. Following treatment, the cells were harvested, 
stained with Trypan blue and counted. The percentage of viable cells was calculated and the 
results normalised to the vehicle control (0.04% DMSO). Error bars represent the standard 
error of the mean (SEM).  
 
  
 
126 
 
In order to determine whether an extended incubation time had an effect on cell 
viability, a primary cancer culture H240/12 was treated with AKTi and mTORi alone or 
in combination for up to 72 hours. The results showed a decrease of 40 to 50% in cell 
viability after 24 and 48 hours respectively. However, 72-hour incubation decreased 
cell viability even further; up to 80% when treated with a combination of 3 μM AKTi + 3 
μM mTORi (Figure 4.7).  
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Figure 4.7. Viability of H240/12 (GL7) cells following treatment with AKTi and mTORi.  
Primary prostate cancer sample H240/12 (GL7) was treated with either 3 μM AKTi,3 μM mTORi 
or a combination of 3 μM AKTi + 1 μM mTORi, 1 μM AKTi + 3 μM mTORi or 3 μM AKTi + 3 μM 
mTORi, for 24h (A), 48h (B) and 72h (C). Cell viability was determined using Trypan blue 
exclusion. Percentage of cell viability was calculated relative to the vehicle control (0.04% 
DMSO). Error bars represent standard error of the mean (SEM).  
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In addition to trypan blue exclusion cell viability assessment, an MTS assay was also 
performed, which gives an indication of cells’ metabolic activity following treatment. 
Primary cell cultures H313/13 (BPH) and H315/13 (Cancer, GL7) were treated with 
increasing concentrations (5 – 50 μM) of AKTi and mTORi for 72 hours and an MTS 
assay performed. The results showed that both cultures responded similarly to each 
inhibitor, with up to 50% decrease in cell viability when treated with 50 μM AKTi or 50 
μM mTORi (Figure 4.8 A and B). Additionally, there was a greater than 27-fold 
difference in response to treatment with mTORi between a primary cancer culture 
H315/13 and the prostate cancer cell line LNCaP, with an EC50 of 25 μM and 0.9 μM for 
H315/13 and LNCaP respectively (Figure 4.8 B).   
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Figure 4.8. MTS viability assay following treatment with AKTi and mTORi.  
An MTS assay was performed with H313/13 (BPH) (A) and H315/13 (GL7) (B) primary prostate 
cultures treated (in triplicate) with increasing concentrations of AKT and mTOR inhibitors, for 
72 hours. Cell viability was calculated relative to the vehicle control (0.5% DMSO). LNCaP 
viability following treatment with up to 10 μM mTORi (green line) was inserted for comparison 
purposes (B). Error bars represent standard error of the mean, n=3 (SEM).  
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4.2.2.1. Viability of primary cells subpopulations following 
treatment with AKTi and mTORi  
Due to the heterogeneity of primary prostate cultures, the effect of treatment on cell 
viability was also assessed in subpopulations of cancer samples. A range of cancer 
cultures (GL7-GL9) were treated with either 3 μM AKTi, 3 μM mTORi or a combination 
of 3 μM AKTi + 3 μM mTORi for 72 hours. The cell subpopulations consisting of Stem 
Cells (SC), Transit Amplifying (TA) and Committed Basal (CB) cells were isolated (as 
described in section 2.1.2.1.) following treatment and subsequently counted using 
Trypan blue.  
Treatment with 3 μM AKTi reduced the number of stem cells in 3 out of 4 cancer 
samples with the highest reduction of 78% in H149/12 (GL9), (Figure 4.9 A). A similar 
decrease in SCs was observed following treatment with 3 μM mTORi in H149/12 cells. 
However, in one sample (H163/12) a surprising increase of over 50% in SC number was 
observed following treatment with AKTi (Figure 4.9 A). Treatment with a combination 
of 3 μM AKTi + 3 μM mTORi resulted in a decrease of SC by 63% and 55% in  two GL9 
samples, H149/12 and H135/11, respectively (Figure 4.9 A).  
An increase of 55% in the number of TA cells, and up to 69% of CB cells was observed 
following treatment with both inhibitors either as a single agent or in combination in 
H252/12 (GL7) and H135/11 (GL9)  (Figure 4.9 B and C).  In contrast, a decrease of up 
to 62% in TAs and CBs was observed, relative to the vehicle controls, in H163/12 and 
H149/12 cells (Figure 4.9 B and C).  
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Figure 4.9. Viability of selected subpopulations of primary prostate cancer samples following 
treatment with AKTi and mTORi. 
Primary prostate cancer samples H252/12 (GL7), H163/12 (GL8), H149/12 (GL9) and H135/11 
(GL9) were treated with 3 μM AKTi, 3 μM mTORi or a combination of 3 μM AKTi + 3 μM mTORi 
for 72 hours. Following treatment, the cells were harvested, sorted into committed basal (CB), 
transit amplifying (TA) and stem cells (SC) and counted using Trypan blue exclusion. 
Percentage of viable cells was calculated relative to the vehicle control (0.06% DMSO).  
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The effect of treatment with AKTi and mTORi on stem-like cells population was also 
determined using flow cytometry. A prostate cancer culture H317/12 (GL7) was 
treated with 10 μM AKTi, 10 μM mTORi and a combination of 10 + 10 for 72 hours. The 
results showed an increase of 50% in a number of CD133-positive cells following 
treatment with mTORi and with a combination of 10+10 (Figure 4.10). However, after 
treatment with AKTi, a decrease of 37.5% in stem-like cells population was observed, 
relative to the vehicle control. Moreover, an increase in non-viable CD133-positive 
cells was evident following treatment with either inhibitor alone or a combination 
(Figure 4.10, bottom panel). 
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Figure 4.10.  Influence of treatment with AKTi and mTORi on stem-like cell population.  
Prostate cancer cells (H317/13) were treated with 10 μM AKTi, mTORi or a combination of 10 + 
10 for 72 hours. The cells were then collected and stained with anti-CD133 antibody and 
analysed on a flow cytometer. Vehicle control cells were treated with 0.2% DMSO.  
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Taken together, the cell viability data showed a patient-specific variability in primary 
cultures’ response to treatment which was not dependent on Gleason grade. However, 
a 72-hour incubation with the inhibitors significantly decreased cell viability in 
comparison to 24-hour treatment. Moreover, primary prostate cancer cultures showed 
much lower susceptibility to AKTi and mTORi than prostate cancer cell lines, for 
example LNCaP, which had a 27-fold higher EC50.   
 
4.2.3. Autophagy is activated in cells treated with the AKT inhibitor  
To follow up the observation of changes in cell morphology and to determine the 
effect on cell fate following treatment with the inhibitors, expression of an apoptosis 
marker (cleaved PARP) and an autophagy marker (LC3 B) were assessed by western 
blotting. A prostate cancer culture H278/13 (GL7) was treated with increasing 
concentrations (10 – 50 μM) of AKTi and mTORi either alone or in combination.  
The results showed that there was no increase in expression of cleaved PARP, 
suggesting that the cells had not undergone apoptosis following treatment with either 
compound (Figure 4.11). However, there was a dose-dependent increase in LC3 B after 
treatment with the AKTi, indicating that the cells had activated autophagy; which is 
primarily a survival mechanism allowing cells to avoid death (Figure 4.11).  
  
 
136 
 
 
 
Figure 4.11. Expression of an apoptosis and an autophagy marker following treatment with 
AKTi.  
A primary prostate culture H278/13 (GL7) was treated with up to 50 μM concentration of 
either AKTi or mTORi or a combination of 10 μM AKTi + 10 μM mTORi for 72 hours. Following 
the treatment, expression of an apoptosis marker, cleaved PARP, and an autophagy marker, 
LC3 B, were determined using western blotting. Whole cell lysates were prepared and 20 µg of 
protein was loaded per lane onto a 10% SDS gel, electrotransferred onto PVDF membranes 
and stained. Lysate of PC3 cells was a positive control for expression of LC3 B. Staining with β-
actin antibody was used as a loading control. 
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In order to confirm whether treatment with AKTi induces autophagy, cancer H310/13 
cells were treated with 25 μM AKTi or 25 μM mTORi for 96 hours and expression of 
LC3 B analysed by immunofluorescence.  
The results showed an increase in vacuolisation of the cells treated with AKTi, but not 
with mTORi (Figure 4.12 A), which correlated with expression of the autophagy marker 
in those cells (Figure 4.12 B).   
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Figure 4.12. LC3 B expression in H310/13 (GL7) cells following treatment with AKTi and 
mTORi. 
Primary prostate cancer H310/13 (GL7) cells were treated with 25 μM AKTi or 25 μM mTORi 
for 96 hours. Phase contrast images were taken following the treatment (A). Expression of an 
autophagy marker, an LC3 B, was determined using Immunofluorescence (B). The cells were 
seeded into collagen I-coated 8-well chamber slides and treated with either 25 μM AKTi or 25 
μM mTORi for 96 hours and then fixed in 4% PFA. The cells were then permeabilised with 
0.25% Triton-100, washed with PBS, blocked with 10% goat serum and incubated with an LC3 B 
antibody overnight. Following staining with primary antibody, the cells were washed with PBS, 
incubated with secondary goat-anti-rabbit antibody for 1 hour, washed with PBS and mounted 
with mounting solution containing DAPI. Control cells were treated with 0.25% DMSO. Scale 
bar on the phase contrast images represents 200 μm and on the fluorescent images 63 μm. 
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4.2.4. Phosphorylation status of selected biomarkers downstream from 
AKT and mTOR following treatment 
The number of cells expressing phospho-AKT and phospho-S6 (biomarkers 
downstream of AKT and mTOR kinases), was determined by flow cytometry following 
72-hour treatment with increasing concentrations of inhibitors of the pathway.  
A primary prostate culture H317/13 (GL7) was treated with either 10 μM AKTi, 10 μM 
mTORi or a combination of 10 + 10 for 72 hours. The phosphorylation status of AKT 
and S6 was determined following treatment. The results showed an increase of 58.4% 
in the number of cells expressing phospho-AKT following treatment with 10 μM AKTi 
(Figure 4.13 A). In contrast, a decrease of 11.1% in phospho-AKT was observed after 
treatment with 10 μM mTORi. Moreover, treatment with a combination of 10 + 10 
resulted in an increase of phospho-AKT of 41.2% relative to the vehicle control, which 
was a decrease of 17.2% in comparison to AKTi-treated cells (Figure 4.13 A).  
Expression of phospho-S6, an indirect substrate of mTORC1, increased by 3.5% and 2% 
following treatment with 10 μM AKTi and 10 μM mTORi, respectively (Figure 4.13 B). 
However, there was a 5.5% decrease in phospho-S6 expression after treatment with a 
combination of 10 + 10, relative to the vehicle control (Figure 4.13 B).   
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Figure 4.13. Biomarkers expression following treatment with AKTi and mTORi. 
Primary prostate cancer cells H317/13 (GL7) were treated with 10 μM AKTi, 10 μM mTORi or a 
combination of 10 + 10 for 72 hours. Following treatment cells were harvested, fixed with 4% 
PFA, permeabilised with methanol and stained with phospho-AKT (Ser473) and phospho-S6 
(Ser235/236) antibodies; negative control cells were stained with FITC-conjugated secondary 
goat anti-rabbit antibody. Vehicle control cells were treated with 0.1% DMSO. 
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4.2.4.1. Biomarker expression following withdrawal of the 
inhibitors   
Next, the effect of inhibitors’ withdrawal on the phosphorylation of the biomarkers 
was tested to determine whether therapeutic effect was reversible, which is clinically 
relevant. Patients receiving treatment, for example chemotherapy which is toxic to 
cancer cells and to normal cells, need breaks in drugs delivery for recovery. It is 
important to establish whether after inhibitors’ withdrawal activity of the pathway 
increases. This was assessed using western blotting. A primary cancer culture H210/12 
(GL7) was treated with 1 μM AKTi or 1 μM mTORi for 5 days, after which fresh media 
(without inhibitors) was added and the cells were incubated for a further 48 hours 
(Figure 4.14 A).  
The results showed a 26-fold increase in phospho-AKT and a 9.4-fold increase in 
phospho-PRAS40 after 5 days treatment with AKTi. However, after withdrawal of the 
inhibitor, phospho-AKT decreased to 12.5-fold and phospho-PRAS40 to 3.6-fold in 
comparison to the control (Figure 4.14 B). 
Five-day treatment with 1 μM mTORi decreased both phospho-AKT and phospho-S6 
levels down to 0.6-fold, relative to the vehicle control. Interestingly, a withdrawal of 
mTORi increased phospho-AKT expression by 2 fold above the vehicle control level, but 
phospho-S6 expression remained at a comparable level (Figure 4.14 B).  
The results suggest that inhibitory activity of AKTi and mTORi is reversible.  
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Figure 4.14. Expression of the phospho-biomarkers following treatment and withdrawal of 
the inhibitors. 
Prostate cancer cells H210/12 were seeded 24 hours before the treatment with 1 μM AKTi or 1 
μM mTORi for 5 days followed by inhibitors’ withdrawal (after 5th day) and replacement with 
fresh culture media for further 2 days (A). Treated cells were collected and whole cell lysates 
prepared. 20 μg of protein was loaded per lane onto a 10% SDS gel, electrotransferred onto a 
PVDF membrane and immunoblotted with antibodies against phospho-AKT (Ser473), total AKT, 
phospho-PRAS40 (Thr246), total PRAS40 and phospho-S6 (Ser235/236). Staining with β-actin 
antibody was used as a loading control. The bands were quantified using Image J software.  
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4.2.4.2. Presence or absence of EGF in medium alters 
biomarkers expression following treatment 
The effect of EGF in the culture medium on expression of PI3K pathway biomarkers 
was determined in a BPH sample (H268/12) and a cancer sample (H282/13) treated 
with 5 μM AKTi, 5 μM mTORi or a combination of 5 + 5.  This experiment was carried 
out to determine whether EGF, which is required for primary cell expansion, affected 
the outcome of treatment with the inhibitors.   
The results showed that in BPH culture the presence of EGF, phospho-AKT and 
phospho-S6 expression increased by 2 fold compared to cells grown without EGF 
(Figure 4.15 A). In contrast, phospho-ERK1/2 expression was higher in the absence of 
EGF (2 fold, relative to β-actin) than in the presence of EGF (1.4 fold). When cells were 
treated with AKTi a 9-fold increase in phospho-AKT was observed in the presence of 
EGF whereas in the absence of EGF a 12.1-fold increase in expression was observed 
relative to the vehicle control (Figure 4.15 A). Phosphorylation of ERK1/2 increased by 
2.8-fold following treatment with AKTi (in the presence of EGF) and by 1.2 in the 
absence of EGF. However, phosphorylation of S6 remained at a comparable level 
following treatment either in the presence or absence of EGF (Figure 4.15 A). In cancer 
culture phospho-ERK1/2 levels were higher when cells were treated in the presence of 
EGF in comparison to cells treated in the absence of EGF (Figure 4.15 B). However, 
levels of cleaved PARP and LC3B were similar in cultures treated in the presence and in 
the absence of EGF. The difference in bands quantification values was mainly due to 
understated β-actin level in the first lane of the blot (Figure 4.15 B).   
Taken together, the data shows that there is a difference in biomarker expression 
when cells are cultured with EGF, but this effect was not significant (p=0.22 for 
phospho-AKT, p=0.08 for phospho-ERK1/2 and p=0.62 for phospho-S6). In subsequent 
experiments, EGF was included in the culture of primary cells.  
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Figure 4.15. Phospho-biomarker expression analysis following treatment with AKTi and 
mTORi in presence or absence of EGF in culture media. 
A BPH (H268/12) (A) and a cancer (H282/13) (B) cultures were treated with either 5 μM of AKTi 
or 5 μM mTORi alone or in a combination of 5 + 5 for 72 hours. Cells were subsequently 
collected, whole cell lysates prepared and quantified. 20 μg of protein was loaded per lane, 
electrotransferred to PVDF membrane and stained with antibodies against phospho-AKT 
(Ser473), phospho-ERK1/2 (T202/Tyr204) phospho-S6 (Ser235/236), cleaved PARP and LC3 B. 
Staining with β-actin antibody was used as a loading control. The bands were quantified using 
Image J software and the expression levels normalized to the vehicle control.      
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4.2.5. Changes in colony forming efficiency after treatment with AKTi 
and mTORi 
In order to establish whether prostate stem-like cells are dependent on the 
PI3K/AKT/mTOR pathway for survival, an ability of the stem-like cells and progenitor 
cells to form colonies was tested following treatment with AKTi and mTORi.  
Cells derived from patients with cancer Gleason 9 (H149/12) and CRPC (H271/13) were 
treated with either 3 μM or 5 μM of AKTi or mTORi alone or with a combination of 3 + 
3 or 5 + 5. The cells were treated for 72 hours after which they were sorted into stem 
cells (SC), transit amplifying (TA) and committed basal (CB) cells (as described in 
section 2.1.2.1.). The cells were then plated and incubated without the inhibitors and 
colony forming efficiency (CFE) determined. 
AKTi treatment increased the number of colonies founded by stem cells, but the effect 
was only significant in 1 of 2 cultures examined and with the higher concentration of 
AKTi.  A similarly significant increase in CFE of stem cells was observed with mTORi.  
However, this increase was abolished with a higher concentration of mTORi. A 
combination of both inhibitors had little effect on CFE of stem cells (Figure 4.16).  
In contrast, transit amplifying cells showed a decrease in colony forming ability 
following treatment, down to approximately 79% and 73% (of control) in H271/13 and 
H149/12, respectively, when treated with AKTi alone (Figure 4.16 A and B, middle 
row). Treatment with mTORi alone decreased number of colonies to around 82-83% 
relative to vehicle control, in both patients. However, simultaneous treatment with 
both inhibitors showed only modest decreases: down to approximately 93% in 
H271/13 and 83% in H149/12, in comparison to vehicle control (Figure 4.16 A and B, 
middle row).   
Although committed basal cells’ potential to form colonies is lower than SCs and TAs, 
treatment with either inhibitor alone or a combination reduced CFE. Indeed no 
colonies were observed from H271/13 following treatment with 5 µM AKTi or 5 + 5 
(Figure 4.16 B, bottom row).    
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In summary, a surprising increase in CFE was observed in stem cells of both cultures, 
which was significant in mTORi-treated H149/12 cells (p value=0.03) and in AKTi-
treated H271/13 cells (p value=0.05), relative to the vehicle control. In contrast, a 
decrease in CFE of TA cells was observed, which was significant in H149/12 cells 
treated with 3 µM AKTi (p value= 0.01), relative to the vehicle control.    
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Figure 4.16. Colony forming efficiency (CFE) after treatment with AKTi and mTORi. 
Primary cancer cultures H149/12 (GL9) (A) and H271/13 (CRPC) (B) were treated with 3 μM or 
5 μM AKTi or mTORi alone or with a combination of 5 + 5 or 10 + 10. Following 72-hour’ 
treatment, the cell cultures were sorted for stem cells (SC), transit amplifying (TA) and 
committed basal (CB) cells. The sorted cells were then plated, in triplicate, onto collagen I-
coated 35 mm-dishes, at a density of 100 cells per dish in the presence of irradiated STO 
feeder cells. The cells were incubated for 10 to 14 days and colonies of >32 cells (5 population 
doublings) were counted.     
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4.2.6. Cell cycle distribution remains unaffected after treatment with 
both inhibitors as single agents or in combination 
To determine whether the inhibitors affected the cell cycle, primary cells were treated 
for 72 hours, with 5 μM AKTi, 5 μM mTORi, and a combination of 5 + 5. The cells were 
subsequently stained with propidium iodide and cell cycle distribution was determined 
by flow cytometry. The results showed no significant change between vehicle controls 
(0.1% DMSO) and cells treated with either inhibitor or with a combination of 5 μM 
AKTi and 5 μM mTORi (Figure 4.17). However, in 1 out of 3 samples, H278/13 cancer 
cells, an increase of 8% in cells in G1 phase and 9% of cells in G2M phase was observed 
following treatment with AKTi and a combination of 5 μM AKTi + 5 μM mTORi, 
respectively (Figure 4.17 B).  
Taken together, the results show that treatment with AKTi and mTORi, either alone or 
in combination, does not induce growth arrest in primary prostate cultures at this 
concentration range.  
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Figure 4.17. Cell cycle distribution after treatment with inhibitors. 
Cell cycle distribution analysis was performed after 72-hour treatment with 5 μM AKTi, 5 μM 
mTORi and 5 + 5 combination on primary cultures in H277/13 (BPH) (A), H282/13 (cancer GL7) 
(B) and in H271/12 (CRPC) (C). Following treatment cells were harvested, fixed with 70% ice-
cold ethanol, and stained with propidium iodide and analysed by flow cytometry. Control cells 
were treated with 0.1% DMSO. 
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4.3. Cross-talk between PI3K/AKT/mTOR and Ras/MEK/ERK pathway 
4.3.1. Phospho-ERK1/2 levels are increased following treatment with 
AKTi  
In order to determine whether inhibition of the PI3K/AKT/mTOR pathway affects the 
activity of the MAP kinase pathway, the phosphorylation status of ERK1/2 was 
assessed following a 72-hour treatment (of primary prostate cultures) with AKT and 
mTOR inhibitors.  
Western blotting performed on a BPH (H277/13) and a cancer sample (H278/13, GL7) 
showed an increase in phospho-ERK1/2 following treatment with the AKTi, but not the 
mTORi. However, treatment of cells with a combination of both inhibitors increased 
phospho-ERK1/2 expression (Figure 4.18 A). An increase in phospho-ERK1/2 also 
correlated with increased expression of an autophagy biomarker (LC3 B).  
To follow up this observation, another primary cancer sample (H282/13; GL7) was 
treated with higher concentrations (10-50 μM) of both inhibitors (for 72 hours) to 
assess if the increase in MAPK activity was dose-dependent. The results showed a 
dose-dependent increase in phosphorylation levels of ERK1/2 when the cells were 
treated with AKTi, but not with mTORi (Figure 4.18 B). This indicates that a cross-talk 
exists between the PI3K/AKT/mTOR and the MAPK pathway in human prostate 
primary epithelial cells, and that inhibition of the PI3K pathway alone might not be 
sufficient to treat prostate cancer.   
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Figure 4.18. Phospho-biomarkers expression in prostate primary cultures following 
treatment with AKTi and mTORi.  
Primary BPH (H277/13) and cancer cells (H278/13) (A) and H282/13 cancer cells (B) were 
treated for 72 hours with increasing concentrations of AKTi and mTORi or a combination of 
both. Whole cell lysates were subsequently prepared and 20 µg of protein was loaded per lane 
onto a 10% SDS gel, electrotransferred onto PVDF membranes and stained for the biomarkers 
indicated (phospho-AKT, total AKT, phospho-ERK1/2, total ERK1/2, phospho-S6, total S6, 
cleaved PARP and LC3 B). Vehicle control cells were treated with 0.1% DMSO (A) or 0.5% 
DMSO (B). Staining with β-actin antibody was used as a loading control. The bands were 
quantified using Image J software and the expression normalized to the vehicle control (A) or 
to β-actin (B).      
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4.3.2. Treatment of primary cultures with a combination of AKT and 
MEK1/2 inhibitors 
 
4.3.2.1. A combination of AKTi with MEKi further increases 
phospho-ERK1/2 expression   
In order to determine whether MEK1/2 inhibitor (MEKi) showed any activity in primary 
prostate cultures, selected cancer samples were treated with increasing 
concentrations (0.1 – 25 µM) of a MEKi for 72 hours.  
Phase contrast images were then taken to determine the effect on morphology and 
density of the cells. At a concentration ≥ 1 µM a decrease of approximately 30-40%, in 
cell density was observed. Cell morphology was also changed; the cells appeared larger 
and their shape was more elongated comparing to vehicle controls (Figure 4.19 A). 
The phosphorylation status of ERK1/2, which is downstream of MEK1/2, as well as 
phospho-AKT and LC3 B, was determined following treatment using western blotting 
(Figure 4.19 B). The results showed a dose-dependent decrease in phospho-ERK1/2 
expression after treatment with the MEKi. A concentration of 1 µM was sufficient to 
completely abolish expression of phospho-ERK1/2. However, an increase in phospho-
AKT levels (2.8-fold at 0.5 μM MEKi) was observed at the lower concentration range 
(0.1 - 1 µM) of MEKi, which might indicate an increase in activity of the PI3K pathway 
in response to inhibition of the MAPK signalling. 
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Figure 4.19. Cell morphology and biomarker expression following treatment with MEKi. 
Primary cancer cells H135/11 (GL9) (A) and H329/13 (GL7) (B) were treated with increasing 
concentrations (0.1 - 25μM) of MEK1/2 inhibitor for 72 hours. Phase contrast images were 
taken and cell morphology assessed following treatment (A). Whole cell lysates were prepared 
after treatment of H329/13 and 20 µg of protein was loaded per lane onto a 10% SDS gel, 
electrotransferred onto PVDF membranes and stained for the biomarkers (phospho-AKT, total 
AKT, phospho-ERK1/2, total ERK1/2 and LC3 B). Vehicle control cells were treated with 0.25% 
DMSO. Staining with β-actin antibody was used as a loading control. Image J software was 
used for densitometry analysis.  
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To overcome the activation of the MAPK pathway following treatment with AKTi,   
primary cells were next treated with a combination of AKTi and MEKi. In order to 
determine the effectiveness of combined treatment, the phosphorylation status of 
specific biomarkers was determined using western blotting. Primary cancer cells 
H236/12 were treated with increasing concentrations of the inhibitors in three 
different treatment experiments (combinations): 
- 1-25 μM AKTi + constant concentration of MEKi of 1 μM for 72 hours; 
- 1-10 μM AKTi + matching concentration of MEKi for 72 hours; 
- 1-10 μM AKTi alone for 24 hours + matching concentration of MEKi for 
additional 24 hours after initial treatment with AKTi; 
Different treatment schedules and combinations were designed in order to test 
whether there was an advantage of using both inhibitors simultaneously or if 
subsequent treatment with MEKi following AKTi would have a better therapeutic 
effect. Concentration range of the inhibitors was chosen on a basis of their optimal 
activity determined in phospho-biomarker analysis in previous experiments.    
The results showed a surprising increase, instead of a decrease in phospho-ERK1/2 
levels, following treatment with a combination of AKTi and MEKi in all three 
experiments (Figure 4.20 A, representative result shown). Moreover, treatment of 
cancer H282/13 (GL7) cells with a higher concentration of 25 μM of AKTi and MEKi, 
increased phospho-ERK1/2 levels even further (Figure 4.20 B). Interestingly, autophagy 
was not induced in cells treated with MEKi alone, only in AKTi-treated cells or in a 
combination of AKTi + MEKi (Figure 4.20 B).  
This result indicates that treatment with a combination of AKTi and MEKi does not 
inhibit phosphorylation of ERK1/2. Moreover, addition of MEKi to AKTi-treated culture 
increases phospho-ERK1/2 even further.    
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Figure 4.20. Phospho-biomarkers expression following treatment with a combination of AKTi 
and MEKi. 
Primary cancer cells H236/12 (GL7) (A) were treated with 1 μM, 5 μM and 10 μM AKTi for 24 
hours, after which matching concentrations of MEKi were added, and treatment continued for 
further 24 hours (sequential treatment). An additional cancer culture H282/13 was treated 
with up to 25 μM concentration of AKTi, MEKi or a combination of AKTi + MEKi for 72 hours (B) 
(simultaneous treatment). Adherent and non-adherent cells were collected and whole cell 
lysates prepared. 20 µg of protein was loaded per lane onto a 10% SDS gel, electrotransferred 
onto PVDF membranes and stained for the biomarkers indicated (phospho-AKT, total AKT, 
phospho-ERK1/2, total ERK1/2 and LC3 B). Vehicle control cells were treated with 0.2% DMSO 
(A) or 0.5% DMSO (B). Staining with β-actin antibody was used as a loading control. Image J 
software was used for densitometry analysis.  
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4.3.2.2. Treatment with AKTi and RO-512 induces senescence, 
but not differentiation in primary prostate cells 
 
Activity of an additional MEK1/2 inhibitor (RO-512) was tested in primary cultures with 
the aim of overcoming the compensatory effect of MAPK pathway activation.  
A BPH (H313/13) and a cancer (H240/12) sample were treated with increasing 
concentrations (0.1 – 10 μM) of RO-512 alone in order to test the effect of treatment 
on biomarker expression. The results showed a complete inhibition of MEK1/2 activity 
with just 0.1 μM RO-512 in H313/13 and with 1 μM in H240/12 cells (Figure 4.21). 
Interestingly, an increase in phospho-S6 following treatment with 0.1 μM RO-512 was 
observed in BPH cells, but not in cancer. Moreover, a transient increase in phospho-
AKT expression was observed in BPH cells treated with 1 μM RO-512. This was not 
observed in the cancer sample.  
Additionally, an apoptosis marker, cleaved PARP, was detected in BPH and cancer cells 
following treatment with 0.1 μM and 1 μM RO-512 (Figure 4.21).  
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Figure 4.21. RO-512 effect on phospho-biomarker expression. 
A primary BPH H313/13 and cancer H240/12 (GL8) cells were treated with increasing 
concentrations of MEK1/2 inhibitor RO-512 for 72 hours. Whole cell lysates were then 
prepared for western blotting analysis of biomarker expression. 20 µg of protein was loaded 
per lane onto a 10% SDS gel, electrotransferred onto PVDF membranes and stained for the 
biomarkers indicated (phospho-AKT, phospho-ERK1/2, total ERK1/2, phospho-S6 and cleaved 
PARP). Vehicle control cells were treated with 0.1% DMSO. Staining with β-actin antibody was 
used as a loading control. Image J software was used for densitometry analysis.  
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After confirmation of inhibitory activity of RO-512 in prostate epithelial cultures, a 
combination treatment with AKTi + RO-512 was performed in a BPH sample (H377) 
and a cancer sample H363/13 (GL8). The effect of a 72-hour treatment was 
determined using western blotting. The results showed a decrease in phospho-ERK1/2 
in BPH cells when treated with RO-512 alone (Figure 4.22 B). However, in both BPH 
and cancer cells, the expression of phospho-ERK increased after treatment with a 
combination of AKTi + RO-512, even when treated with a high concentration of 5 + 5 or 
10 + 10 with AKTi (Figure 4.22). This suggests that despite confirmed inhibitory activity 
against MEK1/2 kinase, RO-512 inhibitor is not capable of preventing ERK1/2 
phosphorylation following compensatory activation of MAPK pathway.   
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Figure 4.22. Expression of phospho-biomarkers following treatment with AKTi and RO-512. 
A primary BPH H377/13 and cancer culture H363/13 (GL8) were treated with up to 10 μM of 
AKTi and RO-512, either alone or in a combination for 72 hours. Whole cell lysates were 
subsequently prepared and 20 µg of protein was loaded per lane onto a 10% SDS gel, 
electrotransferred onto PVDF membranes and stained for the biomarkers indicated (phospho-
AKT, total AKT, phospho-ERK1/2, total ERK1/2, phospho-S6, total S6 and cleaved PARP). 
Vehicle control cells were treated with 0.2% DMSO (A) or 0.1% DMSO (B). Staining with β-actin 
antibody was used as a loading control. Image J software was used for densitometry analysis.  
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Metabolic inhibitors can induce a wide range of cytotoxic effects, but in a stem cell 
context, they can equally induce differentiation (Kroon et al., 2013).  
In order to verify whether treatment with AKTi and MEK1/2 inhibitors could be 
inducing differentiation in prostate epithelial cultures, flow cytometry of cytokeratin 
18 (CK18) expression was performed. A primary cancer sample H366/13 (GL7) was 
treated with either 1 μM RO-512, 1 μM MEKi or a combination of 1 μM RO-512 + 1 μM 
AKTi or 1 μM MEKi + 1 μM AKTi for 72 hours.  
The results showed that treatment with RO-512 affected the number of cells 
expressing CK18. The number of viable CK18 cells reduced by 50% suggesting that the 
inhibitor did not induce differentiation but affected the viability of the CK18+ fraction. 
However, a comparable level of CK18 expression was observed after treatment with 
RO-512 and MEKi either as a single agent or in a combination with AKTi (Figure 4.23). 
This suggests that neither of the inhibitors induces differentiation in primary prostate 
cultures at this concentration range.   
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Figure 4.23. Cytokeratin 18 expression following treatment with AKTi and MEK1/2 inhibitors.  
Primary prostate cancer cells H366/13 (GL7) were treated with 1 μM RO-512, 1 μM MEKi or a 
combination of 1 μM RO-512 + 1 μM AKTi or 1 μM MEKi + 1 μM AKTi for 72 hours. Following 
treatment, adherent and non-adherent cells were collected, fixed in 4% PFA, permeabilised 
with methanol and stained with antibody against Cytokeratin 18 (CK18). Vehicle control cells 
were treated with 0.02% DMSO.  
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In order to test whether treatment with AKTi and MEK1/2 inhibitors can induce 
senescence, β-galactosidase staining was performed. A BPH culture (H373/13) was 
treated with MEKi or RO-512 either as a single agent or in combination with AKTi for 
72 hours (Figure 4.24).  
The result showed a striking increase in β-galactosidase – positive cells after treatment 
with a combination of 1 μM AKTi + 1 μM MEKi and also with 1 μM AKTi + 1 μM RO-512. 
Moreover, treatment with RO-512 in combination with AKTi induced senescence in all 
of the treated cells (Figure 4.24).  
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Figure 4.24. β-galactosidase staining following treatment with AKTi and MEK1/2 inhibitors. 
A primary BPH culture H373/13 was treated with either 1 μM MEKi, 1 μM RO-512 or a 
combination of 1 μM MEKi + 1 μM AKTi or 1 μM RO-512 + 1 μM AKTi for 72 hours. Following 
treatment cells were fixed and stained according to the manufacturer’s instructions and phase 
contrast images were taken. β-galactosidase – positive cells were observed (red arrows) as 
well as β-galactosidase negative cells (green arrows). Scale bar represents 400 μm. 
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Taken together, the data shows that a combined treatment of AKTi with RO-512 
inhibitor induces irreversible growth arrest in primary prostate epithelial cultures, but 
it does not induce differentiation.  
 
4.4. The effect of inhibiting the PI3K/AKT/mTOR pathway on tumour 
outgrowth 
The effect of inhibiting the PI3K/AKT/mTOR pathway on tumour outgrowth was 
determined. A human prostate cancer xenograft (Y042/07), which was derived from a 
patient with hormone-naïve  Gleason 7 disease, was first depleted of mouse blood 
lineage and endothelial cells before treating (ex vivo) with 3 μM and 10 μM of AKTi and 
mTORi either alone or in combination. Cell viability was assessed by counting live cells 
using trypan blue exclusion, following treatment after 24, 48 and 72 hours, in order to 
select the optimal treatment time and concentration of the inhibitor to be used for 
subsequent in vivo experiments (Figure 4.25).  
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Figure 4.25. Y042 xenograft viability following treatment with AKTi and mTORi. 
Y042 xenograft cells were treated with 3 μM, 10 μM, a combination of 3+3 and 10+10 of AKT 
and mTOR inhibitors for 24 hours (A), 48 hours (B) and 72 hours (C). Cell viability was 
determined using Trypan blue exclusion. The percentage of viable cells was calculated and 
expressed as relative to vehicle control (0.2% DMSO). Error bars represent the standard error 
of the mean. 
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The results showed that a decrease of approximately 50% in cell viability was achieved 
at a 10 μM concentration of the mTOR inhibitor alone and in combination with 10 μM 
AKTi (10+10), following 72 hours treatment (Figure 4.25 C). However, treatment with 
AKTi alone (at a concentration of 10 μM) only caused a 30% decrease in viability.   
From these observations, the optimal treatment conditions for the tumour outgrowth 
experiment was decided; 10 μM concentrations of both inhibitors and a combination 
of 10 + 10, for a period of 72 hours. 
 
4.4.1. Effect of AKT and mTOR inhibition on tumour outgrowth 
In order to determine the effect of AKT and mTOR inhibitors on tumour initiating 
frequency, limiting dilution experiment was performed with xenograft Y042. The Y042 
tumour is maintained in vivo and is serially transplantable in Rag2-/-GC-/- mice.  Single 
tumour cells (Lin-/CD31-) were derived following the protocol outlined in section 
2.7.1.1. Resultant human tumour cells (Lin-/CD31-) were treated ex vivo with 10 μM 
AKTi, 10 μM mTORi and a combination of 10 + 10, for 72 hours. Following treatment, 
live cells were counted using trypan blue exclusion and serial dilutions of cells were 
prepared (10,000 – 1 cell) and the cells injected subcutaneously into both flanks of 
Rag2-/-GC-/- mice (Table 4.2). 
The results showed that xenograft tumour cells were still able to initiate tumours after 
treatment with either inhibitor or the combination.  
The tumour initiation frequency was approximately 26 fold lower (relative to the 
vehicle control) (1:434; confidence intervals 1:94 – 1:2008) following treatment with a 
combination of AKTi and mTORi and over 2 fold lower (1:44; confidence intervals 1:10 
– 1:201) when treated with AKTi alone (Table 4.2). Treatment with mTOR inhibitor 
alone did not show any advantage over treatment with DMSO. A pairwise test for 
differences in tumour initiation frequencies between treatment groups showed a 
significant advantage of combination treatment over DMSO and mTORi alone (p 
value=0.00954) (Table 4.3). The difference between combination treatment and AKTi 
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alone was not significant (p value=0.0714), similarly, DMSO versus AKTi alone and AKTi 
versus mTORi (p value=0.443).  
An additional effect of treatment with a combination of the inhibitors was an 8-day 
delay in the tumour latency compared to vehicle control (38 days and 30 days, 
respectively). There was no difference in the tumour latency following treatments with 
either inhibitor alone, relative to a vehicle control.  
 
Table 4.2. Tumour initiation frequency is lower in xenograft cells treated with a combination 
of AKT and mTOR inhibitor. 
 10 000 
cells per 
injection 
1000 
cells per 
injection 
100  
cells per 
injection 
10  
cells per 
injection 
1  
cell per 
injection 
Tumour initiation 
frequency  
(95% CI) 
0.2% DMSO 2/2 2/2 2/2 1/2 0/2 16.6 (98.9-3.16) 
10 µM AKTi 2/2 2/2 2/2 0/2 0/2 43.8 (201.1-9.84) 
10 µM mTORi 2/2 2/2 2/2 1/2 0/2 16.6 (98.9-3.16) 
10 +10 
Combination 
2/2 2/2 0/2 0/2 0/2 434.6 (2008.4-
94.36) 
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Table 4.3. Pairwise tests for differences in tumour initiation frequencies. 
Group 1 Group 2 p value 
AKTi Combination 0.0714 
AKTi DMSO 0.443 
AKTi mTORi 0.443 
Combination DMSO 0.00954 
Combination mTORi 0.00954 
DMSO mTORi 1 
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4.4.2. Flow cytometry analysis of biomarkers in xenograft tumours 
Expression of selected biomarkers downstream from AKT and mTOR was determined 
by flow cytometry in Y042 tumours retrieved from mice following ex vivo treatment 
with AKTi and mTORi. The results showed a decrease of 14.2% and 16.6% in phospho-
S6 in tumours pre-treated with 10 μM AKTi and 10 μM mTORi, respectively, in 
comparison to the vehicle control. However, the cells treated with a combination of 
AKTi + mTORi showed only a modest decrease of 4.8%, relative to control (Figure 4.26). 
Expression of phospho-AKT and phospho-ERK1/2 were comparable to the vehicle 
control cells in all tumours.  
Interestingly, the proportion of dead cells (violet – positive) differed between the 
treatment groups, with the lowest level in 0.2% DMSO-treated cells and highest in 
AKTi-treated cells (Figure 4.26).  
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Figure 4.26. Biomarkers expression in ex vivo treated Y042 xenograft. 
The YO42 tumours retrieved from mice following an ex vivo treatment, were depleted of 
mouse cells and the resultant human fraction (Lin-/CD31-) was analysed by flow cytometry. 
The cells were fixed in 4 % PFA, permeabilised with methanol, and stained with antibodies 
against: phospho-AKT, phospho-ERK1/2 and phospho-S6.   
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5. DISCUSSION 
The aim of this study was to determine the importance of the PI3K/AKT/mTOR 
pathway in human prostate cancer.  This was performed by targeting the pathway with 
AKT and mTOR inhibitors in prostate cancer cell lines, primary cell cultures and ‘near-
patient’ xenografts. Targeting of the PI3K/AKT/mTOR pathway has been investigated in 
a number of studies as an alternative treatment method for patients with over-
activation of the pathway (Cheng et al., 2005, Engelman, 2009). Inhibitors against 
selected elements of the pathway have been designed, including small molecule 
inhibitors against AKT and mTOR kinases, and their activity has been tested in different 
types of tumours (Davies et al., 2012, Garcia-Martinez et al., 2009).  
 
5.1. PTEN expression and PI3K pathway activity in prostate cancer cell lines 
and primary cultures 
The PTEN gene is the second most frequently mutated tumour suppressor gene after 
p53 and its role in human cancer development and progression has been widely 
investigated (Chalhoub and Baker, 2009, Leslie et al., 2008). It is estimated that around 
70% of metastatic prostate cancers have genomic alterations in the PI3K signalling 
pathway, due to mutations, deletions or epigenetic silencing via methylation of the 
PTEN gene (Blanco-Aparicio et al., 2007, Cairns et al., 1997). PTEN negatively regulates 
the PI3K/AKT/mTOR pathway and its frequent loss in cancer leads to over-activation of 
the pathway (Yoshimoto et al., 2007, Kwabi-Addo et al., 2001, Cairns et al., 1997, El 
Sheikh et al., 2008). It has been demonstrated that AKT activation, due to PTEN loss, 
induces resistance to inhibitors of receptor tyrosine kinases, anti-hormonal therapies 
in prostate cancer and also to chemotherapy (Kim et al., 2005, Wendel et al., 2004). A 
number of studies have shown that the PTEN tumour suppressor activity is lost in 
primary and metastatic prostate cancer. Published reports have demonstrated that 
biallelic deletion of PTEN correlates with disease-specific mortality and is associated 
with over-activation of the PI3K/AKT/mTOR pathway (Yoshimoto et al., 2007, Suzuki et 
al., 1998, Lotan et al., 2011).  
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It has been shown, by Li and co-workers, that loss of PTEN in the prostate cancer cell 
line LNCaP is due to a 2 bp deletion in exon 6 of the PTEN sequence resulting in a 
frameshift mutation (Li et al., 1997). Similarly, the absence of detectable expression of 
PTEN in PC3 cells is the result of deletion of the 3’ end of the PTEN gene (Sharrard and 
Maitland, 2000). The analysis reported in this study verified that both PC3 and LNCaP 
do not express PTEN at the protein level. However, PTEN is expressed at the RNA level 
in LNCaP cells.  
PTEN loss also resulted in increased activity of the pathway, as the highest levels of 
phospho-AKT and phospho-S6 were observed in PC3 cells. However, detected levels of 
phospho-S6 did not directly correlate with PTEN status as both PC3 and BPH1 cells had 
more phospho-S6 than either P4E6 or LNCaP cells.  
To confirm if loss of PTEN would increase activity of AKT and mTOR kinases, siRNA 
knock down of PTEN was carried out in PTEN expressing cell lines. As expected, the 
results showed an increased activity of AKT kinase. This result is in agreement with 
other studies, which showed that PTEN siRNA knock down in DU145 and 22Rv1 cells 
resulted in increased PI3K/AKT/mTOR pathway activity (Kim et al., 2014). However, 
PTEN knock down also resulted in a significant decrease in phospho-S6 levels indicating 
a decrease in mTORC1 activity. Masiello and co-workers have shown that a 
combinatorial treatment with rapamycin and receptor tyrosine kinase antagonists 
(PD16839 and imatinib) dramatically decreased phospho-S6 and that it was 
independent of phospho-AKT (Masiello et al., 2007). They have also demonstrated a 
paradoxical activation of p70 S6 kinase and its downstream target S6, in LNCaP cells, 
following treatment with either of the RTK antagonist alone (Masiello et al., 2007). An 
unexpected increase in phospho-S6 could be a result of an activation of a negative 
feedback mechanism, possibly involving MAPK signalling as it has been shown that S6 
kinase can be phosphorylated by both mTORC1 and ERK (Steelman et al., 2011).   
In contrast to prostate cancer cell lines, PTEN expression was observed in all primary 
cells investigated, including Gleason 8 tumours. Although there was variability in PTEN 
expression, none of the cultures showed a loss of PTEN. This might have been due to 
the presence of non-malignant cells (PTEN-positive) contaminating the cultures. 
However, the majority of cultures were derived from patients with early stage disease, 
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whereas it has been reported that PTEN is most frequently lost in advanced prostate 
cancer. Mithal et al reported that only 12% of radical prostatectomy samples showed 
complete loss of PTEN (Mithal et al., 2014). It is also possible that western blotting may 
not be sufficient to address a question of PTEN activity and capability of counteracting 
the PI3 kinase activity. Therefore an additional analysis of PTEN sequence regarding 
possible mutations and loss of heterozygosity (LOH) in PTEN gene is currently being 
investigated in our laboratory.  
It was first demonstrated by Di Cristofano and Pandolfi (2000) that PTEN is involved in 
cell migration. They observed that reintroduction of PTEN into the glioblastoma cell 
line U-87MG led to inhibition of integrin-mediated cell spreading and migration as a 
consequence of direct dephosphorylation of focal adhesion kinase (FAK) (Di Cristofano 
and Pandolfi, 2000). The involvement of PTEN in cell adhesion and migration could 
provide a rationale for the frequent loss of the gene observed in late-stage metastatic 
prostate cancer. In this study the results of a wound healing assay showed an 
increased migration rate in cells treated with PTEN siRNA. Moreover, a significant 
decrease in cell migration rate was observed following treatment with mTORi in both 
PTEN-negative cell lines, LNCaP and PC3. However, treatment with an AKTi did not 
show a significant effect on cell migration in either of those cell lines.  
 
5.2. The effect of treatment with AKTi and mTORi on cell viability and 
morphology  
Pre-clinical testing of new anti-cancer drugs in cancer cell lines alone has its 
limitations. Although the use of cell lines allows testing drugs under highly controlled 
and reproducible conditions, it does not represent the complexity of primary tumours, 
their heterogeneous populations or phenotypic variability (HogenEsch and Nikitin, 
2012). Therefore, in this study, a wide range of primary clinical samples of prostate 
cancer and benign prostatic hyperplasia (BPH) as well as ‘near patient’ prostate 
tumour xenografts were used to determine the effect of AKT and mTOR inhibitors.   
It has been reported in the literature that the allosteric mTORC1 inhibitor rapamycin 
and its analogues did not show a satisfactory efficacy in prostate cancer, which is most 
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likely due to lack of clinical activity against mTORC2 complex, leading to activation of 
AKT kinase (Sarbassov et al., 2006b, Sarbassov et al., 2005). Additionally, an activation 
of receptors, such as AR or RAS can also contribute to treatment resistance. Therefore 
improved dual mTORC1/2 inhibitors were designed showing greater efficacy than 
mTORC1 compounds in prostate cancer. Hsieh et al demonstrated that dual mTORC1/2 
inhibitor (MLN0128) prevented prostate cancer invasion and metastasis and was also 
able to induce apoptosis (Hsieh et al., 2012). A study with another dual mTORC1/2 
inhibitor, AZD8055, has been shown to inhibit cell proliferation and tumour growth in 
vitro in lung cancer cell lines and in a broad range of human tumour xenografts 
(Chresta et al., 2010). However, the loss of S6K-mediated negative feedback loop 
might still lead to activation of the PI3K/AKT/mTOR pathway via activation of the 
receptor tyrosine kinases (Bitting and Armstrong, 2013).    
In this study the results of treatment with up to 10 μM of both inhibitors, AKTi and 
mTORi, showed a relatively small decrease in cell density and minor changes in 
morphology, which were mainly observed in LNCaP cells. This suggested that out of 
four cell lines tested, LNCaP cells were the most susceptible to both inhibitors, which 
was further confirmed by an MTS viability assay. The results showed that only LNCaP 
cells had EC50 lower than 1 μM for AKTi and mTORi. Similarly, treatment of primary 
cultures (derived from patients with BPH and cancer) with up to 5 μM of AKTi and 
mTORi showed a limited effect on cell density and cell morphology. The results of cell 
viability assessment, following treatment, showed that there is variability in response 
between samples, even if they have been diagnosed with the same Gleason grade. Cell 
viability was also measured by an MTS assay and the results showed a comparable 
susceptibility of primary cultures to both inhibitors. However, when compared to a 
cancer cell line LNCaP, prostate primary cultures were more resistant to treatment; 
with ~27-fold higher EC50.  
Additionally, treatment of a matched cancer and normal culture showed different 
susceptibilities to the inhibitors, where only normal control responded. This difference 
in response might have been caused by the presence (or higher expression) of ABC 
transporters in the cancer cells resulting in efflux of the inhibitors from the cells. It has 
been demonstrated that tyrosine kinase inhibitor resistance is mediated by the 
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presence of ABC transporters in a range of human cancers, including breast, prostate, 
head and neck and also leukaemia (Anreddy et al., 2014). It has been also shown by 
Suzuki and co-workers that a significant degree of mutational heterogeneity in PTEN 
was found in different metastatic sites from the same patient (Suzuki et al., 1998). 
Moreover, it is also possible that the presence of pre-existing mutations in the PI3K 
pathway in cancer cells might influence the response to specific inhibitors. 
Susceptibility of cancer cells to PI3K/AKT/mTOR pathway inhibitors has been shown to 
depend on specific mutations, for example Carver and colleagues demonstrated that 
inhibition of the PI3K pathway in PTEN-negative prostate cancer cells led to activation 
of androgen receptor through feedback signalling to the receptor tyrosine kinase 
HER2/HER3 (Carver et al., 2011). Additionally, there is a positive correlation between 
the presence of PI3K mutations and susceptibility to an AKT inhibitor (AZD5363), as 
well as between the presence of RAS mutations and resistance to AZD5363 (Davies et 
al., 2012).  
Despite the limited effects of the inhibitors on primary cell cultures’ viability, dramatic 
morphological changes, such as vacuolation of cells and membrane blebbing were 
observed following treatment with high concentrations (≥ 25 μM) of AKT and mTOR 
inhibitors, respectively. Membrane blebs are spherical outgrowths of the plasma 
membrane that occur upon membrane detachment from the underlying cytoskeleton, 
which is indicative of apoptosis (Norman et al., 2010). However, there was no increase 
in cleaved PARP expression observed with mTOR inhibitor treatment. This could be 
due to the small numbers of cells showing such features, and therefore being 
undetectable by western blotting. Increased vacuolation of cells following treatment 
with the AKT inhibitor could indicate an activation of autophagy and formation of 
autophagosomes. Autophagy is a cellular catabolic degradation process in response to 
starvation or stress, in which cellular organelles, proteins and cytoplasm are digested 
and recycled to maintain metabolism (Mathew et al., 2007). Autophagy activation 
following treatment with AKTi was further confirmed as there was a clear increase in 
the LC3 B marker expression demonstrated by western blotting and 
immunofluorescence. It has been previously shown by others that treatment with the 
ATP-competitive AKT inhibitor (AZD7328) can induce autophagy in human bladder 
cancer cell lines, and that this can be overcome by treating cells with the autophagy 
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inhibitor chloroquine (Dickstein et al., 2012). However, there is evidence that 
autophagy can also prevent tumourigenesis, therefore acting as a tumour suppressor 
(Chen et al., 2013). It has been reported that mice with systemic mosaic deletion of 
autophagy genes atg5 and liver-specific atg7-/- developed hyperproliferative liver 
adenomas (Takamura et al., 2011). Although it has also been shown that ATG 
deficiency is responsible for increasing tumour cell proliferation in vivo, the 
mechanism of this is unclear.  
Interestingly, Chen and colleagues have uncovered that accumulation of the 
autophagy substrate p62/SQSTM1 was sufficient to activate the MAPK pathway and to 
increase cell proliferation in PI3K-expressing mammary 3D structures (Chen et al., 
2013). They emphasised that increased cell proliferation and MAPK activation due to 
inhibition of autophagy was only evident in 3D culture conditions and not in cells 
grown in a monolayer (Chen et al., 2013). In this study the cells treated with AKTi 
showed an increase in autophagy as well as in the MAPK pathway activity.  
 
5.3. Phospho-biomarkers response to the inhibition of the PI3K/AKT/mTOR 
pathway 
The efficiency of the inhibitors was also tested by determining biomarker expression 
using western blotting. The results showed that the majority of cell lines responded to 
treatment as the phosphorylation levels of the biomarkers reduced. However, the 
immediate response of cells to inhibitors can be different to the response following 
prolonged treatment such as the activation of a feedback mechanism, which is often 
observed after 24 hours exposure or even later (Kholodenko, 2006). Therefore the 
effect of prolonged incubation with inhibitors was tested. In cell lines, the results of a 
72-hour treatment showed a reduced inhibitory effect. Phosphorylation levels of 
biomarkers following treatment were comparable to vehicle controls and only 
treatment with the highest concentration (10 µM) of mTORi decreased levels of 
phospho-biomarkers. Additionally, a dose-dependent increase in phospho-S6 was 
observed in P4E6 cells following 72h treatment with mTORi. This implies that during an 
extended incubation with the inhibitors, the cells become more resistant and perhaps 
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activate a mechanism to overcome the inhibition by subsequently activating another 
node of the signalling network.   
Additionally, the question of reversible inhibition is clinically relevant, as with any 
treatment, the dosing of inhibitors in patients will probably not be continuous. 
Therefore, it is essential to establish what possible consequences might arise following 
withdrawal of the inhibitors. Therefore, the effect of treatment withdrawal was 
determined in primary prostate cultures to test whether inhibition of the 
PI3K/AKT/mTOR pathway is reversible. A Gleason 7 cancer culture was treated for 5 
days, treatment was stopped and phospho-biomarker levels were subsequently 
determined. Upon treatment with the AKT inhibitor, a surprising increase in phospo-
PRAS40 was observed, suggesting elevated activity of AKT kinase, which has not been 
reported before. Interestingly, an increase in phosphorylation of AKT (Ser473) upon 
treatment with ATP-competitive AKT inhibitors has been shown previously and it is due 
to the protein being held in a hyper-phosphorylated (but inactive) form as a 
consequence of compound binding (Okuzumi et al., 2009, Davies et al., 2012). This 
suggests that either hyper-phosphorylated AKT has not totally lost its activity or there 
is another kinase which can phosphorylate PRAS40. However, following the withdrawal 
of AKTi the levels of phospho-AKT and phospho-PRAS40 decreased. Interestingly, 
treatment with the mTORi confirmed its inhibitory activity against both mTORC1 and 
mTORC2 by decreasing phospho-S6 and phospho-AKT, respectively. Additionally, after 
48-hour treatment with mTORi a decrease in phospho-PRAS40 was observed, followed 
by an approximate 4-fold increase after treatment was extended to 5 days. However, a 
withdrawal of the mTOR inhibitor did not significantly alter phospho-S6. In contrast, 
phospho-AKT levels increased. This might suggest that release of mTOR inhibition 
could potentially cause a paradoxical increase in the pathway activity and will have to 
be investigated further.  
The PI3K/AKT/mTOR and Ras/MEK/ERK signalling pathways can become activated via 
EGF – induced activation of the epidermal growth factor receptor (EGFR). Therefore it 
was important to assess whether the presence of EGF in the culture medium affected 
treatment with the inhibitors. A BPH culture was treated with the inhibitors either in 
the presence or absence of EGF. The results showed that in the presence of EGF, the 
 
183 
 
levels of phospho-AKT and phospho-ERK were not significantly altered. Therefore an 
EGF-supplemented media was used throughout the experiments with primary prostate 
cultures.  
 
5.4. The effect of treatment on prostate cancer stem-like cells 
In order to verify whether selected subpopulations of primary cultures responded in a 
similar way to cell lines, a range of primary cultures was used. The results showed that 
there was variability between patients. Viability either decreased with treatment or an 
increase in stem cell content was observed. Despite this variability, viable cells were 
present following treatment suggesting that a subpopulation of CD133-positive cells is 
probably dependent on additional factors, such as PTEN expression, pre-existing 
mutations in PI3K or other signalling molecules of the pathway. This heterogeneity in 
response is highlighted by the colony forming assay in which stem-like cells, resistant 
to treatment, were capable of enhanced CFE. In contrast, the CFE of the TA cells 
decreased with treatment. This might suggest that stem-like cells are dependent on 
the PI3K signalling and that inhibition of the pathway affects their survival.  
It has been previously shown by Dubrovska and co-workers that the PI3K/AKT/FOXO3a 
signalling plays a critical role in maintenance and viability of tumour initiating cells 
(CD133+/CD44+) in prostate cancer cell lines (Dubrovska et al., 2009). Their study has 
demonstrated that inhibition of the PI3K pathway led to a decrease in the stem-like 
cell population and in their clonogenic potential (Dubrovska et al., 2009). Furthermore, 
they have also shown that a combination treatment with PI3K/mTOR inhibitor 
(BEZ235) and chemotherapeutic drug Taxotere eliminated stem-like progenitor cells 
and led to a significant tumour regression in a DU145-derived prostate cancer 
xenograft model (Dubrovska et al., 2010). However, they have also shown that, in the 
relapsed DU145 tumours, an expansion of cancer progenitors with a PTEN E91D 
missense mutation was observed, which was the cause of the combination therapy 
resistance (Dubrovska et al., 2010).   
Moreover, it has also been shown in another study that loss of PTEN and therefore an 
increase in the PI3K pathway activity, increased the stem-like properties of the cells, 
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including sphere-forming ability, epithelial-mesenchymal transition-related gene 
expression and multi drug resistance efflux transport ATP-binding cassette sub-family 
G (ABCG2) expression (Kim et al., 2014). This could provide a rationale for targeting the 
PI3K/AKT/mTOR pathway.    
The results reported in the literature regarding targeting the PI3K/AKT/mTOR pathway 
in order to eliminate cancer stem cells are very encouraging. Ke and co-workers 
reported that treatment of anaplastic thyroid cancer with a PI3K inhibitor, LY294002, 
attenuated self-renewal of cancer stem cells and induced cell differentiation (Ke et al, 
2014). Similar findings were also reported in acute myeloid leukaemia and in breast 
cancer stem cells, where it was shown that the PI3K/AKT/mTOR pathway was critical 
for cancer stem cells’ proliferation and survival (Martelli et al., 2006, Dillon et al., 
2007). Moreover, it has recently been shown by Vassilopoulos and colleagues that 
following treatment with a chemotherapeutic drug cisplatin, there was a significant 
increase in breast cancer stem cells number, which was partially attributed to the 
activation of the PI3K/AKT/mTOR pathway (Vassilopoulos et al., 2014). However, they 
have also shown that combined treatment with cisplatin and mTOR inhibitor 
rapamycin, synergistically inhibited cancer stem cells-mediated primary and metastatic 
cancer growth (Vassilopoulos et al., 2014). Those recent findings emphasise the need 
for testing of combination treatments, which might be a more successful approach in 
targeting cancer stem cells. Frame and Maitland have summarised the potential effects 
of different prostate cancer treatments on the stem cell population (Figure 5.1). 
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Figure 5.1: Figure 5.1. Effect of traditional therapies on stem-like cells. 
 Summary of treatment options related to prostate cancer stage and proposed effect on 
cancer stem cell population. (Taken from: Frame F.M. and Maitland N.J. (2013) Cancer stem 
cells provide new insights into the therapeutic responses of human prostate cancer (Chapter 
4). In ‘Stem Cells and Prostate Cancer’. S. Cramer, ed. (Springer Science + Business Media, LLC). 
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A Xenograft model of prostate cancer was next used to determine if treatment with 
AKTi and mTORi had any effect on tumour frequency and tumour latency. The results 
showed a significant advantage of ex vivo treatment with a combination of AKTi and 
mTORi relative to the vehicle control.  
It has been demonstrated in the literature that combination of the PI3K pathway 
inhibitors targeting AKT or PI3Kbeta/delta with androgen deprivation therapy resulted 
in long-lasting tumour regression in PTEN-negative PC346C xenografts (Marques et al., 
2014). It has also been reported by Zhang and colleagues that co-targeting of mTOR 
and AKT in prostate cancer with ridaforolimus/MK-8669 and M1K02206, respectively, 
showed additive anti-tumour effects in vivo in comparison to single agents (Zhang et 
al., 2012).   
A number of studies with PI3K/AKT/mTOR pathway inhibitors have reported growth 
inhibition, G1 cell cycle arrest, induction of apoptosis and an increase in cells’ 
sensitivity to radiation (Shukla et al., 2007, Gottschalk et al., 2005, Gao et al., 2003). In 
this study, treatment with AKT and mTOR inhibitor showed growth arrest in the G1 
phase in LNCaP cells, but not in BPH1, P4E6 or PC3 cells (Figure 3.15). However, 
treatment of primary cultures, including BPH, hormone naïve cancer and CRPC, did not 
affect cell cycle distribution. This result highlights the difference in susceptibility of 
primary cultures compared to cell lines in their response to the different inhibitors. In 
particular, the requirement for a 5-fold higher concentration of the inhibitors in the 
treatment of primary cells. 
 
5.5. Cross-talk between the PI3K/AKT/mTOR and the Ras/MEK/ERK 
pathways 
It has previously been shown by Carver and co-workers that PI3K pathway inhibition 
activates androgen receptor signalling by relieving feedback inhibition of HER kinases. 
Conversely, AR inhibition leads to activation of AKT by reduction of AKT phosphatase 
PHLPP expression (Carver et al., 2011). 
The PI3K/AKT/mTOR and the Ras/MEK/ERK pathways are the two major hyper-
activated pathways, which promote cell proliferation, survival and metastasis in 
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human cancer (Yuen et al., 2012). Activation of the MAPK pathway has been 
implicated in resistance to the PI3K/AKT/mTOR signalling inhibition (Ihle et al., 2009) 
and significant activation of this pathway has been observed in primary and in 
metastatic prostate cancer (Mulholland et al., 2012). Therefore a simultaneous 
targeting of both pathways in prostate cancer could be highly beneficial for patients 
with advanced stage disease (Figure 5.2).   
 
 
Figure 5.2. Combined inhibition of AKT and MEK1/2 kinase.  
A schematic representation of the PI3K/AKT/mTOR and the Ras/MEK/ERK pathways 
interaction and simultaneous inhibition. Growth factor receptor activation results in activation 
of both signalling pathways via Ras and PI3 kinase. AKT can phosphorylate and inhibit the 
effects of TSC2 and PRAS40, which results in mTORC1 activation. ERK can interact with 
mTORC1 signalling via p70S6K. ERK is also involved in negative regulation of MEK1/2 and RAF. 
Simultaneous inhibition of AKT and MEK1/2 is proposed to overcome the compensatory 
activation of ERK signalling following inhibition of AKT.  
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In this study, increased levels of phospho-ERK1/2 were observed in a number of 
primary prostate cancer and BPH cultures following treatment with AKTi, but not 
mTORi. Additionally, a surprising ‘switch’ between phosphorylated ERK1 (AKTi treated) 
and ERK2 (mTORi treated) was revealed. However, a combination treatment of AKTi + 
mTORi increased phosphorylation of both ERK1 and ERK2 by approximately 9 fold. In 
contrast, treatment of primary cancer cultures with mTORi did not increase phospho-
ERK1/2 levels, even when treated with very high concentrations (50 μM) of inhibitor. 
However, treatment with > 25 µM of AKTi resulted in a decrease of phospho-S6, a 
downstream target of mTORC1. Therefore, any increase in phospho-ERK1/2 levels in 
those cells could be due to mTORC1 inhibition as well as inhibition of AKT. This result 
indicates that the MAPK pathway activity increases in order to compensate for loss of 
activity of the PI3K pathway.  
A cross-talk between the Ras/MEK/ERK and the PI3K/AKT/mTOR pathways has been 
previously reported in prostate cancer (Carracedo et al., 2008, Kinkade et al., 2008). 
However, in the studies mentioned above, activation of the MAPK pathway was mainly 
observed in response to inhibition of mTORC1 with rapamycin or its derivatives, 
rapalogs, in breast, prostate and colon cancer (Carracedo et al., 2008). Based on the 
results, Carracedo and colleagues proposed that mTORC1 inhibition increases RTK/IRS-
1/PI3K activity towards Ras/MAPK, and promotes activation of both AKT and ERK, in 
what constitutes a dual feedback mechanism (Carracedo et al., 2008, Carracedo and 
Pandolfi, 2008). This suggests that a combined inhibition of the PI3K/AKT/mTOR 
pathway and the MAPK pathway might be required to improve therapeutic outcome in 
treatment of prostate cancer.        
It has been shown that phosphorylation of S6 ribosomal protein is an indication of 
mTORC1 activation, which is due to AKT inhibitory phosphorylation of tuberous 
sclerosis complex 2 (Tee et al., 2002). In this study a surprising increase of 
approximately 5-fold in phospho-S6 was revealed following treatment with mTORi. A 
similar result was observed in another primary cancer sample in which 72-hour 
incubation with 10 µM mTORi showed no reduction in phospho-S6. This is in contrast 
to the effect observed in cell lines, where following treatment with mTORi, a 
significant reduction of phospho-S6 was evident. An inhibitory activity of mTORi 
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against mTORC1 and mTORC2 has been previously demonstrated by Garcia-Martinez 
and co-workers in HEK-293, HeLa and mouse embryonic fibroblasts (MEFs) (Garcia-
Martinez et al., 2009). The study has shown that mTORi was a potent and highly 
specific inhibitor with an IC50 of ~ 10 nM (Garcia-Martinez et al., 2009). Additionally, an 
ATP-competitive mTOR inhibitor, AZD8055, structurally similar to mTORi, has been 
shown to be an orally bioavailable, potent and selective inhibitor with an IC50 of ~ 0.8 
nM (Chresta et al., 2010). However, all the experiments testing mTOR inhibitors 
mentioned above, were performed in cancer cell lines or xenografts derived from 
them. In this study only a modest effect, or lack of mTORi inhibitory effect was 
observed in primary prostate cancer cultures derived from prostate tumours, which 
represent a different model of the disease, perhaps more accurate for testing new 
drugs. Moreover, a problem of prostate cancer heterogeneity and its’ influence on 
treatment outcome is also represented better in primary cultures than in cell lines.   
To follow up the observation of the MAPK pathway activation in cultures treated with 
AKTi, two MEK inhibitors, AZD6244 (MEKi) and RO-512, were tested in primary 
prostate cultures. In order to verify whether MEK1/2 inhibitors are effective in 
prostate cells, selected primary cultures (with high levels of phospho-ERK1/2) were 
treated with both MEK1/2 inhibitors. Treatment with MEKi has shown a dramatic 
decrease in phospho-ERK1/2 at 1 μM concentration, therefore confirming its inhibitory 
activity in prostate primary cells. There was no evidence of activation of autophagy in 
treated cells despite treatment with high concentrations of MEKi. However, a small 
increase of around 2-fold in phospho-AKT was observed, which could be an effect of 
regulatory feedback between the PI3K and the MAPK pathways. Next, a combination 
treatment with AKTi and MEKi was tested in order to determine whether activation of 
the MAPK pathway following treatment with AKTi can be overcome. Different 
treatment schedules were tested, including treatment with AKTi alone and subsequent 
addition of MEKi, as well as simultaneous treatment of cell cultures with both 
inhibitors at matching concentrations. However, the results were similar and showed a 
surprising increase, instead of a decrease, in phospho-ERK1/2 in all analysed samples. 
Moreover, a combined treatment with AKTi and MEKi AZD, with up to 25 μM 
concentration of each, resulted in an increased phosphorylation of ERK1/2 to even 
greater levels than treatment with AKTi alone. Additionally, a small increase in the 
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autophagy marker, LC3B, was also observed, suggesting activation of survival 
mechanism in cells treated with AKTi or a combination of AKTi and MEKi.  
Davies and colleagues have previously demonstrated activity and efficiency of the 
MEKi (AZD6244) in a large panel of human cancer cell lines as well as in xenografts 
derived from them (Davies et al., 2007). It has been revealed that a majority of cell 
lines with a mutation in KRAS, NRAS or BRAF genes showed a significant increased 
sensitivity to MEK inhibition resulting in cell growth inhibition and induction of 
apoptosis (Davies et al., 2007). In another study it was shown that a combination 
treatment of the MEKi and a chemotherapeutic agent - docetaxel resulted in enhanced 
tumour growth inhibition in comparison to monotherapy in human colon carcinoma 
xenograft HCT-116 (Holt et al., 2012). However, the rate of mutations in Ras/MEK/ERK 
pathway in clinical prostate cancer is very low; up to 7% of clinical samples have 
activating point mutations of Ras and around 4 % are positive for BRAF, the most 
common activating mutation of RAF (Santarpia et al., 2012).  
Following a disappointing lack of inhibitory activity of MEKi in AKTi-treated cultures, an 
additional MEK1/2 inhibitor RO-512 was tested to try to overcome the compensatory 
ERK1/2 phosphorylation. The RO-512 inhibitor has been shown to bind to MEK1/2, 
which in turn forms a complex with RAF, preventing phosphorylation of ERK1/2 and 
also its self-regulatory feedback loop (Beloueche-Babari et al., 2013). An initial 
assessment of RO-512 inhibitor activity in primary prostate cancer cultures showed an 
excellent inhibitory efficacy with phospho-ERK1/2 completely abolished at a 
concentration of 0.1 μM or 1 μM, in a BPH and a cancer culture, respectively. However, 
an unexpected increase in phospho-AKT was observed following treatment with 1 μM 
RO-512 in BPH culture, whereas in cancer cells phospho-AKT remained unaltered. 
Additionally, a surprising variation of phospho-S6 (downstream target of mTORC1) was 
also observed in the BPH cells, but not in cancer. The differences in treatment 
responses of BPH and cancer cells might be due to their differential reliance on 
mTORC1 signalling. Western blotting results showed that in the BPH culture phospho-
S6 was undetectable in vehicle control cells and mTORC1 activity only became 
apparent when cells were treated with RO-512.       
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Similarly to the treatment with MEKi, a combination treatment of BPH and cancer 
primary cultures with AKTi and RO-512 showed no decrease, but rather a small 
increase in phosphorylation levels of ERK1/2. However, a combination of the drugs at 1 
μM concentration decreased phospho-ERK1/2 in both BPH and cancer cultures. 
Interestingly, a ‘switch’ between phospho-ERK1 and phospho-ERK2 became apparent 
following treatment with AKTi alone and a combination with RO-512, and a dose-
dependent decrease in phospho-S6 was observed after treatment with a combination 
of AKTi and RO-512 in a cancer sample, but not in BPH, which might suggest 
differential regulation of both pathways in BPH and cancer cells.   
Both Ras/MEK/ERK pathway and the PI3K/AKT/mTOR have been shown to be over-
activated in many human cancers (McCubrey et al., 2012b). It has been demonstrated 
that Ras/MEK/ERK signalling activity is essential for the maintenance of the growth and 
viability of many tumours, including breast and prostate cancer and most importantly, 
that its increased activity is associated with a poor prognosis (Steelman et al., 2011). It 
has been shown that MEK inhibitors’ ability to inhibit ERK activity might be limited by 
their toxicity and also by relief of ERK-dependent feedback inhibition of RAF, which 
leads to an increase in phosphorylation of MEK (Alessi et al., 1995a). A novel allosteric 
inhibitor of MEK1/2, CH5126766 (RO-512) has been shown to decrease phospho-
ERK1/2 levels, but does not enhance MEK phosphorylation (Ishii et al., 2013). Its 
efficacy has been demonstrated in a number of human cancer cell lines and also in the 
HCT-116 xenograft model, regardless of the mutational status of the Ras/MEK/ERK 
pathway in those cells (Ishii et al., 2013). However, in this study neither of MEK1/2 
inhibitors was able to overcome the compensatory ERK1/2 activation caused by 
inhibition of AKT. It is not clear why a combination treatment of AKTi with MEKi did not 
reduce activity of ERK. However, a ‘switch’ between phospho-ERK1 and phospho-ERK2, 
which was observed in BPH and cancer cultures following treatment with either AKTi 
alone or with a combination with MEK1/2 inhibitor, could indicate that different 
targets of ERK might be activated downstream from ERK depending on the treatment. 
It has been demonstrated that ERK2, but not ERK1 signalling was necessary for Ras-
induced epithelial-to-mesenchymal transition (EMT) (Shin et al., 2010, Shin and Blenis, 
2010). The study has shown that overexpression of ERK2 was sufficient to induce EMT. 
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Interestingly, it has also been suggested that ERK1 and ERK 2 are not functionally 
redundant molecules (Shin et al., 2010).  
Taken together, differential phosphorylation of ERK1 and ERK2 following treatment 
with AKTi or a combination of AKTi with MEKi might indicate that the functional 
outcome of treatment will probably depend on dominant isoform of ERK.  
It has been suggested that inhibition of the MEK/ERK signalling and therefore 
reduction of the activity of anti-apoptotic proteins such as Bcl-2 and Mcl-2, could be 
helpful in decreasing the threshold for induction of apoptosis (Holt et al., 2012). 
Additionally, it has been demonstrated that chronic dosing of MEKi resulted in 
morphological changes to a more differentiated phenotype in a colon carcinoma SW-
620 xenograft (Davies et al., 2007). 
Changes in cell morphology were also observed in this study and to follow up this 
observation, an analysis of differentiation markers was performed on primary cultures 
treated with MEK1/2 inhibitors (MEKi and RO-512) either alone or in a combination 
with AKTi. The results showed that the expression of prostate differentiation marker 
CK18 did not increase following treatment, therefore indicating that primary cells are 
not undergoing differentiation after treatment.  
However, a β-galactosidase staining of treated cultures has revealed that the cells 
became senescent after treatment with a combination with AKTi and MEKi. In the 
literature it has been presented that senescence was frequently triggered in tumours 
in response to chemotherapy and radiotherapy treatment in tumour samples from 
cancer patients (Nardella et al., 2011, Roninson, 2003). It has been demonstrated that 
PTEN-loss-induced cellular senescence inhibits tumorigenesis in vivo in a human 
xenograft model of prostate cancer (Alimonti et al., 2010), and that induction of 
senescence in cancer cells could indeed be a good therapeutic strategy for treatment 
of prostate cancer (Alimonti et al., 2010).  
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5.6. Conclusions 
This work has provided evidence that pharmacological inhibition of the 
PI3K/AKT/mTOR pathway with AKT and mTOR inhibitors in human prostate cancer is 
not sufficient. A compensatory Ras/MEK/ERK pathway activation was observed in all 
analysed patient tissues.  
This study also highlights the importance of using patient-derived tumour cells in 
preclinical assessment of new drugs rather than relying on cancer cell lines alone. In 
this work, treatment with AKTi and mTORi of prostate cancer cell line LNCaP showed a 
significant therapeutic advantage when targeting the PI3K pathway. However, those 
results were not confirmed in primary prostate cultures. Moreover, primary prostate 
cells activated autophagy as well as a compensatory survival pathway in response to 
treatment. Surprisingly, treatment with a combination of AKT and MEK1/2 inhibitors 
did not inhibit ERK signalling in primary prostate cultures, but an irreversible growth 
arrest was observed.  
The majority of preclinical screening is routinely performed in panels of cell lines and 
xenografts derived from them. Drug development research based on those models is 
frequently unsuccessful in patients and new drugs ultimately fail in clinical trials. In 
contrast, many potentially beneficial therapies are discontinued when they fail to show 
efficacy in cell lines (Daniel et al., 2009). Therefore it is crucial to invest in more 
accurate models of human cancers for preclinical testing.     
Future work should focus on determining the functional consequences of combined 
pharmacological targeting of the PI3K/AKT/mTOR and the Ras/MEK/ERK pathways, 
especially in cancer stem-like cells. This would verify whether induction of senescence 
could potentially offer a successful novel strategy for the treatment of prostate cancer.   
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APPENDICES 
Appendix 1: Patient primary sample details 
 Patient ID Diagnosis Age Operation 
1 H135/11 Cancer Gleason 9 (5+4) on 
hormones 
56 Channel TURP 
2 H149/12 Cancer Gleason 9 (4+5) on 
hormones 
78 Channel TURP 
3 H163/12 Cancer Gleason 8 (4+4) on 
hormones 
65 Channel TURP 
4 H209/12 Cancer Gleason 7 (4+3) 64 Radical prostatectomy 
5 H210/12 Cancer Gleason 7 (3+4) 69 Radical prostatectomy 
6 H217/12 Cancer Gleason 7 (3+4) 72 Radical prostatectomy 
7 H224/12 Cancer Gleason 9 (4+5), 
castration resistant  
76 Channel TURP 
8 H233/12 RA Cancer Gleason 7 (4+3) 61 Radical prostatectomy 
9 H233/12 L Normal control 61 Radical prostatectomy 
10 H236/12  Cancer Gleason 8 (4+4) 61 Radical prostatectomy 
11 H237/12 LA Cancer Gleason 7 (3+4) 66 Radical prostatectomy 
12 H239/12 RB Cancer Gleason 9 (4+5) 50 Radical prostatectomy 
13 H240/12 RA + 
RB 
Cancer Gleason 7 (3+4) 66 Radical prostatectomy 
14 H252/12 Cancer Gleason 7 (3+4) 60 Radical prostatectomy 
15 H268/12  BPH 62 TURP 
16 H271/12 Cancer Gleason 9, castration 
resistant 
86 Channel TURP 
17 H277/13  BPH 68 TURP 
18 H278/13 RA Cancer Gleason 6 (3+3) 72 Radical prostatectomy 
19 H282/13 
RA+RB 
Cancer Gleason 7 (4+3) 62 Radical prostatectomy 
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20 H304/13 Cancer Gleason 8 (4+4) 66 Radical prostatectomy 
21 H308/13 R + L Cancer Gleason 7 (3+4) 66 Radical prostatectomy 
22 H310/13 R + L Cancer Gleason 7 (3+4) 67 Radical prostatectomy 
23 H313/13 BPH 65 TURP 
24 H315/13 Cancer Gleason 6 (3+3) 62 Radical prostatectomy 
25 H317/13 LA Cancer Gleason 7 (3+4) 65 Radical prostatectomy 
26 H329/13 LB Cancer Gleason 7 (3+4) 53 Radical prostatectomy 
27 H330/13 Cancer Gleason 7 (3+4) 58 Radical prostatectomy 
28 H359/13  Cancer Gleason 8 (3+5) 64 Channel TURP 
29 H363/13 R  Cancer Gleason 8 (4+4) on 
hormones 
74 Channel TURP 
30 H366/13 Cancer Gleason 7 (4+3) on 
hormones 
67 Radical prostatectomy 
31 H373/13 Cancer Gleason 7 (3+4) 82 TURP 
32 H377/13 Cancer Gleason 7 (3+4) 60 Radical prostatectomy 
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ABBREVIATIONS 
 
%  Percentage 
4EBP1  eukaryotic translation initiation factor 4E binding protein 1 
ABCG2  ATP-binding cassette sub-family G 
ADP  Adenosine diphosphate 
ADT   Androgen deprivation therapy 
AKT  v-akt murine thymoma viral oncogene homolog 
ALDH   Aldehyde dehydrogenase 
APC   Allophycocyanin 
APES  aminopropyltriethoxysilane 
AR   Androgen receptor 
ATCC   American type culture collection 
B. Taurus  Bos Taurus 
BAD  BCL2-associated agonist of cell death 
BCA   Bicinchoninic acid 
BM   Basement Membrane 
bp   Base pairs 
BPE  Bovine pituitary extract 
BPH   Benign Prostatic Hyperplasia 
BRAF  V-Raf Murine Sarcoma Viral Oncogene Homolog B 
BSA   Bovine serum albumin 
c-Myc  v-myc avian myelocytomatosis viral oncogene homolog 
CaP   Prostate cancer 
CB   Committed basal 
cDNA   Complimentary DNA 
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CFE   Colony forming efficiency 
CHK1  Checkpoint kinase 1 
CK   Cytokeratin 
Cl   Chloride 
Cm   Centimetre 
Cm2   Centimetre squared 
CO2   Carbon dioxide 
CPA   Carboxypeptidase 
CRPC   Castrate resistant prostate cancer 
CRU   Cancer research unit 
CSC   Cancer stem cell 
CT   Threshold cycle 
D10   DMEM + 10% FCS 
DAPI  4',6-diamidino-2-phenylindole 
ddH20   Double distilled water 
DEPC   Diethylpyrocarbonate 
dH2O   Distilled water 
DHT   Dihydrotestosterone 
DMEM   Dulbecco’s modified eagle medium 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
dNTPS   Deoxyribonucleotide triphosphate 
DRE  Digital Rectal Exam 
DTT   Dithiothreitol 
EC50  Half maximal effective concentration 
ECACC  European Collection of Animal Cell Culture 
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ECACC   European collection of cell cultures 
ECL   Enhanced chemiluminescence 
ECM   Extracellular matrix 
EDTA   Ethylenediaminetetraacetic acid 
EGF   Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
EGR1   Early Growth Response 1 
EMT   Epithelial-to-mesenchymal transition 
ER   Endoplasmic reticulum 
ERK  Extracellular signal-regulated kinases 
ES   Embryonic stem 
EtOH   Ethanol 
FAK  Focal adhesion kinase 
FCS   Fetal calf serum 
FDA   Food and Drug Administration 
FGF   Fibroblast growth factor 
FITC   Fluorescein isothiocyanate 
FOXO3A forkhead box O3 
FS   Forward scatter 
g   Gram 
G0   G zero phase 
G1   Gap 1 phase 
G2/M   Gap 2 phase/mitosis 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GPCR  G-protein coupled receptor 
GSK3  Glycogen synthase kinase 3 
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GY   Gray 
H. Sapiens  Homo Sapiens 
H&E  Haematoxylin and eosin 
H7   Ham’s F-12 medium + 7% FCS 
HCl   Hydrogen chloride 
HNSCC   Head and neck squamous cell carcinoma 
HRPC  Hormone resistant prostate cancer 
HRP   Horseradish peroxidase 
HSC   Haematopoietic stem cell 
IGF2  Insulin-like growth factor 2 (somatomedin A) 
IGFR  Insulin-like growth factor receptor 
IgG   Immunoglobulin G 
IHC   Immunohistochemistry 
IRS1   Insulin receptor substrate 1 
IRS2   Insulin receptor substrate 2 
IU  International units 
kB   Kilobase 
KCl   Potassium chloride 
kDa   Kilo Dalton 
Ki67 (MKI67)  Antigen identified by monoclonal antibody Ki-67 
KSFM   Keratinocyte serum free medium 
LA   Left apex 
LB   Left base 
LIF   Leukaemia inhibitory factor 
Lin   Linear 
LOH   Loss of heterozygosity 
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LRP   Laparoscopic radical prostatectomy 
M. Musculus  Mus musculus 
MACS   Magnetic-activated cell sorting 
MAPK   Mitogen-activated protein kinase 
MDM2  MDM2 oncogene, E3 ubiquitin protein ligase 
MDR1   Multidrug resistance protein 1 
MEK  MAPK/ERK kinase 
MET   Mesenchymal-to-epithelial transition 
MgCl2   Magnesium chloride 
Min   Minute 
miR  micro RNA 
MiRNA   micro RNA 
ml   Millilitre 
mm   Millimetre 
mM   Millimolar 
mRNA   Messenger RNA 
mSin1  Mitogen-activated-protein-kinase-associated protein 1 
mTORC1 mTOR complex1 
mTORC2 mTOR complex 2 
MTS  [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt] 
Mw   Molecular weight 
NaCl   Sodium chloride 
NaOH   Sodium hydroxide 
NE   Neuroendocrine 
ng   Nanogram 
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NKX3.1  NK3 transcription factor related, locus 1  
nM   Nanomolar 
ORP   Open radical prostatectomy 
P53   Tumour protein 53 
P63   Tumour protein 63 
PAGE   Polyacrylamide gel electrophoresis 
PAP   Prostatic acid phosphatase 
PARP  Poly (ADP-ribose) polymerase 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PDGFR  Platelet derived growth factor receptor 
PDK1  Phosphoinositide-dependent kinase 1 
PE  Phycoerythrin 
PFA  Paraformaldehyde 
PH  Pleckstrin homology domain 
PI   Propidium iodide 
PI3K   Phosphoinositide 3-kinase 
PIC   Protease inhibitor cocktail 
PIN   Prostatic intraepithelial neoplasia 
PIP2  phosphatidylinositol 4,5-biphosphate 
PIP3  phosphatidylinositol (3-5)-triphosphate 
PM   Plasma membrane  
PPARγ  Peroxisome proliferator-activated receptor gamma 
PSA   Prostate-specific antigen 
PTEN   Phosphatase and tensin homolog  
PVDF  Polyvinylidene difluoride 
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qPCR   Quantitative PCR 
qRT-PCR  Quantitative real-time PCR 
R1   Region 1 
R10   RPMI + 10% FCS 
R2   Region 2 
R3   Region 3 
R5   RPMI + 5% FCS 
Radical  Radical prostatectomy 
RAF  v-raf murine sarcoma 3611 viral oncogene homolog 
Rag2   Recombination activating gene 2 
RAS  Rat Sarcoma Viral Oncogene Homolog 
Rb  Retinoblastoma 
RB   Right base 
rictor   rapamycin-insensitive companion of mTOR 
RNA   Ribonucleic acid 
RPLP0   Ribosomal protein, large, P0 
RPM   Revolutions per minute 
RPMI   Roswell Park Memorial Institute medium 
RSK  Ribosomal s6 kinase 
RT   Room temperature 
RT-PCR  Reverse transcriptase PCR 
RTK  Receptor tyrosine kinase 
S6K  Ribosomal S6 kinase  
SC   Stem cell 
SCM   Stem cell medium 
Scr   Scrambled siRNA 
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SDS   Sodium dodecyl sulphate 
SEM  Standard error of the mean 
siRNA   Small interfering RNA 
SS   Side scatter 
Stem   Stem cell 
STOs  STO (Mouse embryonic fibroblast cell line)  
SV40   Simian vacuolating virus 40  
T25  25 cm2 tissue culture flask 
T75  75 cm2 tissue culture flask 
TA   Transit-amplifying cell 
TAE   Tris base, acetic acid and EDTA buffer 
Taq   Thermus aquaticus 
TBS   Tris-buffered saline 
TBST   Tris-buffered saline with Tween-20 
TE   Tris EDTA buffer 
TF   Transcription factor 
tRNA   Transfer ribonucleic acid 
TSA   Trichostatin A 
TSC2  Tuberous Sclerosis 2 
TSE   Tris, sucrose, EDTA buffer 
TURP   Transurethral resection of the prostate 
TX-100   Triton X-100 
U/mg   Units per milligram 
U/ml   Units per millilitre 
UK   United Kingdom 
V   Volts 
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v/v   Volume per volume 
w/v   Weight per volume 
α2β1hi  High expression of alpha 2 beta 1 integrin 
α2β1lo  Low expression of alpha 2 beta 1 integrin 
β-actin   Beta actin 
µg   Microgram 
µl   Microlitre 
µm   Micrometre  
µM   Micromolar 
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